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Abstract 
 
The amorphous silicon electronic portal imaging device (a-Si EPID) was originally 
designed for positional verification in radiotherapy. Several feature of the a-Si 
EPID, such as the high-resolution detector array and ease of operation, have 
made this imaging device an attractive tool for dose measurements. The main 
challenge with a-Si EPID dosimetry is the deviation in scatter and dose response 
characteristics from a water-equivalent detector that makes the conversion of 
EPID signal to dose not straightforward.  
 
The aim of this thesis is to develop a model to perform 2D transit dosimetry for 
patient-specific treatment verification with a-Si EPID. The transit model can be 
used for both pre-treatment and actual treatment verification to ensure safety 
in different stages of the radiotherapy process.  
 
The model was based on a quadratic equation that relates the reduction in 
radiation intensity, represented by the ratio of exit to entrance dose, to the 
water-equivalent path length (EPL) of the attenuator. Coefficients in the 
quadratic equation were derived from a set of calibration dose planes measured 
for a reference beam with water phantoms of known thicknesses. Two sets of 
coefficients were derived separately from calibration dose planes measured with 
EPID and ionisation chamber (IC) in water. Consequently, with two sets of 
coefficients, the EPL of any attenuator can be calculated using either EPID 
measured dose planes or treatment planning system (TPS) computed dose planes 
for the treatment field to be verified. The calculated EPL, which is a property of 
the attenuator and independent of the dosimeter, was used to link the different 
dosimetry systems and provide a two-way relationship for either: (Path 1) 
reconstruction of in-phantom or in-vivo dose from EPID measured dose planes, 
for comparison with TPS planned dose; or (Path 2) prediction of EPID transit dose 
from TPS computed dose planes, for comparison with EPID measurement during 
treatment. 
 
The developed model was first tested with homogeneous and heterogeneous slab 
phantoms using open, enhanced dynamic wedge (EDW) and intensity modulated 
radiation therapy (IMRT) fields. Results showed that the model could accurately 
! iii!
detect deviation between delivered and planned doses. Further evaluation with 
an anthropomorphic pelvic phantom and 65 test fields (open, 3D conformal, 
EDW, IMRT) at different gantry angles showed a mean gamma pass rate (4%/4mm 
criterion) of 97.6% (range: 90.0% to 100%) for in-phantom exit dose comparisons 
(Path 1) and 97.1% (range: 92.9% to 99.8%) for EPID transit dose comparisons 
(Path 2). In addition, the methods in Path 1 were expanded to reconstruct dose 
at other levels besides the exit level. In-phantom isocentre dose comparisons 
resulted in a mean gamma pass rate of 98.2% (range: 91.7% to 100%).  
 
Finally, clinical feasibility of the EPID transit dosimetry model was demonstrated 
for three patients (11 3D conformal fields, 18 verifications) who were undergoing 
radiotherapy treatment at the pelvic region. Gamma analyses with 5%/5mm 
criterion resulted in a mean pass rate of 97.0% (range: 92.4% to 99.6%) and 98.6% 
(range: 96.1% to 100%) for in-vivo comparisons at the exit level and isocentre 
level respectively (Path 1). The mean gamma pass rate for EPID transit dose 
comparisons (Path 2) was 95.6% (range: 90.7% to 99.9%). 
 
In conclusion, the 2D EPID transit dosimetry model developed in this thesis has 
been proven to be valid and suitable for clinical implementation. The model is: 
(1) practical, involving only general measurements and does not require any 
modification to the EPID panel, (2) generic, with the methods applicable to all 
a-Si EPID and TPS regardless of manufacturer and (3) flexible, allowing users to 
verify the accuracy of treatment delivery either at multiple planes in-vivo or at 
the EPID level. These are important characteristics to encourage widespread 
implementation of EPID transit dosimetry in different clinical setting for safer 
radiotherapy. !  
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Chapter 1: General introduction 
 
1.1 Aim of radiotherapy 
 
The aim of radiotherapy is to deliver as much radiation dose as possible to a 
tumour site to kill cancerous cells, while limiting the damage to surrounding 
healthy tissues. This can be achieved: (1) biologically, through dose 
fractionation and (2) physically, through conformal treatment techniques.  
 
Dose fractionation refers to the delivery of a total therapeutic dose in smaller 
fractions over a protracted period of time. For example, instead of delivering 
the total prescribed dose of 70 Gy in one treatment session, 2 Gy is delivered 
daily for 35 sessions. The rationale of dose fractionation is based on the 
knowledge that early responding tissues (such as cancer cells) and late 
responding tissues (such as normal lung, kidney, heart, liver and other normal 
cells) possess different radiobiological properties (Orton, 2007). At lower doses, 
the repair of sub-lethal damage of normal cells exceeds that of cancer cells. 
Also, prolonging the overall treatment time optimally, allows early responding 
normal cells to repopulate and reduces acute side effects. At the same time, 
fractionation increases damage to cancer cells through reoxygenation and 
redistribution of cells into radiosensitive phases of the cell cycle between 
fractions. In short, the practice of dose fractionation maximises the killing of 
cancer cells while limiting the damage to surrounding healthy tissues.  
 
Meanwhile, conformal treatment techniques allow geometrical sparing of organs 
at risk and healthy tissues. Modern linear accelerators use the multi-leaf 
collimator (MLC) to shield part of the radiation field to limit the dose to organs 
at risk (OARs) and healthy tissues. These MLC leaves are controlled and moved 
independently to create a field of any shape. The automation of beam shaping 
with the MLC system makes it possible to incorporate a large number of beam 
shapes into a treatment plan. As a result, the MLC system enables the practical 
delivery of complex radiotherapy techniques such as intensity modulated 
radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). These 
treatment techniques are capable of delivering highly conformal dose 
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distributions with steep dose gradients that allow better sparing of adjacent 
healthy tissues. 
 
Although dose fractionation and conformal treatment techniques can possibly 
improve tumour control and reduce side effects, the treatment outcome 
depends on the ability to accurately deliver the treatment in a reproducible 
manner over many days or even weeks. The accuracy and reproducibility of 
treatment delivery is especially important for complex treatment techniques 
with steep dose gradients, where the margin of error is small and slight 
inaccuracy may lead to under-dosing of target and/or over-dosing of the OARs. 
Moreover, these complex treatment techniques require input from many 
different modalities and professionals and thus may create an environment with 
more potential for error.  
 
1.2 Errors in radiotherapy 
 
An error in radiotherapy is defined as:  
“… a non-conformance where there is an unintended divergence between a 
radiotherapy treatment delivered or a radiotherapy process followed and 
that defined as correct by local protocol.” (The Royal College of 
Radiologists et al., 2008) 
 
In an effort to improve the safety and quality of radiotherapy in the United 
Kingdom (UK), a voluntary National Reporting and Learning System (NRLS) is in 
place to encourage clinical departments and radiotherapy professionals to report 
radiotherapy error (RTE). The purpose of NRLS is to promote nationwide sharing 
of RTE so that the radiotherapy community can learn from these incidents and 
prevent future occurrence of similar errors. The Patient Safety in Radiotherapy 
Steering Group (PSRT) analyses RTEs in the NRLS database and publishes 
quarterly newsletter and biennial reports with recommendations and guidance 
on how to minimise the occurrence of common errors (Patient Safety in 
Radiotherapy Steering Group, 2010, 2012, 2014).  
 
During the period December 2011 to November 2013, a total of 7,655 RTE 
reports were recorded out of an estimated 413,730 radiotherapy sessions 
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delivered in the UK (Patient Safety in Radiotherapy Steering Group, 2014). 
Although the number of RTEs appears to be large, the majority of RTEs were 
lower-level incidents that have little or no critical effect on the patient 
treatments. Only 1.7% (n = 128) of the total RTEs were higher-level incidents 
(defined as dose error of 10% or more than that intended for a whole treatment 
course, or 20% or more than that intended for a given fraction). The risk of a 
radiotherapy error having a clinically significant adverse outcome was estimated 
at 30 per million courses of radiotherapy (The Royal College of Radiologists et 
al., 2008). Meanwhile the risk of death arising from radiotherapy error was 
estimated at two per million courses (Munro, 2007). Although the risk is small, 
the radiotherapy community must not be complacent. Ford et al. (2009) 
identified as many as 127 possible failures in the whole radiotherapy process. 
Therefore, it is important that systems are put in place to prevent the 
occurrence of error or to maximize the detection of error before any harm can 
be done.  
 
1.3 Quality assurance (QA) in radiotherapy 
 
QA in radiotherapy is: 
“… all procedures that ensure consistency of the medical prescription, and 
safe fulfilment of that prescription, as regards the dose to the target 
volume, together with minimal dose to normal tissue, minimal exposure of 
personnel and adequate patient monitoring aimed at determining the end 
result of the treatment.” (Thwaites et al., 2005) 
 
QA checks should be omnipresent in all stages of a radiotherapy process. The 
purpose of QA checks is twofold. First, QA checks improve safety in radiotherapy 
treatment through early detection of errors and prevent severe consequence 
that could affect the outcome of patients’ treatment. Second, QA checks can 
reduce uncertainties in each stage of the radiotherapy process and improves the 
overall treatment accuracy. The International Commission on Radiation Units 
and Measurements (ICRU) has recommended that the delivered dose must be 
within 5% of the prescribed dose (ICRU Report No. 24, 1976). To meet this 
requirement, the accuracy within each step of the radiotherapy process must be 
much better than 5% (Kutcher et al., 1994).  
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The role of QA checks becomes even more critical with the introduction of 
complex treatment techniques such as the IMRT and VMAT. The IMRT and VMAT 
treatments use inverse planning whereby an optimisation engine works to 
produce a treatment plan that best matches the criteria specified by the user. 
The number of monitor units (MU) for IMRT and VMAT plans are dependent on 
the optimal fluence distribution and plan modulation. Unlike the case of a 
conventional treatment, where MU is a straightforward function of beam output, 
field size and depth, the MU values for IMRT and VMAT fields are less intuitive 
and not easy to verify. Furthermore, the numbers of MU for IMRT and VMAT 
treatments are typically much higher than a conventional treatment. For 
example, the total MU for an IMRT treatment can be in the order of thousands, 
roughly five times higher than a conventional treatment for the same 
prescription dose. As a result, the correct delivery of treatment becomes 
critically important because an error in delivery may lead to catastrophic 
consequence or even death. This risk was clearly highlighted in the accident at 
St Vincent’s Medical Center in New York City, where a patient was irradiated 
with a large number of MU, which was planned for an IMRT technique but was 
delivered with an open field due to a corrupted MLC file (NYC Department of 
Health and Mental Hygiene, 2005, ICRP Publication 112, 2010).  
 
1.4 Patient-specific treatment verification 
 
An international review of major radiotherapy incidents over three decades 
(1976 to 2007) found that 45% of radiotherapy incidents occurred during the 
introduction of new systems and/or equipment (Shafiq et al., 2009). The high 
probability of an error occurring in a new technique combined with the high 
severity should an error occur, has prompted several international bodies to 
publish new QA guidelines when IMRT was first introduced for clinical application 
(Ezzell et al., 2003, Mijnheer & Georg, 2008, Moran et al., 2011). The main 
highlight of the IMRT guidelines is the recommendation to perform patient-
specific treatment verification. Patient-specific treatment verification refers to 
the validation of individual patient treatment as opposed to a more general 
system verification. Although patient-specific treatment verification is 
emphasized for IMRT treatment, it is applicable to all types of radiotherapy 
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treatment. There are many variations to the practice of patient-specific 
treatment verification such as the time of verification and the materials and 
methods used for the verification.  
 
1.4.1 Time of verification 
Patient-specific treatment verification can be performed prior to the start of 
treatment (pre-treatment QA), during the actual treatment or both.  
 
Pre-treatment QA is the common term used to describe the verification of an 
individual treatment plan before delivery to the patient. The advantage of pre-
treatment QA is that it allows the detection and rectification of an error before 
it can affect the patient treatment. This is especially important for high dose 
hypo-fractionation radiotherapy and radiosurgery, where an error in the first 
treatment fraction would be difficult or impossible to compensate. Pre-
treatment QA is effective in checking the integrity of data transfer, that the 
correct version of the plan was sent to the record and verify system and the 
deliverability of a treatment plan. However, there has been much debate on the 
value of pre-treatment QA (Ramsey et al., 2003, Smith et al., 2011). Despite the 
wide adoption of pre-treatment QA, roughly 30% of institutions evaluated by the 
Radiological Physics Centre (RPC) in an IMRT credentialing exercise failed to 
meet the 7% dose agreement and 4 mm distance-to-agreement criteria between 
measured and planned dose distribution (Ibbott et al., 2006, Ibbott et al., 2008). 
A retrospective analysis of RPC results from 2003 to 2013 (n = 745 plans) showed 
that institution pre-treatment QA was a poor indicator of delivery accuracy and 
could only detect 18% of plans that failed the RPC phantom evaluation (Kry et 
al., 2014). Also interesting is a study that found pre-treatment QA to be the 
least effective among all the common QA checks, detecting only 1.4% of the 
errors investigated (Ford et al., 2012).  
 
On the other hand, verification during the actual treatment delivery such as in-
vivo dosimetry can serve as an ultimate check to the accuracy of treatment 
delivered to the patient (ICRU Report No. 24, 1976). In addition to the errors 
that can be detected by pre-treatment QA, actual treatment verification can 
also detect patient positioning error, change in patient anatomy, obstruction 
from immobilisation devices or table arm and performance of machine on a 
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particular treatment day (van Elmpt et al., 2008a). Mans et al. (2010b) reported 
that nine out of the 17 serious errors detected in their in-vivo treatment 
verification would not have been detected with pre-treatment verification. 
However, in-vivo treatment verification is expensive, cumbersome and difficult 
to implement. For instance, the capital cost to start an in-vivo dosimetry 
program is estimated to be £6000 per linear accelerator with a subsequent 
annual revenue cost of £19000 (Williams & McKenzie, 2008). Furthermore, in-
vivo dosimetry can only detect an error after the treatment has been delivered.  
 
Therefore, the time of verification should be carefully considered, taking into 
account the risk of different treatment techniques and practical issues such as 
cost, additional machine time and other resources (Williams & McKenzie, 2008, 
Mackay & Williams, 2009). In addition, legal requirements of a country also 
determine when the patient-specific verification should be performed. For 
example, in-vivo dosimetry is legally required in some European countries such 
as France, Sweden, Denmark, Norway and the Czech Republic. 
  
1.4.2 Methods of verification 
There are various methods to perform patient-specific treatment verification.  
 
Firstly, treatment can be verified using either measurement- or software-based 
methods (Siochi et al., 2013). The measurement-based method refers to the 
type of verification where the dose is physically measured and compared against 
the expected dose, to check the accuracy of treatment delivery. On the 
contrary, software-based verification does not require the physical measurement 
of each treatment plan. Instead, an independent calculation is performed and 
verified against the dose computed by the treatment planning system (TPS). The 
input to the independent calculation system can be either field parameters 
exported from the TPS (Siochi et al., 2009) or machine treatment log files that 
contain delivery information such as the MLC position (Rangaraj et al., 2013). In 
recent years, software-based treatment verification of IMRT plans has gained 
popularity mainly because of the time saving factor. Besides being more 
efficient, the use of a software-based QA also helps physicists to make better 
judgements since errors in treatment planning and machine delivery can be 
segregated (Siochi et al., 2008). However, the use of software-based QA in place 
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of physical measurement is still debatable (Childress et al., 2015). For example, 
in the use of treatment log files for software-based QA, concerns were raised on 
the reliability of data recorded in the log files and the fact that this type of QA 
would not detect changes in dose parameters such as beam output, quality and 
profiles (Childress et al., 2015). Pawlicki et al. (2009) highlighted the need to 
perform an initial evaluation of consistency between the two methods using 
control charts before replacing measurement-based QA with software-based QA.  
 
Secondly, treatment verification can be performed for either a single point or 
multiple points, depending on the choice of detector or the capability of the 
software. Clearly, compared to multiple point verification, single point 
verification is inferior because of the lack of information at other areas in the 
treatment field. Furthermore, in the case of modulated field, it is often difficult 
to find a verification point that is located in a high-dose and low-gradient region 
so as to minimise the effect of positioning uncertainty. Instead of single point 
verification, a more efficient and effective method is to perform simultaneous 
verification of dose distributions in a 2D plane or 3D volume. The widely used 
method to evaluate the agreement between evaluated and referenced dose 
distributions is gamma analysis (Low et al., 1998). The gamma analysis 
calculates an index for each point based on the dose difference and distance-to-
agreement (DTA), as shown in Equation 1-1. A point with gamma index less than 
1 represents good agreement (γ≤1, pass) and a point with gamma index more 
than 1 represents disagreement exceeding the specified tolerances (γ>1, fail). 
The acceptance of a test depends on the number of points that passed the 
gamma analysis.  
 
Γ re,rr  = 
r2 re,rr
∆d2
 + δ
2 re,rr
∆D2
                                                                (1-1) 
 
Where:  
r re,rr  is the spatial distance between evaluated point (re) and reference 
point (rr); 
δ re,rr  is the dose difference between point re and point rr; 
∆d is the distance-to-agreement criterion; and 
∆D is the dose difference criterion. 
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Although the gamma analysis method provides a quick representation of the 
quality of agreement between two dose distributions, the region of failure is 
difficult to interpret and the clinical relevance remains unclear. This is mainly 
due to the fact that the gamma result does not provide information on the 
magnitude of disagreement and the location of disagreement relative to 
patient’s anatomy. Several investigators found a weak or no correlation between 
gamma passing rates and deviation in clinical dose volume histogram (DVH) 
metrics and concluded that gamma analysis lacks predictive power to detect 
clinically relevant differences (Nelms et al., 2011, Zhen et al., 2011, Carrasco et 
al., 2012, Stasi et al., 2012, Coleman & Skourou, 2013, Lin et al., 2014). Instead 
of verifying with gamma analysis, verification of anatomical doses based on DVH 
metrics using clinical tolerance would provide more information on the impact 
of delivery inaccuracy (McDermott et al., 2008, Oldham et al., 2012). 
 
Thirdly, patient-specific treatment verification can be analysed either field-by-
field or as a composite delivery. Verification of a composite delivery provides a 
more realistic representation of patient treatment but small differences may be 
masked because of normalisation to higher overall dose. On the other hand, 
field-by-field (or per-beam) verification may magnify irrelevant error in fields 
with low dose weighting (Carrasco et al., 2012). However, field-by-field analysis 
may help to indicate a problem in a particular field especially when 
troubleshooting a plan that failed the QA test.  
 
Finally, in the case of pre-treatment verification, there is a choice of either 
performing the QA in a homogeneous or heterogeneous phantom. Most 
commercial QA devices use homogenous phantoms with simple geometry, such 
as a cube or cylinder. Verification with a homogeneous phantom may not be 
adequate since it does not check for TPS inaccuracies in computing doses in the 
presence of inhomogeneity and the use of phantoms with simple geometry does 
not correctly represent the human body. The use of anthropomorphic phantoms 
with humanoid external shape and organs that mimic the human body (Molineu 
et al., 2005) would allow a more comprehensive evaluation of the treatment 
accuracy.  Apart from the choice of phantoms, pre-treatment verification can 
also be performed using either variable treatment gantry angles or a fixed 
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gantry angle of zero degrees. For measurement-based QA, collapsing all gantry 
angles to zero saves delivery time. In addition, by measuring all beams 
perpendicular to the detectors, no correction is required for detectors that show 
angular dependence. However, irradiation with the gantry at zero degrees 
neglect the effect of gravity on different mechanical parts such as the MLC 
leaves positions and the accuracy of gantry angles.  
 
In summary, it is important to have a thorough understanding of the strengths 
and weaknesses of a particular practice. The method adopted by a department 
should depend on the perceived risk of a certain treatment technique and the 
availability of equipment and manpower. The practice of patient-specific 
treatment verification should be reviewed and updated from time to time as 
technology evolves and risk changes. As a rule of thumb, more vigorous checks 
should be put in place for new techniques to ensure safe implementation. The 
frequency of checks can be reduced and the methods simplified as experience 
and confidences in a treatment technique are gained.        
 
1.5 Types of detectors  
 
Measurement-based patient-specific treatment verification can be performed 
using different types of detectors such as ionisation chamber (IC), diode, metal 
oxide semiconductor field effect transistor (MOSFET), thermoluminescent 
detector (TLD), optically stimulated luminescence detector (OSLD), radiographic 
film, radiochromic film and electronic portal imaging device (EPID). The 
principle of operation and characteristics for each of the detectors are described 
in the following section. An overview of these detectors is provided in Table 1-1. 
Gel dosimeter and alanine are excluded since they are not commonly used for 
routine patient-specific treatment verification. 
 
1.5.1 Ionisation chamber (IC) 
Principle of operation 
The IC consists of an air filled sensitive volume with three electrodes: polarizing 
electrode, collecting electrode and guard electrode. Exposure to radiation 
produces ion pairs in the air cavity. The ionisation charge is collected by the 
collecting electrode, which is held at high bias voltage, and measured by an 
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electrometer. The measured charge is converted to absorbed dose to water 
using a calibration factor (ND,W,Qo) traceable to a Primary Standard Dosimetry 
Laboratory (PSDL). 
 
Characteristics 
The IC is used to measure absolute dose output and is considered the gold 
standard in radiation dosimetry because of its high accuracy. The overall 
standard uncertainty for the determination of absorbed dose to water under 
reference conditions is estimated to be only 1.5% (IAEA Technical Reports Series 
No. 398, 2000). The other advantages of ICs include excellent long-term 
stability, good reproducibility, linear response to dose, small angular 
dependence for cylindrical IC and immediate dose-readout. Although the IC is 
affected by changes in environmental temperature and pressure, ion 
recombination and polarity effect, the correction factors are straightforward 
and well established (IAEA Technical Reports Series No. 398, 2000, Khan, 2010c).  
 
For patient-specific treatment verification, the IC is used to perform pre-
treatment QA measurement. A cylindrical IC is inserted into a phantom to 
measure absolute point dose for comparison with the TPS computed dose. The 
main issue with using an IC to measure modulated fields is the finite size of the 
chamber. Using an IC to measure IMRT subfields smaller than the chamber 
dimension may be inaccurate due to the lack of charged particle equilibrium. 
Therefore, as a general rule, an IC with small volume (0.125 cc or less) should be 
used for IMRT pre-treatment QA measurement (Laub & Wong, 2003, Sánchez-
Doblado et al., 2007). Besides chamber volume, the positioning of the IC also 
plays an important role in minimising uncertainties; it must be positioned in a 
low-gradient region to avoid any fluence-averaging perturbation effect. Using a 
small volume IC (0.007 cc), Capote et al. (2004) found that the dose measured 
within the IMRT subfield could be accurate to within 3%, but 9% deviation was 
observed at the penumbra region.  
 
Alternatively, patient-specific pre-treatment QA can be verified in 2D using an 
array of ICs. Commercially available IC-based 2D array devices include MatriXX 
(IBA Dosimetry GmbH, Schwarzenbruck, Germany) and Octavius (PTW, Freiburg, 
Germany). Typically, the device consists of more than 1000 small volume ICs 
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(0.06 cc to 0.08 cc) embedded in a phantom of different dimensions. Although 
the problem with chamber positioning encountered for single point 
measurement is not applicable to a 2D array device, the poor resolution of a 2D 
array (around 0.7 cm) is still considered not ideal for IMRT/VMAT measurements. 
The other disadvantage of 2D array devices is the limited active area (usually 
less than 27 x 27 cm2) that constrains the maximum field size that can be 
measured. It is also crucial to keep the measurement field size within the 
recommended limit to avoid direct exposure of the electronics, which are prone 
to radiation damage. Nevertheless, the 2D array device remains very popular 
because it is easy to use and provides a relatively efficient method to perform 
patient-specific treatment verification. 
 
1.5.2 Diode 
Principle of operation 
Diode detectors are made of silicon crystal doped with impurities to create p-
type silicon (an electron receptor that contains ‘holes’) and n-type silicon (an 
electron donor). An example of the type of diode detector used in radiotherapy 
is a p-n junction diode, where a bulk of p-type silicon is mixed with a thin layer 
of n-type material to create a junction. This junction, also known as depletion 
zone, is the sensitive volume of the detector. When irradiated, electron-hole 
pairs are created in the depletion zone. The movement of electrons and holes 
across the depletion zone to the p- and n-regions produces a measurable current 
proportional to the incident radiation.     
 
Characteristics 
The main advantage of the diode detector compared to an IC is the high 
sensitivity. The energy needed to produce an electron-hole pair in silicon is 
almost 10 times less than that needed to produce an ion pair in air. Moreover, 
the silicon has a density 1,800 times higher than air. Combining both factors, the 
relative efficiency per unit volume for a diode detector is 18,000 times higher 
than the IC (Khan, 2010c). The high efficiency makes it possible for diode 
detectors to be small in size. Besides the good spatial resolution, the diode is 
also a very reliable detector, with a reproducibility of better than 1% (IAEA 
Human Health Reports No. 8, 2013) and an excellent linear response with dose 
(Jornet et al., 2004). Other advantages of the diode detector include ruggedness 
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and real-time dose readout, making it a suitable detector for in-vivo dose 
measurement.  
 
However, a diode detector shows energy, angular, temperature and dose per 
pulse dependence (Mijnheer et al., 2013). The energy dependence is because of 
the high atomic number of silicon (z = 14) that causes over-response to low 
energy radiation. The response of a diode detector to 48 keV photons was 7.7 
times more than at 6 MV (Edwards et al., 1997). Adding a build up cap to absorb 
low energy radiation can mitigate the energy dependence of the diode but the 
build up cap could perturb the dose to patient. Depending on the beam energy, 
field size and the type of diode, the presence of a build up cap could increase 
the patient’s surface dose by 50% to 90% and decrease the dose at depth by 4% 
to 13% (Nilsson et al., 1988, Alecu et al., 1997). Meanwhile, the angular 
dependence of a diode can affect the detector response by 10% to 15% (Nilsson 
et al., 1988, Seco et al., 2014) and the variation in temperature can cause 0.1% 
to 0.3% deviation in response per degree Celsius (°C) (Lanson et al., 1999, 
Jornet et al., 2004, Seco et al., 2014). As for the dose-per-pulse dependence, 
Saini & Zhu (2004) varied the source to detector distance and found sensitivity 
variation of around 1% to 3% for most of the commercial diode detectors 
investigated in the study.  Before a diode detector can be used for in-vivo dose 
measurement, it must be cross-calibrated against an IC according to beam 
energies and preferably as close to the clinical set-up as possible. Additional 
correction factors must be derived to account for non-reference conditions 
during actual patient measurement such as difference in field size, distance 
from source, angle of incidence and the presence of wedge. Although the diode 
detector has a very long lifespan, it must be routinely re-calibrated to account 
for reduction in diode sensitivity due to radiation damage. Typically, the diode 
sensitivity is reduced by about 0.7% for every kGy of radiation (Lanson et al., 
1999). 
 
Besides in-vivo dosimetry, diodes are also used as detectors for 2D array pre-
treatment QA devices. Examples of commercially available diode-based 2D array 
device include ArcCHECK (Sun Nuclear, Melbourne, FL, USA) and Delta4 
(ScandiDos AB, Uppsala, Sweden). Similar to IC-based 2D array devices, a large 
number of diode detectors (>1000) are embedded in the phantom in different 
! 13!
configurations. Although the diode detector is small in size, the spacing between 
detectors in the phantom is large, resulting in poor resolution (0.5 cm to 1 cm). 
While the characteristics of diode detectors in a 2D array are similar to those 
described in the previous paragraph for a single detector, the number of 
correction factors that must be derived by the user is greatly simplified mainly 
because of automated correction by the software and also because of less 
variation in pre-treatment set-up compared to in-vivo measurement. Depending 
on the frequency of use, it is still necessary to re-calibrate the diode-based 2D 
array periodically due to reduction in diode sensitivity with irradiation. Overall, 
the diode-based 2D array device is still relatively easy to use and provides an 
efficient way to perform pre-treatment verification in more than one dimension. 
 
1.5.3 Metal oxide semiconductor field effect transistor (MOSFET) 
Principle of operation 
The MOSFET is a semiconductor detector, which consists of a silicon substrate 
and three terminals: ‘source’, ‘drain’ and ‘gate’. In a p-channel MOSFET, the 
main substrate is composed of n-type silicon and two p-type regions. The space 
between the two p-type regions is known as the p-channel and above this 
channel is an insulating layer of silicon dioxide (SiO2) with the ‘gate’ terminal. 
Without voltage to the ‘gate’ terminal, the p-channel is not conductive and 
current cannot flow between the ‘source’ and ‘drain’ terminals located above 
the two p-type regions. Threshold voltage (VTH) is the amount of voltage needed 
to allow current, IDS, to flow. When a MOSFET is irradiated, the charge 
generated in the oxide layer is permanently trapped and causes the VTH to 
increase linearly as a function of absorbed dose. The principle of MOSFET is 
based on measuring the change in VTH to derive the amount of absorbed dose.  
 
Characteristics 
Similar to the diode, MOSFET has the advantages of real-time readout, high 
sensitivity and small size. In fact, the size of a micro MOSFET is only 1 mm x 1 
mm x 3.5 mm, allowing excellent spatial resolution and less dose perturbation 
when used for in-vivo dosimetry. The MOSFET also showed excellent linear 
response to dose (Jornet et al., 2004). Meanwhile, the temperature and angular 
response of MOSFET detector varies with its design. A single-detector MOSFET 
system showed strong temperature dependence of as high as 50 mV for a 25°C 
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change in temperature during the readout process (2 mV/°C) (Cheung et al., 
2004) but a double-detector MOSFET system showed negligible temperature 
dependence of around 0.02 mV/°C (Soubra et al., 1994) or 0.5% response 
deviation from 20°C to 40°C (Ramaseshan et al., 2004). The findings on MOSFET 
angular dependence vary substantially between authors from 2% (Ramaseshan et 
al., 2004, Rowbottom & Jaffray, 2004, IAEA Human Health Reports No. 8, 2013) 
to 12% (Lonsdale, 2012) to 27% (Scalchi et al., 2005). The variation in reported 
angular dependence could be due to differences in the thickness of silicon 
dioxide layer and the shape of the detector.  
 
Also, as with diodes, a MOSFET detector exhibits over-response to low energy 
radiation because of the high atomic number of silicon and silicon oxide. The 
response of MOSFET was 4.4 times higher for 33 keV photons compared to 6 MV 
photons (Edwards et al., 1997). Compared to a diode, the reproducibility of 
MOSFET detector was lower at 2% to 3% (Soubra et al., 1994, Ramaseshan et al., 
2004, Scalchi et al., 2005). Lastly, the main disadvantage of the MOSFET 
detector is the short lifespan. Although the MOSFET sensitivity did not change 
with accumulated dose, the detector can no longer be used after approximately 
50 Gy (Jornet et al., 2004). This is because the permanent trapping of charge 
will saturate the traps after accumulating a certain amount of dose.  
 
1.5.4 Thermoluminescent detector (TLD) 
Principle of operation 
A TLD is made of crystalline material that is doped with impurities to create 
traps in the lattice structure. Electrons that are produced during irradiation can 
fall into these traps to create a metastable state. When heated, these trapped 
electrons are released and visible light is produced, a process known as 
thermoluminescence. A photomultiplier (PMT) then converts the visible light to 
electrical current and the amplified current can be related to absorbed dose 
received by the material.  
 
Characteristics 
The most common type of TLD for clinical dosimetry is made of doped lithium 
fluoride (LiF). The TLD can come in many different forms (such as powder or 
solid) and shapes (such as chips, rods or pellets), making it a very adaptable 
! 15!
dosimeter for in-vivo dose measurement in various situations. Furthermore, the 
TLD is easy to use because it is not attached to any cables and bias voltage is not 
needed for its operation. Similar to semiconductor dosimeters, TLD has high 
sensitivity and is small in size. But unlike diodes, TLD has small temperature and 
angular dependence (Essers & Mijnheer, 1999, IAEA Human Health Reports No. 8, 
2013, Mijnheer et al., 2013). As TLD is almost tissue equivalent, the over-
response to low energy radiation (33 keV) was only 1.31 times more than to 6 MV 
photons (Edwards et al., 1997). 
 
The major disadvantage of TLD is the requirement for time consuming pre- and 
post-processing and consequently, delayed dose results. A typical TLD processing 
involves annealing the TLD for 1 hour at 400°C and then cooling it for 24 hours 
at 80°C, although the procedure may vary with manufacturer. The processing of 
TLD must be carried out carefully and consistently to get accurate and 
reproducible results. Generally, the reproducibility of TLD was around 2% (IAEA 
Human Health Reports No. 8, 2013), about 1% to 2% worse than diode detectors 
(Loncol et al., 1996). The poorer reproducibility of TLD was attributed to the 
deviation in the crystal and impurities concentration as well as other 
uncertainties related to the PMT, annealing and readout procedures (Loncol et 
al., 1996). Lastly, the TLD response is only linear to dose up to 1 Gy for LiF 
doped with magnesium and titanium (LiF:Mg,Ti) and 10 Gy for LiF doped with 
phosphorus, magnesium and copper (LiF:Mg,Cu,P). Above the dose threshold, 
the TLD response is supralinear and may cause deviation up to 9% if uncorrected 
(IAEA Human Health Reports No. 8, 2013).  
 
1.5.5 Optically stimulated luminescence detector (OSLD) 
Principle of operation 
An OSLD is made of aluminium oxide doped with carbon (Al2O3:C). The principle 
of OSLD is very similar to TLD except that light, instead of heat, is used to 
stimulate the release of trapped electrons. To discriminate the stimulation light 
from the resultant light produced by the released electrons, the wavelength of 
the stimulation light must be different from the resultant light. In addition, an 
optical filter is placed in front of the PMT to selectively absorb and prevent 
stimulation light from reaching the counter. 
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Characteristics 
OSLD is used for in-vivo dosimetry and shares many of the TLD advantages such 
as high sensitivity, small detector size, no cables and does not require bias 
voltage. The characteristics of OSLD are also rather comparable to TLD with 
small angular and temperature dependence. The angular dependence for OSLD 
was 3% to 4% (Kerns et al., 2011) and the variation in response was less than 1% 
when temperature was varied from 21°C to 36°C (Yukihara et al., 2008). Even 
though the OSLD requires processing, the readout process is much faster than 
TLD and the OSLD response was found to stabilise at 8 minutes post-irradiation 
(Reft, 2009). The ability to re-read the OSLD signal is also an added advantage. 
With careful and consistent processing, the reproducibility of OSLD results was 
reported to be 1.5% (IAEA Human Health Reports No. 8, 2013).  
 
The main disadvantage of OSLD is its change in reproducibility and sensitivity 
with accumulated dose, resulting in a short lifespan. The OSLD dose response 
was observed to be linear up to 2 Gy and supralinear above 2 Gy (Reft, 2009) but 
this dose response relationship altered with historical dose (Jursinic, 2010). The 
change in response with historically accumulated dose is due to the 
ineffectiveness of optical bleaching in emptying electrons in deeper energy traps 
and causes residual signal to build up with repeated use. The IAEA Human Health 
Reports No. 8 (2013) observed substantial changes in OSLD sensitivity and 
reproducibility and advised against using the OSLD without optical bleaching 
after an accumulated dose of 2.5 Gy to 3 Gy. Because of the higher atomic 
number of aluminium oxide (z = 11.2), the OSLD response was 3.6 times higher 
for 35 keV photons compared to 6 MV photons (Reft, 2009).  
 
1.5.6 Radiographic Film 
Principle of operation 
Radiographic film consists of a transparent plastic coated on one or both sides 
with radiation sensitive emulsion containing crystals of silver bromide (AgBr). A 
chemical reaction takes place when the film is exposed to radiation and a latent 
image is formed. Through processing, the AgBr crystals affected by radiation are 
reduced to metallic silver. Subsequently, the remaining unaffected crystals are 
removed through fixing. The degree of darkening of a film, or optical density 
(OD), depends on the amount of deposited silver and is a function of absorbed 
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dose. The conversion of OD to dose is done through the sensitometric curve, 
which is a plot of OD versus dose.  
 
Characteristics 
Radiographic film is used for patient-specific pre-treatment QA. The main 
advantage of radiographic film is the 2D spatial information with excellent 
resolution. However, there are many challenges in using radiographic film for 
dose measurement. First, the relationship between OD and dose may not be 
linear and is dependent on the film emulsion. In addition, the film response is 
very sensitive to variation in developer chemistry composition, temperature and 
processing time. Childress et al. (2002) observed a 7.5% standard deviation due 
to variation in processor conditions. Therefore, it is important to establish the 
sensitometric curve for each batch of film and to process the subsequent films 
carefully and consistently following the exact conditions used during calibration 
to minimise uncertainties (Pai et al., 2007). By following a strict protocol, the 
reproducibility of radiographic film is estimated to be better than 2% (Mijnheer 
et al., 2013).  
 
The main disadvantage of radiographic film is the substantial energy dependence 
because of the high atomic number of silver (z = 45) in the film emulsion. The 
radiographic film exhibits over-response at large field size and depths due to the 
increased proportion of low energy scattered photons. Reports on the extent of 
film energy dependence vary between different authors, ranging from less than 
3% (Martens et al., 2002) to up to 9% (Yeo et al., 2004) outside the penumbra 
region of IMRT fields where the low energy photons are abundant. The 
discrepancies in results from different studies was later attributed to variation 
in phantom material and dimension (Palm & LoSasso, 2005). Also, the 
radiographic film response is dependent on the film plane orientation with 
respect to the beam direction. The sensitivity of film was found to be greater 
when the radiographic film was positioned perpendicular rather than parallel to 
the beam axis (Oldham & Webb, 1997). Danciu et al. (2001) reported a maximum 
of 4% to 6% increase in response for films positioned perpendicular to beam axis 
and became negligible at depth more than 5 cm. For small fields with diameter 
less than 4 cm, the angular dependence of film was less at 1.5% (Robar & Clark, 
1999). The other drawback of radiographic film is the limited dynamic range. For 
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instance, the commonly used XV2 film (Eastman Kodak, Rochester, NY, USA) is 
only suitable for dose measurement within 0.05 Gy to 0.8 Gy. Irradiation with 
doses below this range will be obscured by background density while above this 
range the film saturates. The dynamic range has been extended in later versions 
of radiographic film such as the Kodak EDR2 (Eastman Kodak, Rochester, NY, 
USA), with a useful range of 0.1 Gy to 5 Gy. 
 
1.5.7 Radiochromic film 
Principle of operation 
Radiochromic film has one or two thin radiosensitive layer(s) on clear polyester 
base(s). The radiosensitive layer, consisting of microcrystals of a monomer 
dispersed in gelatin binder, undergoes polymerisation when irradiated with 
ionising radiation (Niroomand-Rad et al., 1998). The polymerisation causes the 
film to progressively change colour to different shades of blue. The darkness of 
the film is proportional to absorbed dose and can be measured as OD using a 
commercial flatbed document scanner in transmission mode (Devic et al., 2005, 
Paelinck et al., 2007). The absorbed dose can then be derived from the OD using 
the sensitometric curve.  
 
Characteristics 
Radiochromic film is also used for patient-specific pre-treatment QA but it has 
many advantages over radiographic film such as insensitivity to visible light and 
does not require tedious chemical processing. Also, radiochromic film has a 
larger dynamic range suitable for verification of a wide range of megavoltage 
treatments (e.g. GafChromic EBT2 film (Ashland, Covington, KY, USA) has a 
dynamic range of 0.01 Gy to 40 Gy). The major advantage of radiochromic film is 
the near tissue equivalence of the sensitive layer that leads to low energy 
dependence (Arjomandy et al., 2010, Borca et al., 2013). This is an important 
characteristic that eliminates some of the uncertainties seen with radiographic 
film.  
 
One of the disadvantages of radiochromic film that is similar to radiographic film 
is the large inter-batch variation in sensitivity up to 13.7% (Reinhardt et al., 
2012). This requires the re-establishment of sensitometric curve for each batch 
of film, resulting in extra workload. Although radiochromic film does not involve 
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processing due to its self-developing nature, the read-out process still requires 
careful handling and strict adherence to standardised protocol. Factors such as 
time of scan, scanner warm up, scan orientation and film position can affect the 
accuracy of results. Because the radiochromic film continues to polymerise post-
irradiation, a consistent wait-time of at least 24 hours (preferably 48 hours) is 
needed (Niroomand-Rad et al., 1998, Arjomandy et al., 2010, Reinhardt et al., 
2012) delaying the availability of results. Meanwhile, the OD reading is also 
sensitive to film orientation due to the polarization effect of the scanner light. 
Depending on the scanner and dose, the OD scanned with landscape orientation 
could be 4% higher than portrait (Butson et al., 2006, Borca et al., 2013) and the 
error due to misalignment of film on scanner bed could be as much as 1% per 
degree of rotation (Butson et al., 2009). So, it is crucial that the film is 
consistently placed on the scanner, possibly with the help of a template. 
 
The other disadvantage of radiochromic film is the additional requirement to 
correct for non-uniformity of film and scan field (Zhu et al., 1997, Paelinck et 
al., 2007). The non-uniform film response and scan field could be up to 3.7% 
(Hartmann et al., 2010) and 8% (Paelinck et al., 2007) respectively, depending 
on the film and scanner model. Furthermore, the read-out process also showed 
temperature dependence and requires proper warm-up of the scanner to reduce 
uncertainty (Paelinck et al., 2007, Buchauer et al., 2009). Additional steps to 
improve read-out accuracy were explicitly described by Devic et al. (2005) that 
included taking an average of five successive scans of non-irradiated and 
irradiated film to reduce noise, scans of empty scanner bed to remove defective 
pixels and an additional scan of an opaque film to account for scanner 
background signal. Only by following a strict read-out protocol consistent with 
calibration, the reproducibility of radiochromic film dosimetry could be kept to 
within 2% (Devic et al., 2005) to 3% (Mijnheer et al., 2013).  
 
1.5.8 Electronic portal imaging device (EPID) 
The electronic portal imaging device (EPID) was first invented to replace film for 
positional verification in radiotherapy. In general, the EPID is advantageous 
because it provides immediate 2D high-resolution digital images without the 
need of manual processing. The EPID is particularly attractive for dose 
measurement because the panel is readily available as an attachment to most 
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linear accelerators (linacs) and the measurement requires only minimal set-up. 
Most importantly, the EPID can potentially be used for both pre-treatment and 
actual treatment dose verification.  
 
1.5.8.1 Scanning liquid-filled ionisation chamber (SLIC) EPID 
Principle of operation 
The earliest EPID model was a scanning liquid-filled ionisation chamber (SLIC) 
EPID. A prototype SLIC EPID was developed at The Netherlands Cancer Institute, 
Amsterdam (Meertens et al., 1985, Van Herk & Meertens, 1988) and was later 
commercialised as PortalVision (Varian, Palo Alto, CA, USA). The PortalVision 
ionisation chamber matrix is constructed from a layer of Isooctane liquid (the 
active volume) sandwiched between two electrode printed circuit boards. Each 
printed circuit board has 256 parallel electrode strips and the strips are arranged 
perpendicular to each other between the two boards. The cross-points of the 
electrode strips form the 256 x 256 matrix detector. A simplified diagram of the 
SLIC EPID is illustrated in Figure 1-1. With an active area of 32.5 x 32.5 cm2, the 
corresponding detector resolution is 0.13 x 0.13 cm2. Apart from the detector 
matrix, the EPID panel also consists of a 256-channel high voltage switch, 256-
channel electrometer and other control electronics. To form one image frame, 
high voltage is applied sequentially row-by-row across the matrix. During the 
time when voltage is applied, the multi-channel electrometer scans the 
activated row to measure the charge of each ionisation chamber simultaneously. 
The acquisition time for one full-frame varies between 1.5 s and 6 s (Boyer et 
al., 1992, Essers et al., 1995). The measured charge (or pixel value) has been 
found to be proportional to the square root of the dose rate (Van Herk, 1991, 
Zhu et al., 1995, Parsaei et al., 1998), with a small correction term linear to the 
dose rate (Essers et al., 1995, Boellaard et al., 1996). Using a calibration curve, 
an image represented in pixel value can be converted to a 2D dose rate matrix. 
Subsequently, the dose rate matrix is multiplied by the time interval or MU for 
that image to form a 2D dose matrix. Finally, multiple 2D dose matrices are 
summed to give an integrated dose matrix.   
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Figure 1-1 A simplified illustration of a scanning liquid-filled ionisation 
chamber (SLIC) EPID. 
 
Characteristics 
As a dosimeter, the SLIC EPID has the advantage of good short- and long-term 
stability with variation less than 1% (Essers et al., 1995, Zhu et al., 1995). More 
importantly, the SLIC EPID exhibited tissue equivalent response with minimal 
energy dependence (Curtin-Savard & Podgorsak, 1999). The response was 
consistent regardless of field size (Parsaei et al., 1998) and comparable to IC 
measurements to within 0.5% (Zhu et al., 1995). The main disadvantage of the 
SLIC EPID is the relatively long acquisition time (or dead time where signal is 
lost), which resulted in poor detector efficiency. Using a commercial SLIC EPID 
with a standard mode, the acquisition of one image frame including storage can 
take up to 9 s (5.5 s to read-out and 3.5 s to store the image) (Chang et al., 
2000). When measuring a dynamic IMRT delivery with continuous MLC 
movements, it is important that leaf motion is small during the sampling time 
between image frames in order to correctly measure a continuous data. Because 
of the slow sampling of SLIC EPID, Chang et al. (2000) deliberately reduced the 
speed of MLC movements by increasing the MU nearly nine-fold from the original 
prescription, thus restricting the application to only pre-treatment verification. 
Although the acquisition rate was improved in a later version of the commercial 
SLIC EPID, the detector was slow in returning to equilibrium state and caused a 
change in response (or memory effect) when continuously irradiated and 
sampled at a fast speed of 1 s/image (Chang et al., 2003). To minimise variation 
due to memory effect, Curtin-Savard & Podgorsak (1999) employed a 1 min per 
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segment wait-time for a step-and-shoot IMRT verification and as a result, the 
delivery time for an IMRT field with 88 segments took 1.5 h. The other problem 
with SLIC EPID dosimetry is the effect of beam hold-off during a dynamic IMRT 
delivery, where the linac beam pauses while MLC leaves move to position (Chang 
et al., 2003). Because the SLIC EPID measures in dose rate, the inappropriate 
increase in delivery time would result in inaccurate dose conversion. The other 
factor that may affect SLIC EPID dosimetric accuracy is the variation in local 
detector response with different gantry angles. This gantry-dependent sensitivity 
variation, also known as the bulging effect, is caused by the non-uniform 
pressure distribution in the liquid layer due to gravity (Yin et al., 1994) and can 
amount to about 3% deviation if uncorrected (Van Esch et al., 2001). 
 
1.5.8.2 Charge-coupled device camera-based (CCD) EPID 
Principle of operation 
Another earlier model of EPID is the camera-based (CCD) EPID. This type of EPID 
comprises a fluorescent screen, mirror(s) and a CCD-based camera (Figure 1-2). 
The fluorescent screen, which consists of a steel plate coated with a phosphor 
layer (gadolinium oxysulphide, Gd2O2S:Tb), converts radiation to visible photons. 
The visible photons are reflected via mirror(s) and imaged by the CCD-based 
camera. The mirror allows the camera to be positioned away from direct 
radiation exposure that could damage the CCD chip. A prototype CCD EPID was 
described by Visser et al. (1990) and was later commercialised as SRI-100 (Philips 
Medical Systems, Best, The Netherlands). The SRI-100 CCD EPID has a fluorescent 
screen that is 40 x 30 cm2 in size, a CCD camera with 512 x 256 pixels and 
consequently a detector resolution of 0.08 x 0.12 cm2. Other commercially 
available CCD EPID includes Beamview Plus (Siemens, Concord, CA, USA) and 
TheraView (Cablon Medical, Leusden, The Netherlands).  
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Figure 1-2 A simplified illustration of a charge-coupled device camera-based 
(CCD) EPID. 
 
Characteristics 
Unlike SLIC EPID, CCD EPID does not require row-by-row scanning of the detector 
matrix. Instead, signals for the whole matrix are detected simultaneously, 
resulting in a fast image acquisition. The image acquisition for CCD EPID involves 
the following steps. First, signals are accumulated in the CCD chip for a pre-set 
amount of time (typically ranging from 0.24 s to 1 s). Then, the accumulated 
signal is transferred from the CCD chip to the frame grabber to form one image 
frame. Although no signal is measured during this transfer, the dead time is 
negligible at only 0.0002 s for newer models of CCD EPID (Franken et al., 2004). 
The final image is formed by the accumulation of multiple image frames in the 
frame processor. For dosimetry purposes, the number of accumulated image 
frames is dependent on the irradiation time and is calculated to capture the 
whole delivery. As an example, if the irradiation time for a treatment field is 30 
s and the accumulating time for one frame is set to 0.24 s, then a total of at 
least 125 frames are needed to capture the complete delivery.    
 
Besides fast acquisition, the CCD EPID also showed good stability with less than 
1% variation in its short- and long-term response (Dirkx, 1995, Heijmen et al., 
1995, De Boer et al., 2000, Franken et al., 2004). The CCD EPID response was 
also found to be independent of gantry angle (De Boer et al., 2000). As for the 
dose-response relationship, the CCD EPID showed linear response to dose (Dirkx, 
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1995, Heijmen et al., 1995, De Boer et al., 2000) but non-linearity was observed 
for certain EPID models when the EPID dose (or pixel value) was high (Pasma et 
al., 1998, Franken et al., 2004). The under-response at high dose was mainly 
attributed to out-dated electronics (Pasma et al., 1998) and was not observed 
for a modified CCD EPID investigated by the same group of researchers (De Boer 
et al., 2000). The other advantage of the CCD EPID is the energy independence. 
Although the fluorescent layer is not water-equivalent, the CCD EPID response 
was not affected by changes in energy spectrum when phantoms of different 
thicknesses were placed in the beam (Heijmen et al., 1995, Pasma et al., 1998). 
 
The general weakness of CCD EPID is the low collection efficiency, with only 
0.01% to 0.1% of the total light emitted by the phosphor layer reaching the 
camera (Herman et al., 2001). In fact, the poor efficiency of system is one of 
the main reasons that both SLIC and CCD EPIDs are now obsolete. For dosimetry 
purposes, the main disadvantage of CCD EPID is the presence of light scattering 
that requires complicated correction. The light scattering, commonly referred to 
as glare or cross-talk, occurs when a photon incident on a point in the 
fluorescent layer emits visible light that gets reflected by the mirror not only 
directly towards the camera but also back to another point on the fluorescent 
layer. In the second scenario, the light then scatters off the fluorescent layer 
again and is reflected by the mirror towards the camera and detected as an 
additional signal (Heijmen et al., 1995, Partridge et al., 1999). The increase in 
signal due to multiple light scattering is dependent on field size and can reach 
up to 20% of the primary signal (Partridge et al., 1999). Partridge et al. (1999) 
proposed the use of an anti-scatter grid placed in contact with the fluorescent 
screen to remove light scattering. Although the anti-scatter grid successfully 
reduced the light scattering to less than 2%, the method involves in-house 
modification of a commercial CCD EPID and causes a uniform 25% reduction in 
overall signal. Alternatively, the measured EPID signal can be de-convolved with 
a cross-talk kernel derived from a set of on-axis measurements with different 
square fields (Heijmen et al., 1995, Pasma et al., 1998). Because the cross-talk 
effect is dependent on position, a more extensive correction method was 
demonstrated by Franken et al. (2006) using a database of 64 x 64 kernels 
measured at different positions on the EPID.  
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1.5.8.3 Amorphous-silicon (a-Si) EPID 
Principle of operation 
Currently, the most widely used EPID model is the indirect detection flat panel 
amorphous silicon (a-Si) EPID. This type of a-Si EPID consists of a copper plate, a 
fluorescent layer and a photodiode system (Figure 1-3). The functions of the 
copper plate are to produce electrons from incident photons to improve 
detective quantum efficiency and to absorb low energy scattered radiation that 
reduces image contrast. For an indirect detection flat panel, an additional 
fluorescent layer with gadolinium oxysulphide (Gd2O2S:Tb) phosphor is used to 
convert incident radiation into visible light. Underneath the fluorescent layer is 
the photodiode system comprising an array of photodiodes coupled to thin-film 
transistors (TFT) embedded on an amorphous-silicon panel. The photodiode 
absorbs visible light and integrates the resulting charge while the TFT acts as a 
switch for the row-by-row read-out process. The read-out, amplification and 
digitisation of signals are controlled by acquisition electronics. A prototype a-Si 
EPID was first described by Antonuk et al. (1995) and Antonuk et al. (1998) and 
it has since become the most popular megavoltage imaging system provided by 
major linac manufacturers. Examples of commercially available a-Si EPIDs are 
iViewGT (Elekta, Stockholm, Sweden), aS500/aS1000 (Varian, Palo Alto, CA, 
USA) and OptiVue 500/1000ST (Siemens, Concord, CA, USA). 
 
 
Figure 1-3 A simplified illustration of an amorphous-silicon (a-Si) EPID. A-Si 
EPID (right) and a cross-sectional view of a detector pixel (left).  
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Characteristics 
The a-Si EPID has the advantage of being compact in size, superior in detector 
resolution (as small as 0.04 cm) and is capable of fast image acquisition 
(typically about 0.3 s/frame). Also, the response of a-Si EPID is found to be 
stable over time, implying that the detector does not require frequent re-
calibration for dosimetry purpose. In general, the response of a-Si EPIDs varied 
by less than 1% to 2% over a 12 months period (Van Esch et al., 2004, Winkler & 
Georg, 2006) and did not show any dependence on gantry angle (Kavuma et al., 
2008).  
 
Furthermore, the dose-response relationship of a-Si EPID is fairly linear which 
simplifies the conversion of EPID signal (or pixel value) to dose. The linearity of 
dose response was within 2% from 30 MU to 1000 MU (Winkler et al., 2005, 
Kavuma et al., 2008) but under-response ranging from 5% to 7% was detected at 
lower MU (McDermott et al., 2004, Winkler et al., 2005, Kavuma et al., 2008). 
The trend of under-response at low MU is common to most commercial a-Si EPIDs 
(McDermott et al., 2006a) and is due to lower sensitivity at the beginning of 
acquisition. The effect is more pronounced for low MU irradiation because of 
larger relative contribution of deficit in the early acquisition and becomes less 
prominent as the total dose increases. The lower response at the start of 
acquisition can mainly be attributed to charge trapping in the photodiodes that 
causes delay in charge read-out and also an alteration in the electric field 
strength that changes the detectors sensitivity (McDermott et al., 2004, 
McDermott et al., 2006a).  
 
Besides that, the slow release of trapped charges also increases the reading for 
subsequent frames and can be observed as a persistent image post-irradiation, 
commonly known as ghosting (Siewerdsen & Jaffray, 1999). Another less 
dominant source of ghosting is the afterglow of visible light from the phosphor 
layer (Siewerdsen & Jaffray, 1999). While the ghosting phenomenon was found 
to be negligible for Varian aS500 EPIDs (Greer & Popescu, 2003, Van Esch et al., 
2004, Kavuma et al., 2008), it was more pronounced for Elekta iViewGT EPIDs 
(Winkler et al., 2005). Variation in ghosting between EPIDs from different 
manufacturers could be due to differences in the a-Si layer, photodiodes, read-
out electronics and image acquisition software settings. Although the signal 
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enhancement from ghosting was reported to be as much as 9% (Winkler et al., 
2005), the experimental setting of 50 MU pre-irradiation followed by a 2.5 MU 
test field was to simulate an extreme condition that is rare even in a segmented 
IMRT delivery. Moreover, the 9% increase in response for a 2.5 MU field may not 
be substantial when evaluated as a complete IMRT delivery with total MU in the 
order of hundreds. In a more common situation, for example a 5 MU pre-
irradiation followed by a 2.5 MU field, the increase in response was generally 
less than 1.5% for Elekta iViewGT (Winkler et al., 2005). To understand how 
these two characteristics, non-linearity at low MU and ghosting, would affect an 
IMRT delivery where multiple low MU segments are integrated, Kavuma et al. 
(2008) compared the Varian aS500 EPID signal for a single 20 MU delivery with 
different combinations of low MU segments totalling to 20 MU. Without any 
correction, the percentage difference between a single 20 MU delivery with 1 
MU x 20 segments (most extreme condition) and 5 MU x 4 segments (a more 
realistic situation) was 2.9% and 1.6% respectively. No comparable experiment 
can be found for other commercial a-Si EPIDs.     
 
Another dosimetric characteristic that should be evaluated, especially when 
used for VMAT verification, is the constancy of a-Si EPID response with linac 
repetition rate (MU/min) setting. Winkler & Georg (2006) investigated 11 Elekta 
iViewGT EPIDs and reported a 1.4% to 2.8% increase in pixel value when linac 
repetition rate was doubled. The relative response of EPID deviated by up to 7% 
when the repetition rate was changed from 12 MU/min to 400 MU/min (Winkler 
et al., 2005). Meanwhile, a smaller deviation, within 1.8%, was reported for 
Varian aS500 EPIDs when repetition rate was changed from 100 MU/min to 600 
MU/min (Kavuma et al., 2008). The variation in response with repetition rate 
was related to dose per frame effect (non-linearity of EPID signal and delivered 
dose in one frame) (Winkler et al., 2005) and may be affected by the EPID 
acquisition settings (Kavuma et al., 2008). 
 
Perhaps the major hindrance in using a-Si EPID for dose measurement is its 
energy dependence. Because of the increased probability of photoelectric 
interaction with high Z material (Gd2O2S, z = 64) in the phosphor layer, the a-Si 
EPID showed an over-response to low energy photons below 1 MeV (Kirkby & 
Sloboda, 2005). Therefore, the EPID response is expected to vary as the beam 
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energy spectrum changes with: (1) off-axis position, (2) field size and (3) the 
presence of an attenuator (either phantom or patient) in the beam.  
 
Firstly, the change in mean energy at off-axis position is a consequence of 
differential beam hardening by the cone-shaped flattening filter. Because the 
mean energy is lower at off-axis positions, the response of a-Si EPID was found 
to be higher than the central axis by up to 29% (Parent et al., 2006). In 
comparison with IC measurement in water, the a-Si EPID over-responded by 13% 
at 15 cm off-axis (Greer, 2005).  
 
Secondly, the variation in beam spectrum with field size is due to increased 
contribution of low energy scattered photons for larger fields. Because of a-Si 
EPID over-sensitivity to low energy photons, the output factor (output for a field 
normalised to a 10 x 10 cm2 reference field) for EPID and IC measurement in 
water was found to vary by as much as 2.5% for a 6 MV beam (Greer & Popescu, 
2003) and 9% for an 18 MV beam (Van Esch et al., 2004). The difference in 
output factor between EPID and water measurement can also be attributed to 
the presence of non-water equivalent components in the EPID that increases 
scattering within the detector itself.  
 
Thirdly, in the presence of an attenuator, the transmitted beam spectrum 
changes due to attenuation of low energy photons. Kirkby & Sloboda (2005) 
found that, for a 6 MV beam, the a-Si EPID calibration curves (relative response 
of EPID versus IC at the same level) measured without and with an attenuator 
differed by up to 8%. The EPID response was found to be lower for attenuated 
beams and this effect was attributed to less low energy photons in the 
transmitted beam that reduces the over-response of EPID. If an attenuator is 
present in the beam, the effect of additional scatter from the object reaching 
the EPID must also be considered. The amount of scatter reaching the phosphor 
layer is inversely proportional to the distance (or air gap) between the object 
and the EPID. The response of EPID was 14% higher with 10 cm air gap relative to 
60 cm air gap for a 6MV beam (McDermott et al., 2004). Grein et al. (2002) 
reported that the difference in relative transmission between EPID and IC 
measured dose for a 6 MV beam transmitted through a 21 cm thick polystyrene 
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phantom was 6% when the air gap was 30 cm and increased to 8% when the air 
gap was reduced to 16.5 cm.  
 
One possible way to reduce the over-response of a-Si EPID due to beam spectral 
change is by placing an additional copper plate above the detector to absorb the 
low energy photons. McDermott et al. (2004) showed that by placing a 2.5 mm 
copper plate on top of the EPID, the variation in response due to different air 
gap distance could be minimised to within 1%. However, the additional weight of 
the copper plate may activate the touch guard of the EPID. Moreover, the 
placement of copper plate on top of the EPID cover only allows measurement at 
gantry zero degree. Although technically the copper plate can be permanently 
fixed inside the EPID, it requires modification of the panel that may not be 
desirable in most clinical departments. Kirkby & Sloboda (2005) recommended 
the use of 7 mm copper plate in an elevated position, 15 cm above the EPID, but 
again this experimental set-up is not practical as it creates mechanical 
limitation and was found to degrade the image quality.  
 
1.6 Advantages of a-Si EPID over other detectors 
 
Despite the dosimetric challenges described in the above paragraphs, the a-Si 
EPID has many inherent advantages over other types of detectors. For instance, 
the a-Si EPID is a 2D detector with much higher spatial resolution compared to 
2D array devices. The spatial resolution for a-Si EPID is less than 0.08 cm while 
the spatial resolution for 2D array devices are typically in the range of 0.5 cm to 
1 cm. Although the spatial resolution for film is also excellent, the a-Si EPID has 
the advantage of not requiring any manual processing and the image is available 
immediately in digital format. Since the EPID comes as an attachment on most 
linacs, the cost of using EPID for treatment verification is relatively low because 
there is no need to purchase additional hardware or consumable items. 
Moreover, unlike any of the other detectors, the a-Si EPID can be positioned 
automatically and thus, very convenient to set-up. Most importantly, the a-Si 
EPID can be used for both pre-treatment and actual treatment verification. The 
position of EPID panel perpendicular to the radiation source and behind the 
patient allows passive measurement of radiation without interfering with the 
delivery of treatment.  
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These advantages have led to the search for solutions to overcome the 
dosimetric challenges associated with a-Si EPID. A literature review on the 
different approaches to a-Si EPID dosimetry are summarised in the next chapter. 
The gap in knowledge and the aim of this research will also be discussed.  
!
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 Table 1-1 Characteristics of different detectors used for patient-specific treatm
ent verification. 
 
IC 
D
iode 
M
O
SFET 
TLD
 
O
SLD
 
Radiographic film
 
Radiochrom
ic film
 
a-Si EPID
a 
M
easurem
ent 
dim
ension 
Point or 2D
c 
Point or 2D
c 
Point 
Point 
Point 
2D
 
2D
 
2D
 
A
pplication 
Pre-treatm
ent 
Actual treatm
ent 
or 
Pre-treatm
ent
c 
Actual treatm
ent 
Actual treatm
ent 
Actual treatm
ent 
Pre-treatm
ent 
Pre-treatm
ent 
Actual treatm
ent 
or/and 
Pre-treatm
ent 
Reproducibility 
G
ood 
G
ood 
M
oderate 
M
oderate
d 
M
oderate
d 
M
oderate
d 
M
oderate
d 
G
ood 
D
ose linearity 
G
ood 
G
ood 
G
ood 
M
oderate
e 
M
oderate 
M
oderate
e 
M
oderate
e 
G
ood 
Energy 
independence
b 
G
ood 
Poor 
Poor 
G
ood 
Poor 
Poor 
G
ood 
Poor 
Tem
perature 
independence 
Poor 
Poor 
G
ood
e 
G
ood 
G
ood 
Poor 
M
oderate 
M
oderate
g 
A
ngular 
independence 
G
ood
f 
Poor 
G
ood
e 
G
ood 
G
ood 
Poor 
G
ood 
G
ood 
Spatial resolution 
Poor 
G
ood 
G
ood 
G
ood 
G
ood 
G
ood 
G
ood 
G
ood 
Read-out 
convenience 
G
ood 
G
ood 
G
ood 
Poor 
M
oderate 
Poor 
M
oderate 
G
ood 
Lifespan 
G
ood 
M
oderate 
Poor 
Poor 
Poor 
N
ot applicable 
N
ot applicable 
G
ood 
O
ther 
advantages 
• 
G
old standard 
• 
Traceable to PSD
L 
• 
W
ell established 
correction factors 
• 
Rugged 
 
• 
Less dose 
perturbation 
com
pared to 
diode 
 
• 
Available in 
different form
s 
and shapes (very 
adaptable) 
• 
N
o cables 
 
• 
Signals can be re-
read 
• 
N
o cables 
 
• 
Perm
anent record 
 
• 
N
ot sensitive to 
visible light 
• 
Self-develop 
 
• 
M
inim
al set-up 
• 
D
igital record 
• 
H
ardw
are readily 
available as part 
of the linac 
O
ther 
disadvantages 
• 
Risk of charge 
particle 
disequilibrium
 for 
sm
all field 
• 
Risk of fluence-
averaging 
perturbation 
effect for high 
gradient field 
• D
ose perturbation 
due to the 
presence of build-
up cap 
• Requires m
any 
correction factors 
• Requires re-
calibration due to 
radiation dam
age 
• 
H
igh cost 
considering the 
short lifespan 
 
• 
Tedious post-
processing 
• 
D
elayed results 
 
• 
C
hange in 
sensitivity and 
reproducibility 
w
ith accum
ulated 
dose 
• 
Inter-batch 
response variation 
• 
Sensitive to light 
and processing 
conditions  
• 
Inter-batch 
response variation 
• 
C
ontinuous 
polym
erisation 
• 
Requires strict 
scanning protocol 
• 
M
uch m
ore 
expensive than 
radiographic film
 
• 
Requires a 
dosim
etric m
odel 
to convert EPID
 
signal to dose 
distribution  
 
N
ote: Perform
ance are categorised into three groups – ‘G
ood’, ‘M
oderate’ and ‘Poor’. N
um
erical values are given in text w
ith the respective references.  
a O
nly a-Si EPID
 is included since it is currently the m
ost com
m
on type of EPID
  
b Energy independence to low
 energy photons 
c C
om
m
ercial 2D
 array detectors in a phantom
 
d Assum
es strict adherence to standardised protocols 
e D
ependent on detector type/m
odel 
f C
ylindrical IC
 
g W
arm
 up effect: D
etector sensitivity low
er by 2.5%
 after an extended period in the standby m
ode (W
inkler et al., 2005)  
! 32!
Chapter 2: Literature review and aim of research 
 
2.1 Literature review 
 
The main challenge with a-Si EPID dosimetry is the presence of high Z material 
in the phosphor layer, which causes deviation from water-equivalent behaviour. 
Various investigators have proposed different methods to workaround the 
dosimetric problem inherent to a-Si EPID. The focus of this literature review is 
on the different approaches to a-Si EPID dosimetry.  
 
Only a-Si EPID is included in this review as it is currently the most widely 
available EPID model. Methods that involved a-Si EPID in direct configuration 
mode (without the phosphor layer) are excluded because the direct detection a-
Si EPID is not commercially available and requires in-house modification of the 
EPID panel. From here onwards, the ‘a-Si EPID’ will be referred to as ‘EPID’ for 
brevity.  
 
2.1.1 Search strategy 
Literature searches were carried out on the Embase, Ovid Medline, Scopus and 
Web of Science databases. The terms used for search were ‘EPID dosimetry’, 
‘portal dosimetry’ and ‘treatment verification’. Primary studies included were 
published from January 1995 until April 2015 with the language of report in 
English. Relevant references cited in the primary studies were also included 
regardless of publication year. Conference abstracts without full papers were 
excluded. 
 
2.1.2 Definition of common terminology  
Different terms are used in the literature when describing EPID dosimetry 
techniques. For clarity, a common set of terminology, defined in the following 
sub-sections, will be used in this literature review. 
 
2.1.2.1 Measurement arrangement: Non-transit & transit dosimetry 
Depending on the measurement arrangement, EPID dosimetry model can be 
referred to as non-transit or transit dosimetry.  
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• Non-transit dosimetry: refers to EPID measurements without attenuator 
between the source and EPID detector. The EPID measures radiation 
through air and without transiting any object.  
• Transit dosimetry: refers to EPID measurements with an attenuator, 
either a phantom or patient, between the source and EPID detector. The 
EPID measures radiation that transits through the attenuator.  
 
Figure 2-1 shows the measurement arrangement for non-transit and transit 
dosimetry. Since no attenuator can be present for non-transit dosimetry, the 
technique is limited to only pre-treatment verification. On the other hand, 
transit dosimetry can be used for both pre-treatment and actual treatment 
verification with phantom and patient in the beam respectively.   
 
 
Figure 2-1 Arrangement for EPID dosimetry measurement. Non-transit 
dosimetry (left) and transit dosimetry (right). 
 
2.1.2.2 Comparison location: EPID plane & in-phantom/in-vivo  
EPID dosimetry models can be differentiated based on where the dose is 
predicted (or reconstructed) and compared.  
• Comparison at EPID plane: refers to a dosimetry model that predicts 
dose at the EPID detector. The predicted dose is compared directly to the 
EPID measured dose plane. 
• Comparison in-phantom/in-vivo: refers to a dosimetry model that 
reconstructs dose inside a phantom (in-phantom) or patient (in-vivo) from 
EPID images. The reconstructed dose is usually, but not always, compared 
to the TPS dose computed for the phantom/patient. 
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Comparison at the EPID plane has the advantage of being more efficient because 
the dose at the EPID is only predicted once and repeatedly used for comparisons 
with EPID images measured on different treatment days. On the other hand, 
comparison in-phantom/in-vivo uses EPID images captured during different 
treatment days as an input and therefore, requires dose to be reconstructed 
each time. However, comparison in-phantom/in-vivo is verified in a more 
clinically relevant location and usually in centigray (cGy) units. Discrepancies 
seen at the EPID plane are less meaningful, especially when the unit of 
comparison is expressed in pixel values. Furthermore, the dose comparison in-
phantom/in-vivo can be extended to a 3D volume. In the case of in-vivo dose 
comparison, patient computed tomography (CT) images can be used to 
reconstruct 3D dose to different organs or regions of interest and comparison 
can be done in terms of DVHs. 
 
2.1.3 EPID dosimetry model 
In general, different EPID dosimetry models reported in the literature can be 
classified into three broad categories based on the methods used for dose 
prediction/reconstruction: Monte Carlo (MC)-based model, convolution-based 
model and empirical-based model.  
 
2.1.3.1 Monte Carlo (MC)-based model 
MC-based EPID dosimetry model uses MC simulation in the dose 
prediction/reconstruction process, which requires detailed modelling of the 
linac’s radiation source, components in the treatment head, phantom/patient if 
present in the beam and the EPID panel. During the simulation process, a phase 
space file is created that specifies energy, position, direction and statistical 
weight of each photon and electron transport. This phase space file is then used 
to score the energy deposition in phantom/patient or EPID detector for absorbed 
dose computation. Because MC is capable of simulating to a high accuracy the 
physical principles of photons and electrons interactions, it is the most accurate 
form of prediction model. 
 
For non-transit dosimetry, EPID response can be simulated and compared 
directly to EPID measured image. This is the simplest form of MC-based EPID 
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dosimetry model and was demonstrated by Parent et al. (2006) and Siebers et 
al. (2004). In both studies, the MC simulated EPID response showed excellent 
agreement with EPID measurement for a small number of IMRT fields. The 
gamma pass rates were above 98% for gamma criterion 3%/2mm and 2%/2mm 
used by Parent et al. (2006) and Siebers et al. (2004) respectively.  
 
As for transit dosimetry, various authors have proposed different MC simulation 
methods. For comparison at the EPID plane, Kairn et al. (2011) used a MC code 
to combine the phantom and EPID model for simulation of EPID response in a 
transit arrangement. The simulated EPID response was compared directly with 
EPID transit measurement. Instead of a single simulation, Lin et al. (2009) 
proposed a two-stage MC simulation that first simulates dose within the phantom 
and then at the EPID plane. For the first stage, EPID images acquired through air 
was needed to simulate the in-phantom dose and comparison with TPS served as 
a pre-treatment verification. For the second stage, the simulated EPID transit 
dose was compared with EPID image measured during treatment for actual 
treatment verification. Excellent gamma agreement (>98.6%, using 3%/3mm 
criterion) for both types of comparisons was reported for three IMRT fields 
tested on homogeneous slab phantom.  
 
Jarry & Verhaegen (2007) described a MC simulation method that used the EPID 
transit image measured during treatment to reconstruct in-phantom dose for 
comparison with a full MC dose calculation engine in place of a commercial TPS. 
The measured EPID image was separated into primary and scattered components 
and the former was back-projected for in-phantom dose reconstruction using MC 
simulation. For an anthropomorphic phantom irradiated with a 10 x 10 cm2 open 
field, the gamma comparisons with 5%/3mm criterion showed 87% agreement 
between in-phantom mid-sagittal dose reconstructed from measured EPID image 
and the reference dose from MC dose calculation engine without measurement 
input. The author attributed the inferior results to uncertainty in phantom 
alignment and EPID position. Despite the inferior results, the study served to 
show that a verification method completely independent of TPS was possible.  
 
An interesting observation from this literature review on MC-based EPID 
dosimetry was that all the studies reported their results based on a very small 
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number of test fields (ranging from one to four fields only). This is probably due 
to the time consuming nature of MC simulation. To speed up the MC simulation, 
Lin et al. (2009) incorporated measurement and convolution in the MC model but 
even so, the time required to simulate one case was almost 6.4 h on a 10 PC 
cluster, each with a 2.8 GHz CPU. Because of the intensive computation 
requirement, the routine application of MC-based EPID dosimetry may not be 
currently possible especially in clinical departments with a large number of 
linacs and limited resources. 
 
2.1.3.2 Convolution-based model 
Convolution-based EPID dosimetry models employ kernels that describe scatter 
or dose deposition properties in EPID or phantom/patient. Convolution and de-
convolution of different kernels are used in various stages of the dosimetry 
model to give a desired parameter. For example, de-convolution of the scatter 
kernel from the EPID measured dose distribution gives the primary fluence while 
convolution of the primary fluence with the dose deposition kernel results in 
absorbed dose distribution. Kernels can be generated either by measurements or 
MC simulations. 
 
Non-transit EPID images can be used to reconstruct in-phantom or in-vivo dose, 
by means of convolution, for comparison with the intended dose. In the model 
described by Ansbacher (2006), the EPID response for non-transit arrangement 
was first calibrated to the equivalent dose at the mid-plane of a cylindrical 
water phantom before the EPID dose distribution was convolved with a scatter 
kernel to account for differences in EPID and cylindrical phantom scattering. The 
reconstructed in-phantom dose was compared to the TPS dose computed for a 
similar virtual cylindrical water phantom. Because the EPID was calibrated to a 
fixed depth in a phantom, the model was limited to dose prediction for that 
particular phantom only. For a wider scope of application, most EPID dosimetry 
models aimed to retrieve the primary fluence incident on EPID detectors. In a 
non-transit arrangement, the primary fluence can be retrieved by de-
convolution of EPID measurement with EPID scatter kernel. Subsequently, the 
primary fluence can be used in different ways to reconstruct dose. Warkentin et 
al. (2003) convolved the primary fluence with a water phantom dose deposition 
kernel to reconstruct in-phantom dose. Meanwhile, Steciw et al. (2005) used the 
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primary fluence as an input to the TPS. Together with patient CT images, 3D in-
vivo dose was recalculated by the TPS using the EPID measured fluence. 
However, the method was not clinically feasible because of the excessive time 
required to convert measurement files into a format recognisable by the TPS. 
Furthermore, the use of TPS for dose reconstruction may mask certain 
inaccuracies in the TPS algorithm. Rather than using the TPS, Renner et al. 
(2005) entered the primary fluence into an independent commercial dose 
calculation algorithm, Dosimetry Check (Math Resolutions, Columbia, MD, US), 
for 3D in-vivo dose calculation. Zhu et al. (2015) used a rather similar approach 
but with an in-house collapsed-cone convolution/superposition calculation 
algorithm implemented on a graphic processing unit (GPU) to achieve fast 
computation speed. Alternatively, Van Elmpt et al. (2006) used the primary 
fluence as input to an in-house MC dose engine to reconstruct 3D in-phantom 
dose distribution. By using a method independent of the TPS for dose 
reconstruction, Van Elmpt et al. (2007) proved that inaccuracies in TPS 
algorithms could be detected, as confirmed by results from film measurements. 
The developed EPID dosimetry model was used as a pre-treatment verification 
tool for 3D conformal as well as IMRT plans, and dose agreement with TPS was 
evaluated in terms of DVHs (Van Elmpt et al., 2008b). 
 
For transit dosimetry, the fluence incident on the EPID consists of both primary 
and scattered radiation from phantom/patient. In the model proposed by 
McCurdy & Pistorius (2000), McCurdy et al. (2001) and Chytyk & McCurdy (2009), 
the primary and scattered fluence incident on the EPID were predicted 
separately using patient CT data and libraries of MC generated scatter kernels. 
Subsequently, the incident fluence was convolved with the EPID dose deposition 
kernel to predict the EPID transit dose for direct comparison with EPID 
measurement. Instead of predicting EPID transit dose, Chen et al. (2006) and 
Nijsten et al. (2007) converted the measured EPID transit image to water-
equivalent dose distribution, for comparison with IC measurement in water at 
the EPID distance. Correction factors and kernels derived from measurements 
with different field sizes and attenuator thicknesses were used in the conversion 
process. The correction factors and kernels served to correct for differences in 
scatter within the EPID and water as well as variation in response as the beam 
energy spectrum changes with attenuator thickness, field size, off-axis position 
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and scatter from the phantom. Although both authors reported good agreement 
between EPID converted and IC measured dose distributions, the need to set-up 
the scanning water tank and perform IC measurements in water for each test 
field was too cumbersome for routine clinical implementation.  
 
Another option for EPID transit dosimetry was to use the convolution method to 
reconstruct dose in-phantom/in-vivo from the EPID measured transit image, as 
reported by the group of researchers from The Netherlands Cancer Institute. 
Briefly, as described by Wendling et al. (2006), the EPID measured dose 
distribution was de-convolved with the EPID scatter kernel and subtracted with 
radiation scattered from phantom to EPID, to retrieve the primary fluence. 
Then, the primary fluence was back-projected to reconstruct 2D dose at the 
mid-plane of a homogeneous phantom using an inverse square law (ISQL) 
correction, attenuation correction from mid-plane to exit surface and correction 
for scattered radiation within the phantom. Pre-treatment verification with a 
slab phantom for 50 IMRT prostate fields showed good agreement with film 
measurement (99.1% pass rate using 2%/2mm criterion) and comparison with TPS 
dose revealed a systematic error that was subsequently traced to an incorrect 
MLC setting in the TPS (McDermott et al., 2006b). The model was also proven to 
be useful for 2D in-vivo actual treatment verification of prostate IMRT treatment 
by comparing reconstructed dose with TPS planned dose at the isocentre level 
(McDermott et al., 2007). Wendling et al. (2009) further extended the model to 
reconstruct 3D in-vivo dose, where multiple 2D planes parallel to the EPID were 
reconstructed for each gantry angle, summed in a 3D grid and overlaid on 
patient CT data. The attenuation at different reconstruction planes was 
estimated from ratio of geometrical path length, from plane of interest to exit 
surface, derived from patient external body contour. Comparison of 3D in-vivo 
reconstructed dose and TPS computed dose showed excellent agreement for 
nine patients undergoing prostate IMRT treatment (99% pass rate using 3%/3mm 
criterion) (McDermott et al., 2008) and the same model was also proven to be 
feasible for VMAT treatments (Mans et al., 2010a).  
 
The only major limitation with the proposed model was the assumption of 
homogeneous condition that caused large deviation in the presence of 
inhomogeneity, such as in the lung region. Wendling et al. (2012) presented a 
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workaround, which involved modification of the measured EPID transit image to 
mimic transmission through a homogeneous patient. The reconstructed dose was 
compared to the TPS computed dose with homogeneity correction turned off. 
Using the modified model for 10 lung cases, the results for 3%/3mm gamma 
evaluations improved from an average of 66.2% to 93.1% for IMRT plans and 
43.6% to 97.5% for VMAT plans (Wendling et al., 2012). Despite the considerable 
improvement in results, the method was not ideal because the comparison was 
not made in a true situation and TPS accuracy in the presence of inhomogeneity 
could not be checked. But overall, the proposed convolution-based model was 
proven to be suitable for large-scale implementation. Since January 2008, the 
EPID transit dosimetry model has been routinely used for verification of almost 
all IMRT and VMAT treatments in The Netherlands Cancer Institute (Mijnheer et 
al., 2010). The analysis and reporting of results has since been automated to 
improve efficiency and further streamline the clinical workflow of EPID in-vivo 
verification (Olaciregui-Ruiz et al., 2013).  
 
In general, compared to MC-based models, convolution-based models are less 
accurate in the presence of inhomogeneity, especially if the kernels and 
correction factors were derived in homogenous medium. However, convolution-
based EPID dosimetry models are less computationally intensive and the use of 
pre-generated kernels saves calculation time. The shorter calculation time for 
convolution-based models made it practical for clinical implementation, as 
demonstrated by The Netherlands Cancer Institute. But convolution-based 
models still require appropriate expertise, software and hardware for 
mathematical modelling and therefore, are mostly contained in the research 
department where the model was developed. 
 
2.1.3.3 Empirical-based model 
An empirical-based model uses only experimental measurements in the 
calibration and dose prediction/reconstruction process. Due to the limited 
number of measurements that can be carried out, assumptions are usually made 
that may affect the accuracy of results. However, models with only physical 
measurements are the most practical and can be adopted in all centres. 
Different approaches have been described in the literature for empirical-based 
EPID dosimetry model. They include: (1) measuring EPID beam model to replace 
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the usual water-based beam model in the TPS; (2) measuring at a reference 
condition where EPID response can be considered identical to water; or (3) 
measuring coefficients and corrections factors to account for differences 
between EPID and water phantom. 
 
The first type of approach used output factors and profiles measured with the 
EPID, rather than an ionisation chamber in water, to create a dedicated EPID 
beam model in a commercial TPS. While maintaining the original water dose 
deposition kernel in the TPS, Khan et al. (2008) iteratively optimised various TPS 
parameters such as energy spectrum, source size, jaw transmission, MLC 
transmission and electron contamination until a best fit was achieved between 
TPS computed and EPID measured profiles and output factors. The optimised 
EPID beam model in the TPS was then used to compute EPID dose for direct 
comparison with the EPID dose measured in a non-transit arrangement. 
Evaluation of a nine-field IMRT plan resulted in more than 95% of evaluated 
points passing the 3%/3mm gamma criterion.  Van Esch et al. (2004) and Rosca & 
Zygmanski (2008) also proposed models that involved modification of a water 
beam model in commercial TPS for EPID dose prediction. But rather than 
adjusting various parameters without any physical meaning, the original water 
dose deposition kernel in the TPS was replaced by the EPID dose deposition 
kernel. The EPID kernel was derived from fitting the computed and measured 
EPID dose distribution for a single dynamic MLC test field (Van Esch et al., 2004) 
or for a set of MLC test fields (Rosca & Zygmanski, 2008). Since all the above-
mentioned models were for non-transit dosimetry, Berry et al. (2012) extended 
the model by Van Esch et al. (2004) to allow EPID dose prediction in a transit 
arrangement. The model used MC simulation to quantify the decrease in primary 
fluence as a function of attenuator thickness and a set of EPID measurements to 
account for variation in EPID response as the beam spectrum changed with field 
size and thickness. The two components were added to the initial TPS prediction 
of EPID dose. Verification with an anthropomorphic phantom for 33 IMRT fields 
showed that an average of 98.1% pixels passed the 3%/3mm gamma evaluation. 
Apart from the model by Khan et al. (2008), all the other models were not 
strictly empirical-based models but were included in this section since the basic 
concept, of replacing TPS water-based beam model with an EPID beam model, 
was the same. The main disadvantage of this approach was the inability to verify 
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the accuracy of actual clinical beam model since the EPID beam model was used 
for the TPS calculation. 
 
The second type of empirical-based EPID dosimetry model involved determining 
a reference condition, where the EPID showed similar dosimetric behaviour as 
water measurements. EPID measurement under this condition can be calibrated 
to dose and compared directly to TPS calculated dose in water. To find this 
reference condition, Talamonti et al. (2006) evaluated the EPID response for 
different combinations of field size, phantom thickness, air gap and Copper 
filter. The authors established that for a 6 MV beam, the variation of EPID 
response with field size (from 3 x 3 cm2 to 20 x 20 cm2) could be minimised to 
within 3% if measured with a 20 cm water phantom, 56 cm air gap and a 3 mm 
Copper filter. By measuring at this reference condition, a universal calibration 
factor independent of field size could be used for straightforward conversion of 
EPID signal to equivalent dose in water. Comparison between EPID measured 
dose and TPS calculated dose in a water phantom showed a mean gamma 
agreement of 97.6% for 15 IMRT fields investigated. Meanwhile, Lee et al. (2009) 
found that the same could be achieved with a simpler set-up with no attenuator 
(non-transit arrangement). The EPID measured profiles and output factors for 
field size 2 x 2 cm2 to 15 x 15 cm2 were similar to measurements in water at a 
reference depth of 5 cm and 3 cm for 6 MV and 18 MV beam respectively. Using 
a universal calibration factor independent of field size, the EPID signal was 
converted to dose and compared with TPS computed dose in water at the 
reference depth. The gamma pass rate for 14 6 MV IMRT fields ranged from 
93.6% to 99% when the analysis criteria was set at 3%/3mm. Results for 
comparison with TPS were not presented for 18 MV IMRT fields. Although 
relatively simple and straightforward, both non-transit and transit EPID 
dosimetry models based on this approach were restricted to pre-treatment 
verification because of the fixed measurement set-up.   
 
The third, and most common, type of empirical-based EPID dosimetry model 
involved performing a series of measurements to derive correction factors and 
coefficients to account for differences between EPID and water measurements. 
For non-transit dosimetry, the EPID response is dependent on field size and 
different from water measurement. Instead of using a pre-generated table of 
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correction factors, Nicolini et al. (2006) proposed the use of general coefficients 
to calculate correction factors based on field size (General Linear calibration 
Algorithm, GLAaS). The general coefficients were derived separately for primary 
and MLC transmission radiation by fitting a limited number of open and MLC-
closed fields respectively. With these coefficients and field size extracted from 
MLC file, the appropriate correction factor could be determined for every 
segment in an IMRT delivery for the conversion of EPID signal to dose. The sum 
of converted EPID dose was compared to TPS computed dose in water. To avoid 
dose comparison at surface (the inherent build up of EPID was only 0.8 cm), 
slabs of water phantom were placed on the EPID for all measurements and the 
TPS dose was computed for the same depth. The mean gamma agreement 
between EPID measured and TPS computed dose for 34 IMRT fields evaluated 
using 4%/3mm criterion was 97.7% and 96.9% for build up 1.5 cm and 3.8 cm 
respectively, comparable with film verification of the same fields (97.6%).  
 
For a transit arrangement, the EPID signal to dose in water correction factor is 
dependent not only on field size, but also attenuator thickness and air gap. With 
the additional variables, it is impractical to physically measure the correction 
factor for all possible combinations of parameters. Francois et al. (2011) and 
Piermattei et al. (2006) have described different ways to reconstruct in-vivo 
point dose at the central axis from EPID transit signal. The model by Francois et 
al. (2011) first converted the EPID transit signal to transit dose in water at 
maximum depth (dmax) via a correction factor. Then, dose in water at dmax 
without attenuator was derived using the Transit Tissue Maximum Ratio (TMRt), 
defined as the ratio of dose in water at dmax measured with and without 
attenuator. Because TMRt was dependent on field size, thickness and air gap, 
fitting coefficients were derived to reduce the number of measurements 
required. Finally, in-vivo dose at the isocentre was reconstructed by applying 
ISQL correction and conventional Tissue Maximum Ratio (TMR). Comparison 
between reconstructed and TPS computed point dose for 145 patients 
undergoing pelvis treatment showed a mean deviation of -1.0±2.2% (1SD) and -
0.3±2.6% (1SD) for 3D conformal and IMRT treatment respectively (Camilleri et 
al., 2014) . As for the model by Piermattei et al. (2006) and Piermattei et al. 
(2007), a set of correlation functions, defined as the ratio of EPID transit signal 
to IC dose at the mid-plane of a homogeneous phantom, was measured at the 
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central axis for a limited number of square fields and phantom thicknesses. 
Fitting coefficients were derived so that correlation function and consequently, 
the in-vivo mid-plane dose could be reconstructed if the field size, phantom 
thickness and EPID transit signal were known. The same group of researchers 
later published generalised correlation functions for Elekta (Cilla et al., 2011), 
Varian (Fidanzio et al., 2011a) and Siemens (Fidanzio et al., 2011b) linacs to 
allow easier implementation by other users without having to repeat the 
calibration measurements. Piermattei et al. (2012) reported the first results of 
using the generalised procedure in three centres with different linacs for 3D 
conformal pelvis treatments. Out of the 480 fields analysed, 45 fields deviated 
from the TPS dose by more than 5% and the discrepancies were attributed to the 
presence of bowel gas, incorrect set-up and error in TPS wedge parameter. A 
later report by Fidanzio et al. (2015) included results for other 3D conformal 
treatment sites (pelvis, breast, lung and head and neck) over three years in a 
centre with three linacs (n = 1287) and again showed that the in-vivo dose 
verification was effective in detecting errors, which led to intervention in 19 
cases. The model has since been extended for point dose verification of IMRT 
(Greco et al., 2013) and VMAT delivery (Fidanzio et al., 2014). The use of 
generalised factors is an advantage as it saves measurement time and is, 
therefore, more likely to be accepted by users. The main shortcoming of both 
methods was the point comparison at central axis, which was not ideal because 
treatment accuracy could not be verified elsewhere in the field.  
 
Instead of reconstructing dose to a point, Peca & Brown (2014) adapted the 
model by Piermattei et al. (2006) for 2D in-vivo dose reconstruction from EPID 
transit signal. In the original model, the correlation functions were defined only 
at the central axis. To quantify the variability of these correlation functions at 
off-axis positions, 2D EPID image was divided by TPS computed 2D dose (instead 
of IC measured point dose) at the mid-plane of water phantom and then, 
normalised to the central axis. From this 2D relative matrix, 1D in- and cross-
plane correction profiles were extracted and multiplied to the original 
correlation function derived at the central axis. Also, a 2D map of radiological 
path length was derived from CT data to account for tissue inhomogeneity. 
Validation with 3D conformal fields on an anthropomorphic phantom showed 
good agreement in the head region (≥96.5% with 3%/3mm criterion) but over-
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estimation of dose up to 9% was observed in the lung region. The authors 
attributed the dose discrepancies to inadequate in-phantom scatter correction 
and failure of the 1D correction profiles to properly account for off-axis 
variation for highly irregular fields. The model was not validated for delivery of 
IMRT fields.  
 
Alternatively, Kairn et al. (2008) proposed the use of a quadratic equation to 
convert EPID transit signal to 2D radiological or equivalent path length (EPL) as a 
form of treatment verification. The quadratic equation, established by Swindell 
(1983), relates the reduction in radiation intensity due to the presence of an 
attenuator to the thickness of the attenuator. The coefficients in the quadratic 
equation were generated in 2D to include off-axis variations by fitting, pixel-by-
pixel, a set of EPID transit signal measured for homogeneous phantoms of 
different thicknesses (Morton 1991). Since dose, and not EPL, is the preferred 
metric for treatment verification, Kavuma et al. (2010) used the EPL calculated 
from EPID transit signal to reconstruct 2D entrance and exit in-phantom doses. 
The conversion of EPL to dose required a pre-generated look-up table of 
percentage exit thickness dose (PETD) values given as a function of field size and 
thickness. The PETD values were derived from Tissue Phantom Ratio (TPR) and 
theoretically justified by the authors. Envelope and boundary profiles generated 
from the Pencil Beam Convolution algorithm in Eclipse TPS (Varian, Palo Alto, 
CA, USA) were also required for off-axis dose calculations. The model was 
evaluated with 3D conformal fields on anthropomorphic phantom. Comparison 
between reconstructed and TPS computed in-phantom dose resulted in 90% of 
points passing 3%/3mm gamma criterion, with discrepancies observed at the 
penumbra region (Kavuma et al., 2011). Despite the advantage of being a 2D 
empirical-based EPID transit dosimetry model, the method was also not 
validated for IMRT fields, which is the main focus of treatment verification.  
 
Sabet et al. (2014) reported a 2D empirical-based EPID transit dosimetry model 
that could be used to verify IMRT fields. However, the model only aimed to 
convert measured EPID transit signal to equivalent dose in water. The converted 
EPID transit dose was then compared to another transit dose measured by a 
commercial 2D IC-array, MatriXX (IBA Dosimetry, Schwarzenbruck, Germany), 
positioned at the EPID level. This strategy cannot be used for actual treatment 
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verification since it is not possible to perform two deliveries in a single 
treatment fraction for a patient. In fact, there is little value in comparing two 
consecutive measurements, albeit using different devices, with no information 
on the agreement with the intended or planned dose. Therefore, despite the 
transit arrangement and validation with IMRT fields, the usefulness of the model 
is limited. 
 
Overall, empirical-based EPID dosimetry model is possibly the most practical 
model for clinical centres with limited resources for computationally intensive 
MC simulations or mathematical modelling. In addition, most methods in 
empirical-based models involved general measurements that can be 
accomplished by a clinical physicist without requiring special expertise. Also, 
general measurements can be performed on all linacs and EPIDs regardless of 
manufacturer. However, there is a lack of publication on empirical-based EPID 
transit dosimetry for 2D or 3D verification of modulated IMRT or VMAT fields.  
 
2.1.3.4 Others 
Baek et al. (2014) used the EPID to measure transit radiation and compare it 
with TPS computed dose at the EPID level. The described method does not fall 
into any of the categories above because, aside from a simple calibration curve 
to convert EPID pixel value to dose in cGy, no other considerations were given to 
account for the dosimetric differences between EPID and a water-equivalent 
detector. In the TPS, an over-simplified virtual EPID was created at 130 cm from 
source and contoured as part of the body for dose computation. Relative gamma 
comparisons (using 3%/3mm criterion) between TPS-computed and EPID-
measured dose for 24 IMRT fields with an anthropomorphic phantom resulted in 
average pass rate of 86.8%. The author suggested that the method could 
potentially be used as a crude way to detect delivery of a wrong treatment field 
or treating a wrong patient.     
 !  
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2.2 Commercial software 
 
2.2.1 Non-transit EPID dosimetry software 
The majority of commercial software packages are for non-transit measurement 
and can only be used for pre-treatment verification. Non-transit EPID dosimetry 
software that are currently commercially available are: 
• Portal Dosimetry by Varian (Palo Alto, CA, USA) 
• EPIDose by Sun Nuclear (Melbourne, FL, USA) 
• Epiqa by EPIdos (Danube, Slovakia) 
 
2.2.1.1 Portal Dosimetry (Varian, Palo Alto, CA, USA) 
The Portal Dosimetry software is based on the method described by Van Esch et 
al. (2004) (see Section 2.1.3.3). The software predicts the 2D EPID dose plane 
for comparison with EPID measurements in a non-transit arrangement. The 
Portal Dosimetry Image Prediction (PDIP) algorithm, a module in the Eclipse TPS, 
uses a dedicated EPID beam model instead of the clinical water-based beam 
model to predict the EPID dose plane. In the Portal Dosimetry mode, both the 
PDIP and EPID are calibrated to produce dose plane values in Calibrated Units 
(CU). The Portal Dosimetry solution has a unique advantage of being completely 
integrated with the clinical workflow. The EPID image acquisitions, TPS 
prediction and dose plane comparisons, are seamlessly integrated and stored as 
part of the clinical database. As a consequence, the Portal Dosimetry treatment 
verification does not require any import/export and the analysis of results can 
be easily reviewed and managed in modules built into the TPS and oncology 
information system. On the other hand, integration of Portal Dosimetry into TPS 
and oncology information system limits its availability to only Varian users. Also 
because of this integration, the Portal Dosimetry cannot be considered as an 
independent verification system. Another inherent weakness of Portal Dosimetry 
software is that the use of a separate EPID beam model does not check the 
accuracy of actual clinical dose calculation. 
 
2.2.1.2 EPIDose (Sun Nuclear, Melbourne, FL, USA) 
EPIDose uses an algorithm to convert a non-transit EPID image to equivalent 2D 
dose at depth in a homogenous water phantom for comparison with TPS 
calculated dose and a description of the reconstruction algorithm can be found 
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in Nelms et al. (2010). Briefly, the conversion process from pixel value to dose in 
water involves: (1) per segment field size output correction, weighted according 
to primary and transmitted radiation exposure, (2) convolution with a kernel 
that accounts for scatter difference between EPID and water and finally (3) 
absolute dose calibration by comparing EPID signal with dose measured with 
diode array (MapCHECK, Sun Nuclear, Melbourne, FL, USA), for open fields of 
different MUs. The EPIDose, when used in conjunction with 3DVH (Sun Nuclear, 
Melbourne, FL, USA), allowed reconstruction of 3D dose on patient CT data for 
DVH analysis. The 3DVH is based on the concept of applying dose perturbation 
(quantified from difference between measured and expected dose) to the 3D 
dose originally computed by the TPS algorithm. It provides an estimate of the 
effect of dose discrepancies on organs of interest but does not check the 
accuracy of TPS algorithm. Although comparisons can be made in-vivo using the 
additional 3DVH software, it should not be confused with actual treatment 
verification since the EPID measurement is done prior to treatment and without 
the patient.  
 
2.2.1.3 Epiqa (EPIdos, Danube, Slovakia) 
Epiqa is based on the GLAaS algorithm detailed by Nicolini et al. (2006) (see 
Section 2.1.3.3). The aim of Epiqa is also to convert the EPID image measured in 
a non-transit arrangement to dose in water for comparison with the TPS 
computed dose in a water phantom. Similar to EPIDose, the GLAaS algorithm 
applies per segment field size output correction weighted according to fractional 
contribution of primary and transmitted radiation. The field size correction 
factor was calculated using general coefficients derived from a limited number 
of measured data. But unlike EPIDose, the algorithm does not include a scatter 
kernel. Also, build-up in the form of solid water phantom slabs must be placed 
atop the EPID panel during measurement. This requirement limits the irradiation 
to a fixed gantry angle. 
 
2.2.2 Transit EPID dosimetry software 
Transit EPID dosimetry software can be used for both pre-treatment and actual 
treatment verification. At present, there are only two commercial transit EPID 
dosimetry software systems:  
• EPIgray by DOSIsoft (Cachan, France) 
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• Dosimetry Check by Math Resolutions (Columbia, MD, USA) 
Of the two, only the Dosimetry Check software is capable of verifying dose in 
2D/3D. With IMRT and VMAT, it is warranted that dose is verified in at least 2D.  
 
PerFRACTION by Sun Nuclear (Melbourne, FL, USA) is excluded from the list 
above because it is not a dosimetry package, although it uses the EPID to 
capture radiation exiting the patient during treatment. The software only 
performs relative comparison between the EPID image captured daily with the 
EPID image captured on the first treatment fraction, to check for inter-fraction 
variation of treatment delivery. It does not verify the accuracy of delivered 
treatment with the intended prescription. 
 
2.2.2.1 EPIgray (DOSIsoft, Cachan, France) 
The EPIgray software is based on the method described by Francois et al. (2011) 
(see Section 2.1.3.3). The algorithm converts the EPID transit signal, captured 
during treatment, to in-vivo point dose using TMR and other correction factors. 
The reconstructed point dose is compared to the TPS computed point dose to 
verify the accuracy of treatment delivery. An additional module, the InVivo 
Manager (DOSIsoft, Cachan, France), provides a useful tool that manages the 
automatic analysis and notification of EPIgray results. This is a very attractive 
feature as it allows in-vivo EPID dosimetry to be implemented almost effortlessly 
with minimal staff involvement. The major shortcoming of the EPIgray solution is 
the single point comparison, which is not ideal for IMRT/VMAT treatment since it 
does not check the accuracy at other parts of the treatment field. Furthermore, 
it is often difficult to identify an optimal comparison point for highly modulated 
fields. 
 
2.2.2.2 Dosimetry Check (Math Resolutions, Columbia, MD, USA) 
At the time of writing (December 2014), Dosimetry Check is the only commercial 
software package that offers EPID transit dose verification in 3D. The software is 
based on a convolution-based model described by Renner et al. (2005) for non-
transit dosimetry (see Section 2.1.3.2) that has since been extended for transit 
application. The method involves retrieving primary fluence incident on the EPID 
by de-convolution of the EPID transit image with a kernel. Subsequently, the 
primary fluence is used as an input for 3D dose reconstruction with a pencil 
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beam algorithm. The reconstructed volume dose is compared with TPS computed 
dose for treatment verification. Volumetric in-vivo dose verification is 
advantageous as it provides a complete evaluation of the treatment delivery and 
allows better clinical judgement. Despite promise, the accuracy of Dosimetry 
Check software still requires further validation. In a recent technical note by 
Gimeno et al. (2014), it was found that in the presence of heterogeneity, the 
isocentre point dose from Dosimetry Check software deviated by up to 15% 
compared to TPS dose computed by AcurosXB algorithm (Varian, Palo Alto, CA, 
USA). 3D gamma evaluation using 3%/3mm criterion revealed that only 11.7% of 
points passed the comparison (Dosimetry Check versus AcurosXB) for a VMAT 
delivery on a thorax anthropomorphic phantom. The gamma pass rate was also 
unsatisfactory, at only 77.4%, for a simple 10 x 10 cm2 field delivered to a 
homogeneous cylindrical phantom. The authors concluded that improvements 
are required in the software calculation algorithm. Besides dosimetric accuracy, 
the authors also highlighted practical issues such as laborious process because of 
poor integration and long calculation time that could take up to an hour to 
calculate a case.  
 
2.3 Summary 
 
From the literature reviews and evaluations of commercial software, the gap in 
knowledge on EPID dosimetry, which serves as the motivation of this research, 
can be summarised as below: 
• The MC-based EPID dosimetry model requires long calculation time and 
thus, is impractical for routine clinical application. Furthermore, accurate 
MC simulation requires detailed information of different components in 
the linac and EPID, which may not be easily available to all.  
• Convolution-based EPID dosimetry models are suitable for routine clinical 
application due to the shorter calculation time. But the method is not 
easy to replicate outside the research centre because it requires a level 
of expertise and software that is not usually available in clinical centres.  
• Empirical-based EPID dosimetry models can gain wider acceptance, as the 
method is easier to replicate with only general measurements and can be 
performed on all linacs and EPIDs regardless of manufacturer. However, 
there were only two publications on 2D empirical-based EPID transit 
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dosimetry that were suitable for actual treatment verification (Kavuma et 
al., 2010, Peca & Brown, 2014) and both were not tested for IMRT (or 
VMAT) application.  
• The majority of commercial EPID dosimetry software packages are for 
non-transit application. Non-transit EPID commercial software merely 
provides an alternative method to perform patient-specific pre-treatment 
verification. Although EPID is better than the widely used 2D array devices 
in terms of convenience and superior detector resolution, non-transit EPID 
commercial software does not fulfil the need for an effective way to 
perform actual treatment verification. 
• At present, there are only two options for commercial EPID transit 
dosimetry software, the EPIgray and Dosimetry Check. Although the 
software can be used for in-vivo actual treatment verification, the EPIgray 
only verifies dose to a point and the accuracy of Dosimetry Check 
software requires further validation. 
 
2.4 Aim of this research 
 
The aim of this research is to build an EPID dosimetry model that addresses the 
above problems and: 
• Is completely based on empirical approach and generic to allow broad-
scale implementation 
• Is relatively simple for practical implementation in the routine clinical 
workflow 
• Is applicable for transit measurement to allow both pre-treatment and 
actual treatment verification 
• Can predict/reconstruct dose in 2D for a more complete verification of 
treatment accuracy 
• Can offer user the flexibility to choose either to predict dose at the EPID 
level or reconstruct dose in-vivo 
• Is applicable for both 3D conformal and modulated IMRT fields 
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Chapter 3: Evaluation of six TPS algorithms in computing 
entrance and exit doses 
 
3.1 Publication/presentation arising from work in this chapter 
 
• Evaluation of six TPS algorithms in computing entrance and exit doses, 
Tan, Y., Metwaly, M., Glegg, M., Baggarley, S. & Elliott, A., 2014, Journal 
of Applied Clinical Medical Physics, 15 (3), 229-240. 
• Accuracy of six commercial TPS algorithms in computing entrance and 
exit doses, Tan, Y., Metwaly, M., Glegg, M., Baggarley, S. & Elliott, A., 
2013, Oral presentation (Best Oral Presentation award), 13th Asia-Oceania 
Congress of Medical Physics, 11th South-East Asian Congress of Medical 
Physics, Singapore.  
 
3.2 Introduction 
 
Patient-specific treatment verification, especially in-vivo dosimetry, is 
recommended to prevent major errors in radiotherapy (Garavaglia et al., 1993, 
Essers & Mijnheer, 1999, Derreumaux et al., 2008, Williams & McKenzie, 2008, 
Mans et al., 2010b). As described in Chapter 1, in-vivo dosimetry can be 
performed in various ways using different types of detectors. Ideally, detectors 
should be placed close to the organ of interest but most in-vivo measurements 
are done at the beam entrance, exit or both to avoid invasive application. In the 
case where an EPID is used as the detector, the measured transit dose can be 
used to reconstruct dose at the entrance or exit level of the patient (Kavuma et 
al., 2010, Kavuma et al., 2011). To verify the accuracy of treatment delivery, 
the measured or reconstructed dose at the entrance or exit level is compared to 
an expected range, usually generated by the TPS. When using the TPS as a 
reference for dose verification, it is essential that the TPS calculates the dose to 
a high degree of accuracy for all conditions in the clinical setting. However, due 
to the limited build up and backscatter at the entrance and exit level 
respectively, the accuracy of the TPS dose computation must be validated. 
Although the accuracy of different TPS algorithms has been extensively 
reported, they mainly focused on dose nearer to the isocentre and with the 
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presence of inhomogeneity. Examples of such studies were published by Knoos et 
al. (2006), Van Esch et al. (2006), Fogliata et al. (2007), Bush et al. (2011), 
Fogliata et al. (2011), Han et al. (2011), Alhakeem et al. (2012), Fogliata et al. 
(2012) and Han et al. (2012). 
  
The primary aim of this study was to perform a fundamental evaluation of the 
accuracy of TPS algorithms in computing entrance and exit doses. This subject 
was of general interest because a better understanding of TPS performance at 
the entrance and exit level would help in the interpretation of in-vivo dosimetry 
results when using the TPS as a reference. More importantly, this study was 
necessary because entrance and exit doses were extensively used in the EPID 
dosimetry model developed in this research and hence, any inaccuracies in the 
TPS algorithms must first be identified and quantified. The secondary aim of this 
study was to experimentally quantify the backscatter correction factor (BCF) as 
a function of field size, depth and backscatter thickness. The BCF values served 
as a useful gauge of the backscatter effect under different conditions.  
 
In this study, a total of six commercial TPS algorithms were evaluated. 
Ionization chamber (IC) measurements were used as a reference. Entrance and 
exit doses were defined as doses at depth of 1.5 cm from the beam entry and 
exit surfaces respectively, this depth being chosen to provide reasonable 
electronic equilibrium condition for the 6 MV photon beam investigated. Dose 
uncertainties in the build up region were beyond the scope of this study. The 
same depth for exit dose was chosen for a symmetric geometry. Central axis 
point dose, 1D relative profiles and 2D absolute dose comparisons were 
investigated for a range of clinically relevant field sizes and thicknesses in 
homogeneous water phantoms.  
 
3.3 Materials and methods 
 
3.3.1 Central axis point dose analysis 
3.3.1.1 TPS virtual simulation 
Virtual water phantoms with dimensions of 30 cm x 30 cm x ‘1.5+Th+1.5’ cm 
(where thickness, Th, ranged from 0 cm to 30 cm) were created in Eclipse, XiO 
and Monaco TPSs (Figure 3-1). The range of Th was chosen to include all 
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clinically relevant thicknesses. Entrance and exit doses, defined as doses at 1.5 
cm from the beam entry and exit surface, were computed for a 6MV beam, 
source to surface distance (SSD) 100 cm, at a gantry angle of zero degrees and 
field sizes ranging from 5 x 5 cm2 to 20 x 20 cm2 using six different algorithms on 
three TPSs: 
• Eclipse TPS (version 10.0.28, Varian, Palo Alto, CA, USA) 
− Pencil Beam Convolution (Eclipse PBC) 
− Analytical Anisotropic Algorithm (Eclipse AAA) 
− AcurosXB (Eclipse AXB) 
• XiO TPS (version 4.70, Elekta, Stockholm, Sweden) 
− FFT Convolution (XiO Convolution)  
− Multigrid Superposition (XiO Superposition) 
• Monaco TPS (version 3.20.02, Elekta, Stockholm, Sweden) 
− Monte Carlo Photon (Monaco MC) 
 
The different algorithms can be categorised into three broad groups: (a) 
correction-based algorithms, (b) model-based algorithms and (c) Monte Carlo-
based algorithms. Correction-based algorithms, such as Eclipse PBC and XiO 
Convolution, use data measured in water with additional correction factors or 
analytic functions to calculate dose in patients. The corrections are used to 
account for deviation between water measurements and patients, for examples, 
contour irregularity, distance from source and change in attenuation due to 
tissue inhomogeneity based on equivalent path lengths. Scattered photons and 
electrons from primary interaction are not considered when calculating dose to 
a point. Model-based algorithms, such as Eclipse AAA and XiO Superposition, 
simulate the incident primary photon energy fluence and energy spectrum with a 
physical model. Scattered photons and electrons from the primary interaction 
are considered when calculating dose to a point. A convolution kernel, derived 
from measurement or Monte Carlo simulation, is used in the dose calculation. 
Monte-Carlo based algorithms, such as Monaco MC, simulate photons and 
particles transport and use fundamental physics to determine the probability of 
interactions. Dose is determined by scoring interaction and energy deposition in 
each voxel. Instead of Monte Carlo method, the Eclipse AXB algorithm uses 
numerical method to explicitly solve the linear Boltzmann transport equation, 
which describes the interactions of radiation particles with matter. The method 
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involves discretization of photon and electron fluences in space, angle and 
energy and is an alternative solution to the time consuming Monte Carlo 
simulation. 
 
 
Figure 3-1 Set-up for TPS dose computation. The entrance and exit doses were 
defined as doses at 1.5 cm from the beam entry and exit surface respectively. 
Doses were computed for virtual water phantoms with total thickness 
(1.5+Th+1.5) cm, where Th ranged from 0 cm to 30 cm. 
 
Doses on all TPSs, except for Monaco MC, were calculated using 0.1 cm grid size 
with the calculation box enclosing the outer border of the virtual phantoms. The 
Monaco MC calculation grid was set to 0.2 cm with 1% standard deviation per 
plan criteria because of hardware limitations. 
 
The TPSs were located in two separate and independent institutions; Institution 
A (Inst. A) is equipped with the Eclipse TPS commissioned for the Varian Clinac 
21EX (Palo Alto, CA, USA) linac while Institution B (Inst. B) is equipped with XiO 
and Monaco TPSs commissioned for the Elekta Synergy (Stockholm, Sweden) 
linac. All comparisons described in this study were performed between TPS and 
the corresponding linac for which the TPS was commissioned. 
 
3.3.1.2 Experimental measurement 
Using a 0.6 cc Farmer IC (Inst. A: NE2581, Nuclear Enterprises, Fairfield, NJ, USA 
and; Inst. B: PTW30001, Freiburg, Germany) in water-equivalent solid phantoms 
of dimension 30 x 30 cm2 (Inst. A: Solid Water with density 1.04 g/cm3, Gammex 
Inc., Middleton, WI, USA and; Inst. B: Plastic Water with density 1.03 g/cm3, 
CIRS Inc., Norfolk, VA, USA) set-up at SSD 100 cm, entrance and exit central axis 
point doses were measured for a 6 MV beam on the Clinac 21EX and Synergy 
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linacs. Entrance doses were measured at depth 1.5 cm with backscatter 
thickness ranging from 1.5 cm to 31.5 cm while exit doses were measured at 
depths 1.5 cm to 31.5 cm with backscatter thickness of 1.5 cm. Doses were 
measured at a gantry angle of zero degrees for field sizes 5 x 5 cm2 to 20 x 20 
cm2. This experimental set-up, illustrated in Figure 3-2, replicates the condition 
for TPS dose computations described in Section 3.3.1.1.  
 
 
Figure 3-2 Set-up for experimental measurement with IC and water-
equivalent solid phantoms. Entrance doses were measured at depth 1.5 cm 
with backscatter thickness ranging from 1.5 cm to 31.5 cm while exit doses were 
measured at depths 1.5 cm to 31.5 cm with backscatter thickness of 1.5 cm. 
Measured doses were used as reference for comparison with TPS computed 
doses. 
 
To avoid uncertainties related to differences in chambers, electrometers and 
water-equivalent solid phantoms in the two institutions, a ‘relative’ approach 
was taken. As outputs for linacs at both institutions were calibrated in water to 
1 cGy/MU at calibration condition, readings were first taken in charge mode at 
calibration condition to obtain the charge to dose conversion factor. Subsequent 
measurements were performed in charge and converted to dose using this 
factor. This method also allowed variation in daily output to be corrected. In 
addition, measurements were repeated with a CC04 IC (IBA Dosimetry, 
Schwarzenbruck, Germany) to provide a crosscheck on the accuracy of the data 
measured with the 0.6 cc Farmer IC, especially for the smallest field size of 5 x 
5 cm2. To maintain consistency, the same investigator performed all 
measurements in both institutions. Finally, the measured doses were used as a 
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reference for comparison with TPS computed doses to evaluate the accuracy of 
different algorithms.  
 
3.3.1.3 Deriving Backscatter Correction Factor (BCF) 
BCF was defined as the ratio of dose without full backscatter to dose with full 
backscatter (Equation 3-1).   
 
Backscatter Correction Factor, BCF= Dose without Full$Backscatter
Dose with Full Backscatter
,!where BCF is ≤1  (3-1) 
 
Doses without full backscatter were the doses measured using methods 
described in Section 3.3.1.2. Doses with full backscatter were calculated using 
percentage depth dose (PDD) and field size output factor (OF) according to 
Equation 3-2. PDD and OF were measured with CC13 IC (IBA Dosimetry, 
Schwarzenbruck, Germany) in a scanning water tank (IBA Dosimetry, 
Schwarzenbruck, Germany).  
 
Dosefs
d  = Ddmax × PDDfs
d  × OFfs                                                                  (3-2) 
 
where ‘d’ is the depth where dose is calculated, ‘fs’ is the field size at distance 
100 cm, ‘Ddmax’ is the dose at depth of maximum for reference field size (usually 
10 x 10 cm2), ‘PDDfs
d ’ is the percentage depth dose and ‘OFfs’ is the field size 
output factor.  
 
3.3.2 1D relative profile analysis 
To check the accuracies of the TPS algorithms in computing off-axis doses, TPS 
profiles were compared with profiles measured with IC (Inst. A: CC04 and Inst. 
B: CC13, IBA Dosimetry, Schwarzenbruck, Germany) in the scanning water tank. 
The 1D TPS profiles were extracted from 2D entrance and exit dose planes 
computed by the six TPS algorithms for a 6 MV beam with different field sizes (5 
x 5 cm2 to 20 x 20 cm2) and depths (1.5 cm to 31.5 cm) in virtual water 
phantoms. The IC profiles could not be measured at the exit plane because of 
limitations in measuring with 1.5 cm backscatter using the scanning water tank, 
but the differences in set-up between TPS and IC profiles were not critical as 
backscatter thickness affects the relative profiles only minimally (Vial et al., 
2009).  
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However, since the IC measured profiles were used as a reference, they were 
independently checked against exit measurements performed with commercial 
2D array devices, MapCHECK2 (Sun Nuclear, Melbourne, FL, USA) in Inst. A and 
MatriXXEvolution (IBA Dosimetry, Schwarzenbruck, Germany) in Inst. B. Water-
equivalent solid phantoms of appropriate thicknesses were placed on top of the 
devices to measure 2D exit dose planes at various depths (the inherent thickness 
of material behind the detectors, less than 3.5 cm, were ignored). Profiles were 
extracted from the 2D array measured dose planes for comparison with the IC 
measured profiles.  
 
All profiles were normalized to the central axis for relative comparisons. Image 
processing and analysis were performed using MATLAB (R2011a_Student, The 
Mathworks, Natick, MA, USA) software. 
 
3.3.3 2D absolute dose analysis 
The 1D relative profiles measured with IC in the scanning water tank, either in 
the in-line or cross-line direction, were used to generate 2D dose planes. For 
each depth and field size, the measured 1D relative profile was duplicated to fill 
a 2D matrix. Assuming that the in-line and cross-line profiles were identical in 
shape, the same 1D relative profile was used to fill another 2D matrix but in a 
direction perpendicular to the previous matrix. Then, the two matrices, 
representing the in-plane and cross-plane, were multiplied to generate a 2D 
relative dose plane. Finally, the 2D relative dose plane was converted to a 2D 
absolute dose plane by multiplication with the measured central axis point dose.  
 
The 2D absolute dose planes derived from IC measurements were compared to 
TPS computed dose planes using 2D global gamma evaluations. Results were 
given as percentage points that passed the gamma criterion of 3%/3mm. 
 
3.4 Results 
 
3.4.1 Central axis point doses: TPS versus IC 
Repeated entrance and exit central axis point measurements using two different 
chambers, 0.6 cc Farmer and CC04 ICs, showed excellent agreement with 
! 58!
difference less than 0.7% for the whole range of field sizes (5 x 5 cm2 to 20 x 20 
cm2) and backscatter thicknesses or depths (1.5 cm to 31.5 cm) measured in this 
study. To account for set-up uncertainties, repeated measurements with the 
same chamber on different occasions showed a maximum disagreement of less 
than 0.5%. The consistency in these results gave confidence to the measured 
data. 
 
Comparison of central axis entrance doses between TPS computed and IC 
measured for different field sizes (5 x 5 cm2 to 20 x 20 cm2) and backscatter 
thicknesses (1.5 cm to 31.5 cm) showed good agreement to within 2%. All six TPS 
algorithms accurately computed the entrance doses at depth 1.5 cm for the 6 
MV beam.  
 
Central axis point dose comparisons at the exit level, where the thickness of 
underlying material was 1.5 cm, showed a variable degree of accuracy among 
the different algorithms. Figure 3-3 shows the percentage difference in TPS 
computed and IC measured exit doses as a function of depth (for clarity of 
presentation, only field size 20 x 20 cm2 results are shown in the figure). Exit 
doses computed with XiO Convolution, XiO Superposition and Monaco MC agreed 
with the IC measured doses to within 2.3%. Eclipse AXB showed similar results 
except for the smallest field size (5 x 5 cm2) where deviation was 3.3%. Poorer 
results were seen with Eclipse PBC and Eclipse AAA where the computed exit 
doses deviated from IC measured doses by up to 5.3% and 4.8% respectively. In 
the case of Eclipse PBC and Eclipse AAA, deviations of exit doses increased with 
increasing field size and depth. Figure 3-4 shows the percentage exit dose 
difference between Eclipse AAA and IC measured doses for different field sizes 
as a function of depth. For clearer illustration, only Eclipse AAA results are 
shown in the figure. 
 
! 59!
 
Figure 3-3 Percentage difference in central axis exit doses between 
computed by different TPS algorithms and measured by IC. For clarity, only 
field size 20 x 20 cm2 results are plotted.  
(Note: Percentage difference was calculated as [(TPS/IC)-1]*100). 
 
 
Figure 3-4 Percentage difference in central axis exit doses between Eclipse 
AAA and IC measured as a function of depth for different field sizes, 5 x 5 
cm2 to 20 x 20 cm2. Eclipse AAA computed exit doses were all higher than IC 
measured exit doses. The discrepancies increased with increasing field size and 
depth. For clarity, only Eclipse AAA results are plotted.  
(Note: Percentage difference was calculated as [(TPS/IC)-1]*100). 
  
3.4.2 Backscatter Correction Factor (BCF) values 
To quantify the effect of backscatter on the entrance and exit doses, BCF values 
were experimentally derived and are presented in Table 3-1 for the 6 MV beam 
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from Clinac 21EX and Elekta Synergy linacs. The BCF tables were separated into 
entrance BCF and exit BCF. Entrance BCF was derived at a fixed depth of 1.5 cm 
with underlying material thickness ranging from 1.5 cm to 31.5 cm. Exit BCF was 
derived at depths ranging from 6.5 cm to 31.5 cm with the thickness of 
underlying material being kept constant at 1.5 cm. The BCF values are presented 
for field size ranging from 5 x 5 cm2 to 20 x 20 cm2.  
 
BCF values were found to be very similar for both beams as the beam quality 
was almost identical for the 6MV beam from Clinac (TPR20,10 = 0.669) and Synergy 
(TPR20,10 = 0.687). The average differences in BCF values between the two linacs 
were 0.1%±0.07% (1 SD) and 0.5%±0.47% (1 SD) for the entrance and exit BCF 
respectively. Entrance BCF initially increased before it reached unity as the 
thickness of underlying material and field size increased. The minimum entrance 
BCF occurred when the underlying material was the smallest, 1.5 cm, and the 
field size largest, 20 x 20 cm2. The values were 0.972 for Clinac and 0.978 for 
Synergy beams. The dose reduction became negligible (less than 0.5% dose 
reduction) when the thickness of underlying material was equal to or more than 
11.5 cm. Meanwhile, the exit BCF ranged from 0.995 to 0.963 and 1.000 to 0.960 
for the Clinac and Synergy beam respectively. The largest correction occurred at 
the largest depth, 31.5 cm, and field size, 20 x 20 cm2.  
 
As most clinical treatments are isocentric with variable SSD, BCF values were 
also derived for phantoms set-up at 100 cm to the centre. Comparison of BCF 
values between fixed SSD 100 cm and variable SSD showed very similar results 
with a maximum difference of 0.8% and standard deviation of 0.15% (1 SD) for 
the whole range of depths and field sizes tested. 
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Table 3-1 Entrance and exit backscatter correction factor (BCF) for 6 MV 
photon beams from Clinac and Synergy linacs. BCF values were tabulated as a 
function of field size and thickness of underlying material (backscatter 
thickness) for the entrance BCF and thickness of overlying material (depth) for 
the exit BCF. 
Entrance BCF (Depth 1.5 cm) 
        
 Backscatter thickness (cm) 
Field size (cm2) 1.5a 6.5 11.5 16.5 21.5 26.5 31.5 
Clinac 21EX 
(TPR20,10 = 0.669) 
 
       
5 x 5 0.991 0.995 0.998 0.998 0.999 0.999 1.000 
10 x 10 0.985 0.994 0.998 0.999 0.999 1.000 1.000 
15 x 15 0.978 0.991 0.997 0.999 0.999 1.000 1.000 
20 x 20 0.972 0.990 0.996 0.999 0.999 1.001 1.000 
        
Synergy 
(TPR20,10 = 0.687) 
 
       
5 x 5 0.993 0.996 0.997 0.997 0.998 0.998 1.000 
10 x 10 0.987 0.995 0.997 0.998 0.999 0.999 1.000 
15 x 15 0.981 0.993 0.996 0.998 0.999 0.998 1.000 
20 x 20 0.978 0.992 0.996 0.999 1.000 1.000 1.000 
        
Exit BCF (Backscatter thickness 1.5 cm) 
        
 Depth (cm) 
Field size (cm2) 1.5a 6.5 11.5 16.5 21.5 26.5 31.5 
Clinac 21EX 
(TPR20,10 = 0.669) 
       
5 x 5 0.991 0.995 0.991 0.984 0.976 0.970 0.972 
10 x 10 0.985 0.987 0.983 0.980 0.973 0.970 0.960 
15 x 15 0.978 0.983 0.978 0.974 0.972 0.968 0.965 
20 x 20 0.972 0.981 0.972 0.973 0.969 0.965 0.963 
        
Synergy 
(TPR20,10 = 0.687) 
 
       
5 x 5 0.993 1.000 0.993 0.987 0.984 0.977 0.975 
10 x 10 0.987 0.988 0.987 0.986 0.985 0.982 0.983 
15 x 15 0.981 0.978 0.978 0.976 0.971 0.972 0.971 
20 x 20 0.978 0.971 0.968 0.966 0.965 0.962 0.960 
        
a Exit BCF for depth 1.5 cm was equivalent to entrance BCF with backscatter 
thickness 1.5 cm.  
 !  
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3.4.3 1D relative profiles: TPS versus IC 
Comparisons between TPS and IC relative profiles at depths 1.5 cm to 31.5 cm 
are presented in Figure 3-5. Only the maximum field size, 20 x 20 cm2, is shown 
for brevity. The profiles are compared in the diagonal direction, rather than in-
line or cross-line, to maximise the area of analysis.  
 
From the figure, it can be observed that the relative profiles from Eclipse PBC, 
XiO Convolution and XiO Superposition algorithms matched well with IC 
measured relative profiles at all depths. As for Eclipse AAA, slight mismatches 
with IC measured relative profiles were seen at depth 1.5 cm and 11.5 cm. 
Mismatches were also observed between Eclipse AXB and IC measured relative 
profiles at depths 21.5 cm and 31.5 cm. The Eclipse AXB profiles were found to 
be higher than IC measured profiles at the shoulder regions. The discrepancies 
worsened as depth increased from 21.5 cm to 31.5 cm. Similarly, mismatches 
were observed between Monaco MC and IC measured relative profiles at depths 
21.5 cm and 31.5 cm. But unlike Eclipse AXB, the Monaco MC profiles were lower 
than the IC measured profiles and the disagreements were seen nearer to the 
centre. The arrows in Figure 3-5 indicate the different areas of mismatch.  
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Figure 3-5 Comparisons between TPS computed and IC measured relative 
profiles. TPS (red solid line) and IC (blue dashed line) relative profiles for 20 x 
20 cm2 open field at depths 1.5 cm to 31.5 cm. The profiles were extracted in 
the diagonal direction from TPS computed dose planes and IC measured dose 
planes and normalised to the central axis. The arrows show areas of mismatch.  
 
3.4.4 Validation of IC dose planes: IC versus 2D array 
The IC dose planes were derived from simple cross-multiplication of in-line and 
cross-line profiles measured in a scanning water tank. Since the IC dose planes 
were used as a reference, they were independently verified with a commercial 
2D array device. Figure 3-6 shows the comparisons of relative profiles extracted 
from IC dose planes derived in this study and from 2D array measured dose 
planes.  Good agreements were seen for all depths, confirming the validity of 
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the method used to create the IC dose planes and thereby, justifying the use of 
the IC dose planes as a reference for evaluating the accuracy of TPS algorithms. 
 
 
Figure 3-6 Comparisons between IC and 2D array measured relative profiles. 
IC (blue dashed line) and 2D array (magenta solid line) relative profiles for 20 x 
20 cm2 open field at depths 11.5 cm to 31.5 cm. The profiles were extracted in 
the diagonal direction from IC derived dose planes and 2D array measured dose 
planes and normalised to the central axis. Good agreements were observed for 
all comparisons, confirming the validity of IC dose planes for use as reference. 
 
3.4.5 2D absolute gamma: TPS versus IC  
Figure 3-7 shows the results for the 2D absolute gamma comparison between TPS 
computed dose planes and IC measured dose planes. The percentage of points 
that passed the global gamma criterion of 3%/3mm in the whole field and at the 
centre 80% of the fields are given in Table 3-2. The boundaries of region for 
analysis (whole field and centre 80% of the fields) are defined manually without 
applying automatic threshold. The 2D absolute gamma analysis could not be 
performed for Eclipse PBC and Eclipse AAA because of the large deviation in 
dose, of more than 3%, up to about 5%, as reported in Section 3.4.1. 
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Figure 3-7 2D absolute gamma comparisons between TPS computed and IC 
measured dose planes for 20 x 20 cm2 open field. Areas that passed the 
gamma criterion of 3%/3mm are indicated in green and areas that failed are 
indicated in red. The outer dashed box and the inner dashed box mark the 100% 
and 80% field areas used for analysis respectively. 2D absolute gamma 
comparisons could not be performed for Eclipse PBC and Eclipse AAA because of 
the large deviation in dose. Additional comparisons for Monaco MC using a 
2%/2mm criterion (last row) are included to show the effect of relative profile 
mismatches seen in Figure 3-5.  
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Table 3-2 2D absolute gamma comparisons between TPS computed dose 
planes and IC measured dose planes for 20 x 20 cm2 open field. The gamma 
comparison results were given as percentage of points that passed the gamma 
criterion of 3%/3mm. 2D absolute gamma comparisons could not be performed 
for Eclipse PBC and Eclipse AAA because of the large deviation in dose. 
  Depth (cm) 
bCentral axis 
point dose 
difference 
Gamma criterion 
(3%/3mm) 
  100% of field area 80% of field area 
Eclipse AXB 11.5 0.9% 99.8% 100.0% 
 
21.5 1.7% 89.2% 100.0% 
 
31.5 2.3% 73.7% 98.1% 
 
     
XiO Convolution 11.5 1.7% 100.0% 100.0% 
 
21.5 1.7% 100.0% 100.0% 
 
31.5 0.4% 100.0% 100.0% 
 
     
XiO Superposition 11.5 1.6% 100.0% 100.0% 
 
21.5 1.1% 100.0% 100.0% 
 
31.5 -0.2% 100.0% 100.0% 
 
     
Monaco MC 11.5 0.2% 100.0% 100.0% 
 
21.5 1.3% 100.0% 100.0% 
  31.5 1.7% 100.0% 100.0% 
b The central axis point dose difference was calculated as [(TPS/IC)-1]*100 
 
XiO Convolution, XiO Superposition and Monaco MC absolute dose planes showed 
excellent agreement with IC measured dose planes. The gamma pass rates with 
3%/3mm criterion were 100% for these three algorithms. Meanwhile, the gamma 
pass rates for Eclipse AXB ranged from 73.7% to 99.8% with poorer pass rates as 
depth increased. When only the centre 80% of the field was analysed, the Eclipse 
AXB gamma pass rates improved to above 98.1%. 
 
3.5 Discussion 
 
3.5.1 Consistency of data from different institutions 
This study compared TPS computed doses with IC measured doses in two 
different institutions with TPS, linac and dosimetry equipment of different 
models. To ensure that the results in this study were not affected by these 
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differences, the quality of TPS beam models and the methods used to collect 
data for this study must remain consistent in both institutions.  
 
Commissioning data for all TPSs in both institutions were measured according to 
manufacturers’ requirements. Similarly, beams were modelled according to 
manufacturers’ methods, with no additional users’ intervention for the Eclipse 
and Monaco TPSs. Although XiO TPS beams were modelled in-house, the 
procedures were also consistent with manufacturer’s requirements. Therefore, 
any variation would be TPS/manufacturer specific and not due to differences 
introduced by users. In general, the manufacturers state an accuracy of better 
than 3% for the beam models. This specification was independently verified for 
each of the beam models by comparing the measured and modelled PDD curves 
for all the field sizes investigated in this study (5 x 5 cm2 to 20 x 20 cm2). The 
measured PDD curves referred to the PDD values measured with an IC in a 
scanning water tank. The modelled PDD curves were represented by normalised 
doses computed with the beam models at different depths in a virtual water 
tank (dimension 65 cm x 65 cm x 50 cm). By comparing the two curves, accuracy 
of the beam models can be quantified. Comparisons of values at different points 
along the PDD curves, up to depth 31.5 cm, showed an accuracy of better than 
2% for all the beam models tested in this study. The mean percentage 
differences (±1SD) were 0.4%±0.44% (Eclipse PBC), 0.6%±0.57% (Eclipse AAA), 
0.8%±0.75% (Eclipse AXB), -0.4%±0.41% (XiO Convolution), -0.4%±0.67% (XiO 
Superposition) and 0.2%±0.50% (Monaco MC). This validation was important to 
ensure that baseline differences in beam models were not large enough to affect 
the outcome of this study.  
 
As for the consistency in TPS dose calculations on virtual phantoms, the same 
settings, as far as possible, were used for all calculations. The same investigator 
created the virtual phantoms in all TPSs to avoid inter-personal variation. As 
these virtual phantoms were simple cubes with assigned uniform water density, 
the uncertainties related to inaccuracies in creation of the virtual phantoms 
were negligible. Lastly, the differences in dosimetry equipment in the two 
institutions were mitigated by using a ‘relative’ measurement technique. 
Readings were first taken in charge mode and later converted to dose using 
factors derived from measurements under calibration condition. 
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3.5.2 Central axis point dose deviation 
Exit doses computed by Eclipse PBC and Eclipse AAA were found to be higher 
than IC measured doses by up to 5% (Figure 3-3 and Figure 3-4). To further 
investigate the large deviation seen with Eclipse PBC and Eclipse AAA, an 
additional virtual water phantom with dimension 65 cm x 65 cm x 50 cm was 
created to simulate full scatter condition. Using the same beam settings, doses 
to this phantom were computed with full scatter condition (Figure 3-8, right) as 
well as to another phantom with only 1.5 cm backscatter (Figure 3-8, left). The 
dose to point ‘P’ for both phantoms was compared for a wide range of field sizes 
(5 x 5 cm2 to 20 x 20 cm2) and depths (1.5 cm to 31.5 cm). In theory, the dose at 
the exit, where the backscatter thickness was 1.5 cm, should be lower because 
of reduced backscattered photon. However, results from Eclipse PBC and Eclipse 
AAA showed similar doses for both phantoms, with and without full backscatter. 
The average percentage dose difference was 0.4%±0.29% and 0.2%±0.20% for 
Eclipse PBC and Eclipse AAA respectively.  
 
 
Figure 3-8 TPS virtual water phantoms without and with full backscatter. 
Virtual water phantoms, created in the TPS, to represent conditions without full 
backscatter (or exit dose) (left) and with full backscatter (right). The dose to 
point ‘P’ was computed for the same beam settings (6 MV, field size 5 x 5 cm2 to 
20 x 20 cm2, SSD 100 cm) on both phantoms and compared. Results from Eclipse 
PBC and Eclipse AAA showed that the algorithms computed similar dose to point 
‘P’ for both conditions, with and without full backscatter, implying that the 
effect of backscatter thickness was not taken into account by the algorithms.  
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Furthermore, comparisons between Eclipse PBC and Eclipse AAA exit doses with 
doses calculated from PDD using Equation 3-2, where full backscatter existed, 
again showed very similar values with an average difference of 0.5%±0.41% and 
0.4%±0.44% for Eclipse PBC and Eclipse AAA respectively. This suggested that 
both algorithms do not consider the lack of backscatter and assume that full 
backscatter exists even at the exit level. This omission caused the dose at the 
exit level to be over-estimated by the TPS as indicated in the comparison with IC 
measured dose in Section 3.4.1. In clinical treatment planning, an error of 5% in 
the computed exit dose, where the dose is originally low, would be of limited 
implication. However, this shortcoming in the TPS algorithms must be taken into 
account especially in the case where in-vivo exit dose measurements were 
directly compared to the TPS computed values to avoid wrong interpretation of 
in-vivo dosimetry results. To facilitate the estimation of backscatter effect for 
different conditions, the BCF values were provided in Table 3-1.  
 
3.5.3 BCF values 
BCF values were almost identical for the two 6 MV beams with very similar beam 
quality investigated in this study. BCF is influenced by beam energy because the 
probability of Compton interaction and the direction of scatter are energy 
dependent. The effect of backscatter is less for higher energy beams due to 
more forward scatter and less large-angle scatter photons.  
 
For the entrance BCF, the effect of backscatter contribution was as much as 2% 
to 3% (for backscatter thickness 1.5 cm and field size 20 x 20 cm2). However, the 
extremely small vertical thickness is not common in clinical practice. In this 
study, the dose reduction became negligible when the thickness of underlying 
material was equal to or more than 11.5 cm. For a 6 MV beam with the same 
field size and depth, Hu & Zhu (2011) reported a smaller thickness, 5 cm, to 
reach full backscatter condition. As for the field size influence on BCF, the 
backscatter effect is more prominent for bigger field sizes due to the larger area 
of scattering.  
 
For the exit BCF, the lack of backscattered photons at the exit level resulted in 
an approximately 4% reduction in dose at depth 31.5 cm and field size 20 x 20 
cm2. This value was within the ICRU recommendation of less than 5% (ICRU 
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Report No. 24, 1976) and agreed favourably with published data. For example, 
at depth 20 cm and field size 20 x 20 cm2, Kappas & Rosenwald (1991) reported 
a value of 0.967 compared to our values of 0.969 (Clinac) and 0.965 (Synergy). 
The backscattering effect was more obvious at larger depths because, as the 
beam traverses the medium, the change in the beam spectrum results in higher 
relative contributions of backscattered photons.  
 
Finally, BCF values were found to be very similar between fixed SSD 100 cm and 
variable SSD. Since the fractional scatter contribution to depth dose is 
independent of the beam divergence (Johns et al., 1958), the backscatter effect 
would be expected to be independent as well. The results shown above confirm 
that the BCF table was independent of SSD and the same was reported by 
Lambert et al. (1983) and Kappas & Rosenwald (1991). 
 
3.5.4 1D relative profile and 2D absolute dose analysis 
Mismatches in the relative profiles from TPS and IC measured were observed for 
Eclipse AAA, Eclipse AXB and Monaco MC (Figure 3-5). While the Eclipse AAA dose 
planes could not be evaluated using absolute gamma comparisons because of the 
large deviation in dose, the profile mismatches seen with Eclipse AXB and 
Monaco MC could be seen in the absolute gamma comparison results presented 
in Figure 3-7. The Eclipse AXB profiles mismatched at the shoulders causing 
gamma failure at the field borders, which explained the improvement in gamma 
pass rate when only the central 80% of the field area was analysed. Meanwhile, 
mismatches for Monaco MC profiles, which were lower than IC profiles near the 
centre of the fields, were cancelled off by the higher central axis point dose 
calculated by Monaco MC and this resulted in good gamma agreement using the 
3%/3mm gamma criteria. The effect of the profile mismatches, which was 
nearer to the centre, became noticeable when the gamma evaluation criterion 
was set to 2%/2mm, as shown in Figure 3-7. 
 
3.6 Conclusions 
 
In conclusion, all six TPS algorithms accurately computed the central axis 
entrance doses to within 2%. However, for the exit doses, Eclipse PBC and 
Eclipse AAA algorithms failed to account for the lack of backscatter, which 
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resulted in central axis dose errors of up to 5%. Since the tolerance level for in-
vivo dosimetry is commonly set at 5%, the dose error for Eclipse PBC and Eclipse 
AAA must be considered to avoid misinterpretation of results. The correction 
factors to account for the effect of reduced backscatter under different 
conditions were presented in the result section as BCF values.  
 
Away from the central axis, slight mismatches were observed between IC and 
TPS relative profiles computed with Eclipse AAA, Eclipse AXB and Monaco MC 
algorithms at certain depths. Comparisons of two-dimensional dose planes in 
absolute term, using gamma analysis with 3%/3mm criterion, showed good 
agreement between IC and TPS dose planes computed by XiO Convolution, XiO 
Superposition and Monaco MC. Meanwhile, the Eclipse AXB dose planes disagreed 
with IC measured dose planes mostly at the outer 20% of the field area. The 2D 
absolute gamma evaluation was not performed for Eclipse PBC and Eclipse AAA 
dose planes because of large deviation in absolute dose of more than 3%. 
 
Accurate computation of entrance and exit dose is essential if a TPS is to be 
used for reference dose comparisons in in-vivo dosimetry. The findings of this 
study, therefore, serve as a useful baseline for the implementation of entrance 
and exit in-vivo dosimetry in clinical departments utilizing any of these six 
common TPS algorithms for reference comparison. Also, this study was necessary 
as a preliminary assessment on the accuracy of TPS computed entrance and exit 
dose planes before the dose planes were used in the EPID dosimetry model 
developed in this research, as described in the following chapters.   
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Chapter 4: Relating EPID and TPS – Proof of concept 
 
4.1 Publication/presentation arising from work in this chapter  
 
• EPID and TPS: Connecting the dots, Tan, Y., Metwaly, M., Glegg, M. & 
Elliott, A., 2012, Oral presentation, Scottish Plus Radiotherapy Physics 
Meeting, Glasgow, Scotland, UK.  
• A simple method to predict 2D EPID transit dose, Tan, Y., Metwaly, M., 
Glegg, M., Baggarley, S. & Elliott, A., 2013, Oral presentation, 
Engineering and Physical Sciences in Medicine Conference, Perth, 
Australia. !
4.2 Introduction 
 
EPID and TPS are markedly different in their response and scatter 
characteristics. While the TPS is based on water measurements, the presence of 
high Z material in the a-Si EPID detectors causes deviation from water-
equivalent behaviour. Because of this reason, the comparison between EPID 
measured dose and TPS computed dose is not straightforward.  
 
In this chapter, a novel method that uses radiological thickness or water 
equivalent path length (EPL) to relate two different dosimetry systems, EPID and 
TPS, is presented. The rationale for using EPL to link two different dosimetry 
systems is based on the premise that the EPL is a property of the attenuator and 
hence, a common parameter for both systems.  
 
The EPL was calculated using a quadratic equation that was established by 
Swindell (1983), which relates transmitted radiation to attenuator thickness. 
Earlier description of the calibration method to derive coefficients in the 
quadratic equation can also be found in the publication by Morton et al. (1991). 
Historically, the quadratic calibration method was intended for use in image 
reconstruction and restoration. Swindell (1983) established the quadratic 
equation to calculate integral linear attenuation coefficients for CT image 
reconstruction, in an attempt to modify a megavoltage (MV) accelerator for 
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concurrent use as a CT scanner. Separately, Morton et al. (1991) used the 
quadratic calibration method to remove artefacts from raw MV images acquired 
with a prototype imaging panel during radiotherapy treatment. The image 
processing was necessary to improve the quality of MV images, which were 
inherently low in contrast because of the predominant Compton interaction with 
high scatter contribution and low differential attenuation between materials of 
different Z. Also for image processing, Fielding et al. (2002) investigated the use 
of the quadratic calibration method to remove intensity modulations from EPID 
images captured during IMRT treatment delivery, in order to view the outline of 
bony anatomy for positional verification.  
 
Apart from image processing, the quadratic calibration method could also be 
extended for dosimetric application, as reported by several investigators and 
also the intention of this research. For example, Evans et al. (1995) and 
Symonds-Tayler et al. (1997) calibrated an in-house imaging panel for the 
conversion of the patient transit image to an EPL map, which was subsequently 
used to design compensators for breast treatment. Rather than actual CT scans, 
the EPL map was used to estimate a ‘pseudo-CT’ slice for the calculation of 
compensated beams to achieve a desired dose distribution. The method was 
later applied to a commercial SLIC EPID for the same purpose (Evans et al., 
1999). More recent studies had suggested that the quadratic calibration method 
was also applicable to the newer a-Si EPID (Kairn et al., 2008). Kairn et al. 
(2008) proposed the use of a 2D EPL map calculated from the measured EPID 
transit signal as a form of treatment verification. Although, in theory, any 
deviation in EPL from the expected value could be indicative of inaccuracy in 
treatment delivery, the comparison in unit length was undesirable since the 
dosimetric impact could not be immediately quantified. Instead of using EPL to 
verify the accuracy of treatment delivery, Kavuma et al. (2010) extended the 
application of EPL to reconstruct in-phantom entrance and exit doses for 
comparison with TPS computed doses. In the EPID transit dosimetry model 
described by Kavuma et al. (2010), the conversion of EPL to 2D in-phantom doses 
required additional parameters such as TPR values and envelope and boundary 
profiles generated by the Eclipse TPS (Varian, Palo Alto, CA, USA). For dose 
reconstruction of enhanced dynamic wedge fields, the golden segmented 
treatment table (GSTT) implemented by Varian was also required (Kavuma et 
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al., 2011). The need for parameters specific to Varian in the dose reconstruction 
process was a major drawback, as it disallowed the application of the dosimetry 
model in centres with models of linac and TPS from other manufacturers.  
  
The focus of this chapter is to describe a concept, capable of converting EPL to 
dose without requiring input parameters specific to any manufacturer. The 
method involves calibrating the quadratic equation and deriving the coefficients 
for TPS as well as EPID. Consequently, with two sets of coefficients, EPL of any 
attenuator can be calculated using either EPID measured dose planes or TPS 
computed dose planes. The EPL, together with the sets of coefficients, are then 
used to provide a two-way relationship for the:  
 
1. Reconstruction of in-phantom exit dose from EPID measured dose planes, 
for comparison with TPS planned dose. (The in-phantom exit dose was 
defined as dose at 1.5 cm upstream from the beam exit surface of the 
phantom); and 
 
2. Prediction of EPID transit dose from TPS computed dose planes, for 
comparison with EPID measurement during treatment.  
 
As a preliminary study to prove the validity of this concept, the method was 
tested with open fields of different field sizes on homogeneous water-equivalent 
phantoms of different thicknesses. To demonstrate that the method was generic 
and non-manufacturer specific, the study was performed in two separate and 
independent institutions with different models of linac, EPID and TPS.  
 
4.3 Materials and methods !
4.3.1 Photon beam attenuation and quadratic formalism 
For a very narrow mono-energetic photon beam that traverses an attenuator, 
the reduction in radiation intensity is proportional to the thickness of the 
attenuator and can be described with a linear exponential function, given in 
Equation 4-1 (Podgorsak, 2005, Khan, 2010b). 
 
I
I0
 =  e-µt                                                                                           (4-1)    
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where ‘I0’ is the intensity of incident photons, ‘I’ is the intensity of photons 
after the beam traverses an attenuator with thickness ‘t’ and ‘µ’ is the linear 
attenuation coefficient. The linear attenuation coefficient represents the 
attenuation per unit length and is dependent on the beam energy and the 
attenuator material (Khan, 2010b). If the attenuator thickness were given in 
centimetres, then the unit of the linear attenuation coefficient would be cm-1. 
 
In practice, clinical photon beams are not mono-energetic nor are they very 
narrow and, therefore, may not strictly follow the linear exponential function. 
Through experimental measurements, Swindell (1983) showed that, for a broad 
poly-energetic beam, the relationship between amount of attenuation and 
attenuator thickness could be described accurately with a quadratic equation.  
 
I
I0
 =  e-(At + Bt2)                                                                                    (4-2) 
 
where ‘A’ is the linear coefficient analogous to µ in Equation 4-1 and ‘B’ is the 
coefficient for the quadratic term that describes the non-linear relationship 
mainly due to spectral variation in a photon beam, with minimal contribution 
from scatter. By taking the logarithm on both sides of Equation 4-2, a variation 
to the quadratic equation could also be expressed as follows (Equation 4-3): 
 
-ln I
I0
 =  At + Bt2                                                                              (4-3) 
 
4.3.2 Quadratic formalism in this model 
For the purpose of this study, the terms in quadratic Equation 4-3 were re-
designated as:  
 
- ln M i,j
M0 i,j
 = A i,j  × EPL i,j  + B i,j  × EPL2 i,j                                  (4-4) 
 
where ‘M0’ is the entrance dose plane before a beam traverses an attenuator, 
‘M’ is the exit (or transit) dose plane after a beam traverses an attenuator and 
‘EPL’ is the water-equivalent path length of the attenuator. The ‘i’ and ‘j’ 
denote the Cartesian coordinate of pixels in a 2D plane.  
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The A and B coefficients were derived separately for EPID and TPS, (A and B)EPID 
and (A and B)TPS, using sets of calibration M and M0 dose planes from EPID 
measurements and TPS computations respectively. The calibration dose planes 
were acquired for both EPID and TPS using the same reference beam (6 MV, 100 
MU, and field size 20 x 20 cm2) and the same set of water-equivalent phantoms 
thicknesses (0 cm to 35 cm, in 5 cm increment). Detailed descriptions of the 
EPID and TPS calibration dose planes acquisition are provided in sub-Sections 
4.3.3.1 and 4.3.3.2.  
 
Following Equation 4-4, the A and B coefficients could be derived by applying a 
second-order polynomial fit to the negative logarithm of transmission, -
ln(M/M0), against the phantom thickness, PT, for the whole set of calibration 
dose planes. Since the density of phantoms used in the calibration process was 
equivalent to water, the PT could be used to represent EPL. The fitting process 
was repeated pixel-by-pixel to derive A and B coefficients in 2D. To account for 
the slight variation in phantom thickness due to beam divergence away from the 
central axis, the PT was calculated for each pixel according to Equation 4-5. This 
equation was briefly mentioned in Kairn et al. (2008) and a detailed 
mathematical derivation is provided in Appendix A of this thesis. 
 
PT i,j  = 
PT 0,0  × i2+j2
SDD 0,0  × sin θ
  ,!!!where   θ = tan-1 i2+j2
SDD 0,0
                             (4-5) 
 
where ‘PT(i,j)’ is the phantom thickness corrected for beam divergence, 
‘PT(0,0)’ is the phantom thickness at the central axis  and ‘SDD’ is the source to 
detector distance defined at the central axis. ‘Θ’ is the angle between the 
central axis ray and the divergent ray. 
 
With the availability of A and B coefficients, EPL of any attenuator could be 
calculated from Equation 4-6 (inversion of Equation 4-4) if the value of M/M0 
were known.  
 
EPL i,j  = 
-A i,j  ± A2 i,j  – 4B i,j  × ln M i,j M0 i,j
2B i,j
                                       (4-6) 
! 77!
 
Although mathematically, the quadratic equation should be solved with both 
plus and minus sign, the negative answer was excluded since the EPL must be a 
positive value. Also, depending on whether the M and M0 were measured with 
EPID or computed with TPS, the coefficients must be chosen accordingly when 
calculating the EPL. For example, to calculate EPL from EPID measured M and M0 
dose planes, the (A and B)EPID coefficients must be used. 
 
Another important point to note was that the calibration process to derive A and 
B coefficients was carried out under a fixed reference condition. Therefore, 
Equation 4-6 could only calculate the EPL correctly if the same reference 
condition was observed. Deviation from the reference condition must be 
addressed using additional correction factors. One such correction was the field 
size correction factor (FSF), defined as the ratio of dose for the reference field 
size to dose for other field sizes of interest. The FSF was experimentally 
measured and tabulated for a range of field sizes (3 x 3 cm2 to 20 x 20 cm2) and 
attenuator thicknesses (0 cm to 35 cm) for both EPID and TPS. The FSF was 
necessary to account for changes in head scatter as well as changes in the 
amount of phantom scatter to detector, when the field size deviated from the 
reference field size of 20 x 20 cm2. This correction factor was included as a 
coefficient to the M/M0 term to become: 
 
EPL i,j  = 
-A i,j  ± A2 i,j  – 4B i,j  × ln FSF(i,j) × M i,j M0 i,j
2B i,j
                           (4-7) 
 
Lastly, the EPL was calculated using an iterative numerical method similar to 
that described by Kavuma et al. (2010). The iteration method was required since 
the FSF was a function of attenuator thickness. Using the value from Equation 4-
6 as an initial approximation (EPLn), the calculation was set to repeat itself five 
times until a converged solution was reached (EPLn+1). The equation used for the 
iterative calculation is given in Equation 4-8 and the derivation of this iterative 
equation is presented in Appendix B.  
 
EPLn+1 i,j  =  
B i,j  × EPLn
2 i,j  - ln FSF(i,j) × M i,j M0 i,j
A i,j  + 2B i,j  × EPLn i,j
                               (4-8) 
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4.3.3 Commissioning process: Calibration dose planes for A and B 
derivation 
The calibration dose planes were acquired separately for EPID and TPS using the 
same reference beam (6 MV, 100 MU and field size 20 x 20 cm2) and the same set 
of thicknesses (0 cm to 35 cm, in 5 cm increment). The EPID measurements and 
TPS computations were performed in two institutions, ‘Inst. A’ and ‘Inst. B’, 
equipped with linac, EPID and TPS from different manufacturers as shown in 
Table 4-1. 
 
Table 4-1 Linac, EPID and TPS models used in this study.  
 Institution A (Inst. A) Institution B (Inst. B) 
Manufacturer Varian (Palo Alto, CA, USA) Elekta (Stockholm, Sweden) 
Linac Clinac Synergy 
EPID panel 
aS500 (Pixels: 384 x 512, Active 
area: 30 x 40 cm2) 
iViewGT (Pixels: 1024 x 1024, 
Active area: 41 x 41 cm2)  
EPID software IAS3 Revision 3.4 
TPS (Algorithm) Eclipse (AAA), version 10.0.28 XiO (Superposition), version 4.70 
 
4.3.3.1 Measurements of EPID calibration dose planes to derive (A and B)EPID 
The experimental set-up to measure EPID calibration dose planes is shown in 
Figure 4-1. The same experimental set-up was used in both institutions except 
for the source to EPID distance. The source to EPID distance was fixed at 140 cm 
in ‘Inst. A’ and 160 cm in ‘Inst. B’. The shorter 140 cm distance was selected in 
‘Inst. A’ because the aS500 panel has a smaller active area (30 x 40 cm2) that 
limits the maximum irradiation field size to approximately 20 cm at the 
isocentre. Meanwhile, the iViewGT panel in ‘Inst. B’ was by default fixed at 160 
cm distance and not adjustable in the vertical direction. No filter was added and 
no modification was done to the EPID panels for practical implementation.  
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Figure 4-1 Experimental set-up for EPID calibration dose planes 
measurements. Using a reference beam (6 MV, 100 MU, field size 20 x 20 cm2) 
at zero gantry angle, the entrance (M0) calibration dose planes were measured 
without any phantom in the beam, while the exit (M) calibration dose planes 
were measured with water-equivalent solid phantoms of different thicknesses 
(PT = 5 to 35 cm, in 5 cm increment) positioned isocentrically at source to axis 
distance (SAD) 100 cm.  
 
As can be seen from Figure 4-1, the M0 dose planes were measured without a 
phantom in the beam (PT = 0 cm) while M dose planes were measured with slabs 
of water-equivalent solid phantoms of different thicknesses (PT = 5 cm to 35 cm, 
in 5 cm increment) positioned isocentrically at source to axis distance (SAD) of 
100 cm. The couch was placed in the beam for both M0 and M measurements. All 
measurements were done at a gantry angle of zero degrees. The phantoms used 
for measurements in the two institutions were: ‘Inst. A’ - Solid Water with 
density 1.04 g/cm3 (Gammex Inc., Middleton, WI, USA); and ‘Inst. B’ - Plastic 
Water with density 1.03 g/cm3 (CIRS Inc., Norfolk, VA, USA). 
 
All the EPID images in this study were acquired using default manufacturer’s 
settings that automatically perform dark field, flood field and defect pixel 
corrections as part of the standard image processing procedure. 
 
EPID image = Raw image -!DF
FF - DF
                                                                   (4-9) 
 
where ‘DF’ is the dark field (or offset correction) used to remove background 
signal detected when no radiation is present and ‘FF’ is the flood field (or gain 
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correction) used to correct for non-uniform response of each pixel caused by 
intrinsic differences of the photodiodes. After the DF and FF corrections, any 
bad pixels were automatically identified and replaced with an average value 
based on the neighbouring pixels. Although the DF and FF corrections may 
change due to routine EPID re-calibration, the calibration dose planes need not 
be re-measured because the A and B coefficients were derived based on ratios 
(M/M0) and any signal differences would be cancelled out. In the case of 
iViewGT, the EPID images were by default stored after multiplication with a 
scaling factor. Therefore, the pixel value readout from the iViewGT EPID image 
must be divided by the scaling factor, which could be retrieved from the image 
log file. 
 
Since the EPID was not absolutely calibrated to dose, the more appropriate term 
to describe the EPID measurements should be ‘EPID image’ or ‘EPID signal’. 
However, the term ‘EPID dose plane’ is used in this thesis for consistency with 
the TPS computed dose planes. 
 
4.3.3.2 Computations of TPS calibration dose planes to derive (A and B)TPS 
Virtual water phantoms of dimensions 30 cm x 30 cm x ‘1.5+PT+1.5’ cm (where 
PT = 0 cm to 35 cm, in 5 cm increment) were created in the Eclipse TPS in ‘Inst. 
A’ and the XiO TPS in ‘Inst. B’. With the virtual water phantoms set 
isocentrically at SAD 100 cm, doses were computed for the reference beam (6 
MV, 100 MU, field size 20 x 20 cm2) at gantry angle zero degrees. The algorithm 
used for the dose computation was AAA (Eclipse, version 10.0.28, Varian, Palo 
Alto, CA, USA) in ‘Inst. A’ and Multigrid Superposition (XiO, version 4.70, Elekta, 
Stockholm, Sweden) in ‘Inst. B’. Doses were computed with 0.1 cm grid size with 
the calculation box enclosing the outer borders of the virtual phantoms. The set-
up dimension for TPS dose computation is illustrated in Figure 4-2.  
 
The M0 and M, defined as dose at 1.5 cm from the beam entry and exit surface 
respectively, were exported as the TPS calibration dose planes. The 1.5 cm 
depth was chosen to provide reasonable electronic equilibrium conditions for the 
6 MV photon beam used in this study. Before the exported dose planes were used 
to derive the ATPS and BTPS coefficients, all the M0 and M dose planes were scaled 
to the same reference level using inverse square distance correction. In this 
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study, the isocentre (100 cm from source), which was also the mid-plane of the 
phantom, was chosen as the reference level. The inverse square distance scaling 
was done so that the ratio of M and M0 will reflect the reduction of dose due to 
object attenuation entirely without the effect of distance. 
 
!
Figure 4-2 Set-up for TPS calibration dose planes computations. Doses were 
computed for the reference beam (6 MV, 100 MU, field size 20 x 20 cm2) on 
virtual water phantoms with dimension 30 cm x 30 cm x ‘1.5+PT+1.5’ cm (where 
PT = 0 cm to 35 cm, in 5 cm increment) positioned isocentrically at SAD 100 cm. 
The M0 and M calibration dose planes were exported at depth 1.5 cm from the 
beam entry and exit surface respectively. !
4.3.4 Relating EPID and TPS based on quadratic formalism 
The principle of the quadratic formalism, including the derivation of A and B 
coefficients and the calculation of EPL of attenuator, was explicitly described in 
previous paragraphs. Figure 4-3 illustrates the function of these A and B 
coefficients and EPL in relating the two different dosimetry systems, EPID and 
TPS. 
 
The two areas framed in Figure 4-3 were used to visually distinguish the EPID 
dosimetry system (on the left) from the TPS dosimetry system (on the right). 
From the figure, it can be observed that the EPL plays a central role in linking 
the EPID and TPS. The EPL could be used for this purpose because it is a 
property of the attenuator and, thus, common to both dosimetry systems. On 
the other hand, it was necessary to derive (A and B)EPID and (A and B)TPS 
separately and use the correct coefficients in the calculations since the dose 
response and scatter characteristics of the EPID are different from the water-
based TPS. 
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Also as can be seen from the figure, the two-way prediction model allows users 
to either: (Path 1) predict in-phantom TPS dose ratio from EPID measured dose 
planes (Figure 4-3, blue arrows from left to right) or; (Path 2) predict EPID dose 
ratio from TPS computed dose planes (Figure 4-3, green arrows from right to 
left). From the predicted dose ratios, the final reconstruction of in-phantom exit 
dose and prediction of EPID transit dose are provided in sub-Sections 4.3.5 and 
4.3.6 respectively.  
 
In this study, all image processing and calculations were performed using 
MATLAB software (R2011a Student version, The MathWorks, Natick, MA). 
 
!
Figure 4-3 The role of (A and B)EPID, (A and B)TPS and EPL in relating the two 
different dosimetry systems, EPID and TPS. Equations 4-4 and 4-7 are the 
different forms of quadratic equation, as given in the text. From left to right is 
the path to predict in-phantom dose ratio (M/M0)TPS from EPID measured dose 
planes (Path 1). From right to left is the path to predict EPID dose ratio 
(M/M0)EPID from TPS computed dose planes (Path 2). Depending on the path 
chosen by the user, the predicted (M/M0)TPS or (M/M0)EPID were subsequently 
used to either reconstruct in-phantom exit dose or predict EPID transit dose 
respectively. Descriptions of the final dose re-construction/prediction process 
are given in sub-Sections 4.3.5 and 4.3.6. 
 
4.3.5 Path 1: Reconstruction of in-phantom exit dose 
Figure 4-3, from left to right, shows the pathway to predict in-phantom exit to 
entrance dose ratio (M/M0)TPS from EPID measured dose planes (Path 1). Besides 
the EPID transit dose plane captured during treatment delivery (MEPID_tx), an 
additional measurement of the same treatment field without attenuator in the 
beam was also required (M0EPID_tx). The M0EPID_tx can either be measured once for 
repeated use in the subsequent dose prediction or a new dose plane can be 
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captured each time on the day of verification. By using the latter, machine 
output variation for the day was taken into account and would not be reflected 
in the results. In this study, the M0EPID_tx was measured on the same day as the 
MEPID_tx. Then, the ratio of MEPID_tx to M0EPID_tx together with the (A and B)EPID 
coefficients were used as input to Equation 4-7 for the calculation of EPL of the 
attenuator. The FSFEPID, tabulated for EPID measured dose planes as a function 
of field sizes (3 x 3 cm2 to 20 x 20 cm2) and attenuator thicknesses (0 cm to 35 
cm), was used in Equation 4-7 to correct for non-reference treatment field size. 
Moving from the EPID environment to the TPS environment, the calculated EPL 
was used in combination with (A and B)TPS coefficients to derive the equivalent 
TPS ratio (M/M0)TPS based on Equation 4-4.  
 
Once the equivalent TPS ratio was derived, the in-phantom exit dose could be 
reconstructed by multiplying this equivalent TPS ratio with a TPS entrance dose 
plane (M0TPS ref) (reference field size 20 x 20 cm2) that was previously computed 
as the calibration dose plane. An inverse square correction was also added to 
scale dose from the reference level (100 cm) to the exit level. The mathematical 
expression to calculate in-phantom exit dose from the TPS ratio is given in 
Equation 4-10. 
 
MTPS!pred = MM0 TPS  × M0TPS!ref ÷ FSFTPS × 100SDD 2                                       (4-10) 
 
where ‘MTPS pred’ is the reconstructed in-phantom exit dose plane, ‘(M/M0)TPS’ is 
the equivalent TPS ratio predicted from EPID measured dose planes as shown in 
Figure 4-3, ‘M0TPS ref’ is the TPS entrance calibration dose plane computed for 
the reference beam and ‘SDD’ is the source to detector distance (or source to 
exit distance in this case). The FSFTPS is the field size correction factor, defined 
as the ratio of dose for the reference field size to dose for other field sizes of 
interest, tabulated for TPS computed doses as a function of field sizes (3 x 3 cm2 
to 20 x 20 cm2) and attenuator thicknesses (0 cm to 35 cm).  
 
Finally, the 2D in-phantom exit dose reconstructed from EPID dose planes was 
compared to TPS computed dose to verify the accuracy of treatment delivery.  !!  
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4.3.6 Path 2: Prediction of EPID transit dose 
Figure 4-3, from right to left, shows the pathway to predict EPID exit to 
entrance dose ratio from TPS exported dose planes (Path 2). The TPS exported 
entrance (M0TPS_tx) and exit (MTPS_tx) planned doses, along with the (A and B)TPS 
coefficients were used to calculate the EPL matrix of the attenuator from 
Equation 4-7. The FSFTPS was used in Equation 4-7 to correct for non-reference 
treatment field size. The calculated EPL was used to move from the TPS 
environment to the EPID environment. Using the calculated EPL together with 
the (A and B)EPID coefficients, the equivalent EPID ratio (M/M0)EPID was calculated 
from Equation 4-4.  
 
With this equivalent EPID ratio, the EPID transit dose (MEPID pred) can be predicted 
by multiplying the EPID ratio with an EPID dose plane captured for the reference 
beam without any phantom in the beam (M0EPID ref). The M0EPID ref can be either 
the original EPID commissioning dose plane or a newly captured dose plane on 
the day of verification as noted above. Equation 4-11 below shows the 
mathematical expression to predict EPID transit dose using the EPID ratio 
derived from TPS computed dose planes.  
 
MEPID!pred = MM0 EPID  × M0EPID!ref ÷ FSFEPID                                                 (4-11) 
 
where ‘MEPID pred’ is the predicted EPID transit dose plane, ‘(M/M0)EPID’ is the 
equivalent EPID ratio derived from TPS exported dose planes as shown in Figure 
4-3 and ‘M0EPID ref’ is the EPID entrance calibration dose plane measured for the 
reference beam. The FSFEPID is the field size correction factor, defined as the 
ratio of dose for the reference field size to dose for other field sizes of interest, 
tabulated for EPID measured dose planes as a function of field sizes (3 x 3 cm2 to 
20 x 20 cm2) and attenuator thicknesses (0 cm to 35 cm). 
 
Finally, the 2D EPID transit dose predicted from TPS dose planes was compared 
to EPID measured dose plane to verify the accuracy of treatment delivery.  
 !  
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4.4 Results 
 
4.4.1 Quadratic equation coefficients for EPID and TPS 
Figure 4-4 shows the plots of negative logarithm of transmission, -ln(M/M0), 
against the phantom thickness for both EPID and TPS calibration dose planes. 
Data in the graphs represent the mean value of 12 x 12 pixels in the central 
region of a 2D dose plane (equivalent to a 1.0 cm2 region for Varian and a 0.5 x 
0.5 cm2 region for Elekta). All data points, from both EPID and TPS, could be 
fitted very well with a second-order polynomial (also known as the quadratic 
function), y = Bx2 + Ax. The goodness of fit of the trend lines to the data, as 
indicated by the R-squared values, were very close to unity, ranging from 0.9988 
to 0.9999. In general, it can be seen that the linear term (A coefficient = 10-2) 
dominates over the quadratic term (B coefficient = 10-4). Nevertheless, the 
quadratic term should be included for better accuracy especially with thicker 
attenuators where the non-linear component becomes more important.  
 
It can also be observed from Figure 4-4 that the values of A and B coefficients 
for EPID and TPS were different, for the same photon beam. The value of A 
coefficient was higher for the EPID (Varian = 0.043 cm-1; Elekta = 0.046 cm-1) 
compared to the TPS (Varian = 0.023 cm-1; Elekta = 0.022 cm-1). The value of B 
coefficient, observed as deviation from the arbitrary straight line in the graphs, 
highlights the difference between EPID and TPS in the pattern of deviation from 
linearity. As thickness increases, the amount of attenuation was less compared 
to a linear relationship for EPID measured doses (Varian = -0.0001 cm-2; Elekta = 
-0.0002 cm-2), but more compared to a linear relationship for TPS computed 
doses (Varian = 0.0003 cm-2; Elekta = 0.0003 cm-2). As noted from the values, the 
variation between EPID and TPS was consistent for both manufacturers. 
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Figure 4-4 Plot of negative logarithm of transmission, -ln(M/M0), versus 
phantom thickness, PT. Data from EPID calibration dose planes and TPS 
calibration dose planes are shown in the top and bottom row respectively. Data 
represent the mean value of 12 x 12 central pixels in a 2D dose planes. The data 
were fitted with a second-order polynomial, y = Bx2 + Ax, (solid line) and 
compared with an arbitrary linear trend line (dashed line). The values of A and B 
coefficients were found to be different for EPID (top row) and TPS (bottom row), 
but fairly consistent between the two manufacturers, Varian (left column) and 
Elekta (right column).  
 
The fitting of data to a second-order polynomial was performed for each pixel, 
resulting in a 2D matrix of A and B coefficients. Figure 4-5 shows the cross-line 
profiles extracted from 2D A and B coefficients for EPID and TPS. From the plots, 
it can be observed that the A and B coefficients vary in a symmetrical manner 
with off-axis positions. Discontinuity of profile at the sides of B coefficient 
derived from iViewGT EPID images could be due to slight misalignment of the set 
of calibration dose planes caused by jaw position inaccuracy. Although the 
absolute values of the coefficients were different between the EPID and TPS, the 
patterns of variation across the fields were similar. For the A coefficient of the 
linear term, the minimum value occurred at the centre of the field and increases 
with increasing distance from the central axis. On the contrary, the maximum 
value of the B coefficient for the quadratic term was at the centre of the field 
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and decreases with increasing distance from the central axis. The same 
observation was true for both Varian and Elekta. 
 
!
Figure 4-5 Cross-line profiles extracted from 2D A and B coefficients. Profiles 
for Varian and Elekta are shown in the top and bottom row respectively. Blue 
data points indicate the (A and B)EPID while green data points indicate the (A and 
B)TPS.  !
4.4.2 Accuracy of EPL calculated from EPID and TPS dose planes 
The accuracy of EPLs calculated from the quadratic equation (Equation 4-7 and 
4-8) and the derived coefficients were verified using slabs of homogeneous 
water-equivalent phantoms with thickness ranging from 5 cm to 35 cm. The 
reference beam (6 MV, 100 MU, field size 20 x 20 cm2) was used in this 
evaluation. The EPLs were calculated from EPID measured dose planes and (A 
and B)EPID  as well as TPS computed dose planes and (A and B)TPS. Both sets of 
calculated EPLs were compared to the expected values. Since the phantoms are 
of the same density as water, the expected EPL values were equivalent to the 
physical thickness of the phantoms. Table 4-2 summarises the accuracy of EPL 
values calculated from EPID and TPS dose planes for both Varian and Elekta. 
Although all EPLs were calculated as 2D matrices, for clarity the EPL 
comparisons are presented as the mean value of 12 x 12 pixels in the central 
region.  
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Table 4-2 Comparisons of calculated versus expected EPL of attenuators. The 
EPLs calculated from EPID measured dose planes and (A and B)EPID are listed in 
the ‘EPID’ column, while the EPLs calculated from TPS computed dose planes 
and (A and B)TPS are listed in the ‘TPS’ column. 
    EPID TPS 
  Expected EPL (cm) 
aCalculated 
EPL (cm) 
Difference 
(cm) 
aCalculated 
EPL (cm) 
Difference 
(cm) 
V
ar
ia
n 
5 5.36 0.36 4.65 -0.35 
10 10.14 0.14 9.88 -0.12 
15 14.93 -0.07 15.04 0.04 
20 19.90 -0.10 20.22 0.22 
25 24.84 -0.16 25.13 0.13 
30 29.91 -0.09 29.79 -0.21 
35 35.19 0.19 35.04 0.04 
El
ek
ta
 
5 5.19 0.19 4.71 -0.29 
10 10.09 0.09 9.79 -0.21 
15 15.02 0.02 14.96 -0.04 
20 19.90 -0.10 20.17 0.17 
25 24.88 -0.12 25.17 0.17 
30 29.95 -0.05 30.00 0.00 
35 35.12 0.12 34.90 -0.10 
a Mean values of 12 x 12 pixels in the central region of the calculated 2D EPL 
matrix. 
 
The maximum difference between calculated and expected EPL values was ±0.36 
cm. The difference in EPL calculated from EPID dose planes and its coefficients 
ranged from -0.16 cm to 0.36 cm for Varian and -0.12 cm to 0.19 cm for Elekta. 
Meanwhile, the accuracy of EPL calculated from TPS dose planes and its 
coefficients ranged from -0.35 cm to 0.22 cm for Varian and -0.29 cm to 0.17 cm 
for Elekta.  !
4.4.3 Comparisons of in-phantom exit dose: Reconstructed versus 
TPS 
Figure 4-6 shows the in-phantom exit dose profiles comparisons between those 
reconstructed from EPID dose planes and TPS computed. The accuracy of dose 
reconstruction was initially tested with the reference beam of field size 20 x 20  
cm2 and slabs of homogeneous water-equivalent phantoms placed at the 
isocentre. The thickness of homogeneous phantoms used in this test was: 5 cm, 
10 cm, 15 cm, 20 cm, 25 cm, 30 cm and 35 cm. Differences in in-phantom exit 
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doses at the central region between the reconstructed and TPS computed are 
listed in Table 4-3. 
 
!
Figure 4-6 In-phantom exit dose profiles comparisons between reconstructed 
versus TPS computed for a 6 MV, 100 MU beam with field size 20 x 20 cm2 
irradiated at gantry angle zero degrees. The reconstructed (blue dashed line) 
and TPS (red solid line) profiles were extracted in the in-line direction from 2D 
dose planes. Profiles, from top to bottom, were the in-phantom exit doses for 
homogeneous water-equivalent phantoms with thickness 5 cm, 10 cm, 15 cm, 20 
cm, 25 cm, 30 cm and 35 cm positioned at the isocentre. The tests were done on 
both Varian (left) and Elekta (right) systems. Dose values in the central region 
are given in Table 4-3.  !
Table 4-3 Comparisons of in-phantom exit dose values between 
reconstructed and TPS computed (various phantom thicknesses, field size 20 
x 20 cm2). Doses (represented by the mean values of 12 x 12 pixels in the 
central region) were compared for homogeneous water-equivalent phantoms 
with different thicknesses ranging from 5 cm to 35 cm and a 6 MV reference 
beam with field size 20 x 20 cm2. 
Homogeneous 
phantom 
thickness (cm) 
Varian Elekta 
TPS computed 
(cGy) 
Reconstructed 
(cGy) 
aDifference 
(%) 
TPS computed 
(cGy) 
Reconstructed 
(cGy) 
aDifference 
(%) 
5 92.2 89.2 -3.3% 114.2 111.7 -2.2% 
10 76.1 74.9 -1.5% 94.4 93.0 -1.5% 
15 61.7 61.9 0.4% 77.1 76.8 -0.4% 
20 49.5 50.2 1.6% 61.9 62.8 1.5% 
25 39.3 40.0 1.7% 49.4 50.2 1.6% 
30 31.3 31.1 -0.7% 39.3 39.3 0.0% 
35 23.7 23.5 -0.7% 30.7 30.4 -1.0% 
a Percentage dose difference was calculated as [(Reconstructed/TPS computed)-1]*100 
 
Comparisons of in-phantom exit dose profiles, between reconstructed from EPID 
dose planes and TPS computed, showed good matching even at the penumbra 
region. All reconstructed in-phantom exit doses, represented by the mean of 12 
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x 12 pixels in the central region, deviated by less than 1.7% from the TPS 
computed doses except for the smallest phantom with thickness 5 cm. The 
reconstructed exit dose for the 5 cm thick phantom was lower than the TPS 
computed dose by 3.3% and 2.2% for Varian and Elekta system respectively.  
 
Comparisons of in-phantom exit doses were also performed for open fields of 
different sizes: 3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2 and 15 x 15 cm2. The results 
are presented for homogeneous phantoms with thickness 10 cm, 15 cm, 20 cm 
and 30 cm. The in-phantom exit dose profiles comparisons are shown in Figure 4-
7 while dose differences in the central region are given in Table 4-4. 
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Figure 4-7!In-phantom exit dose profiles comparisons between reconstructed 
versus TPS computed for a 6 MV, 100 MU beam with field sizes 3 x 3 cm2, 5 x 
5 cm2, 10 x 10 cm2 and 15 x 15 cm2. Blue dashed lines and red solid lines 
represent the reconstructed and TPS profiles respectively. The thicknesses of 
homogeneous water-equivalent phantoms used were 10 cm, 15 cm, 20 cm and 30 
cm. Dose values in the central region are given in Table 4-4. 
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Table 4-4 Comparisons of reconstructed and TPS computed in-phantom exit 
dose values for beams with different field sizes (3 x 3 cm2 to 15 x 15 cm2). 
Doses are represented by the mean values of 12 x 12 pixels in the central region. 
Homogeneous 
phantom 
thickness (cm) 
Field size 
(cm2) 
Varian Elekta 
TPS 
computed 
(cGy) 
Reconstruc
ted (cGy) 
bDifference 
(%) 
TPS 
computed 
(cGy) 
Reconstruc
ted (cGy) 
bDifference 
(%) 
10 3 x 3 56.1 55.0 -2.0% 71.2 69.8 -2.0% 
  5 x 5 60.9 59.7 -2.0% 76.7 75.2 -2.0% 
  10 x 10 68.8 67.4 -2.0% 85.7 84.1 -1.9% 
  15 x 15 73.5 72.0 -2.0% 90.8 89.1 -1.9% 
           
15 3 x 3 42.6 42.5 -0.4% 54.9 54.5 -0.7% 
  5 x 5 46.8 46.7 -0.4% 59.6 59.2 -0.7% 
  10 x 10 54.3 54.1 -0.4% 67.9 67.4 -0.7% 
  15 x 15 59.0 58.7 -0.4% 73.1 72.6 -0.7% 
           
20 3 x 3 32.4 32.9 1.6% 42.4 42.8 0.9% 
  5 x 5 35.8 36.4 1.6% 46.2 46.7 1.1% 
  10 x 10 42.4 43.0 1.5% 53.3 53.8 0.9% 
  15 x 15 46.6 47.4 1.6% 58.2 58.8 1.0% 
           
30 3 x 3 19.1 19.3 0.9% 25.7 25.7 0.0% 
  5 x 5 21.3 21.5 0.8% 28.2 28.2 0.0% 
  10 x 10 25.9 26.0 0.5% 32.9 32.9 0.0% 
  15 x 15 29.1 29.2 0.5% 36.4 36.4 0.0% 
b Percentage dose difference was calculated as [(Reconstructed/TPS computed)-1]*100 !
It can be observed from Figure 4-7 and Table 4-4 that the method proposed in 
this study can accurately reconstruct in-phantom exit doses from EPID measured 
dose planes even when the field size differed from the reference condition. 
Good matching between reconstructed in-phantom exit dose and TPS computed 
dose profiles can be seen for all field sizes including the smallest field of 3 x 3 
cm2. Although the difference between reconstructed dose profiles and TPS dose 
profiles seems to be more prominent for the phantom with thickness 10 cm, the 
dose differences were 2% or less. From Table 4-4, it can also be noticed that the 
percentage dose deviations were fairly consistent for different field sizes for the 
same phantom thickness, indicating that the method of FSF correction was 
accurate.  
 
In general, the in-phantom exit dose could be reconstructed from EPID measured 
dose planes with an accuracy of approximately 2% for open fields of different 
sizes (3 x 3 cm2 to 20 x 20 cm2) tested on homogeneous water-equivalent 
phantoms of different thicknesses (5 cm to 35 cm). The only exception was the 
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3.3% dose deviation for the 5 cm thick phantom tested with a 20 x 20 cm2 field 
on the Varian system. !!
4.4.4 Comparisons of EPID transit dose: Predicted versus measured 
Instead of comparing doses in-phantom at the exit level, doses can also be 
compared at the EPID level. Figure 4-8 shows the profiles comparisons between 
EPID transit doses predicted from TPS dose planes and EPID transit doses 
measured during treatment delivery, with dose differences in the central region 
listed in Table 4-5.  
 
!
Figure 4-8 EPID transit dose profiles comparisons between predictions from 
TPS dose planes and measured with EPID for a 6 MV, 100 MU, field size 20 x 
20 cm2 beam irradiated at gantry angle of zero degrees. The TPS predicted 
(red solid line) and EPID measured (blue dashed line) profiles were extracted in 
the in-line direction from 2D dose planes. Profiles, from top to bottom, were the 
EPID transit doses for homogeneous water-equivalent phantoms with thickness 5 
cm, 10 cm, 15 cm, 20 cm, 25 cm, 30 cm and 35 cm positioned at the isocentre. 
The tests were done on both Varian (left) and Elekta (right) systems. Dose values 
in the central region are listed in Table 4-5. 
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Table 4-5 Comparisons of predicted and measured EPID transit pixel values 
(various phantom thicknesses, field size 20 x 20 cm2). Doses (represented by 
the mean values of 12 x 12 pixels in the central region) were compared for 
homogeneous water-equivalent phantoms with different thicknesses ranging 
from 5 cm to 35 cm and a reference beam with field size 20 x 20 cm2. 
Homogeneous 
phantom 
thickness (cm) 
Varian Elekta 
EPID 
measured 
(pixel value) 
Predicted  
(pixel value) 
cDifference 
(%) 
EPID 
measured  
(pixel value) 
Predicted  
(pixel value) 
cDifference 
(%) 
5 43.0 44.3 3.1% 1.1E+06 1.1E+06 1.9% 
10 35.0 35.4 1.1% 8.6E+05 8.7E+05 1.2% 
15 28.8 28.6 -0.5% 7.0E+05 7.0E+05 0.1% 
20 23.7 23.4 -1.2% 5.8E+05 5.7E+05 -1.0% 
25 19.8 19.6 -1.0% 4.8E+05 4.7E+05 -1.1% 
30 16.6 16.6 0.4% 4.0E+05 4.0E+05 0.0% 
35 13.9 14.0 0.6% 3.3E+05 3.4E+05 0.9% 
c Percentage difference was calculated as [(Predicted/EPID measured)-1]*100 
 
Figure 4-8 shows very good matching of profiles, across the whole field area, 
between predictions from TPS dose planes and planes directly measured with 
the EPID. Comparisons of doses in the central region revealed that most of the 
doses agreed to within 2% except for the smallest phantom thickness of 5 cm 
tested on the Varian system, where the predicted dose was higher than the 
measured by 3.1%. Overall, the difference between predicted and measured 
EPID transit dose ranged from -1.2% to 3.1% for the Varian system and -1.1% to 
1.9% for the Elekta system.  
 
In addition to the reference beam with field size 20 x 20 cm2, results for EPID 
transit dose comparisons for other field sizes are presented in Figure 4-9 (for 
profiles comparisons) and Table 4-6 (for central region dose comparisons). 
Beams with different field sizes (3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2 and 15 x 15 
cm2) were selectively tested on homogeneous water-equivalent phantoms with 
thickness 10 cm, 15 cm, 20 cm and 30 cm on both the Varian and Elekta systems.  
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Figure 4-9 EPID transit dose profiles comparisons between predictions from 
TPS dose planes versus measured with EPID for a 6 MV, 100 MU beam with 
field sizes 3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2 and 15 x 15 cm2. Red solid lines 
and blue dashed lines represent the TPS predicted and EPID measured profiles 
respectively. The thicknesses of water-equivalent phantoms used were 10 cm, 
15 cm, 20 cm and 30 cm. Differences in pixel values at the central region are 
given in Table 4-6.  
! 96!!
Table 4-6 Comparisons of predicted and measured EPID transit pixel values 
for beams with different field sizes (3 x 3 cm2 to 15 x 15 cm2). Doses are 
represented by the mean values of 12 x 12 pixels in the central region. 
Homogeneous 
phantom 
thickness (cm) 
Field size 
(cm2) 
Varian Elekta 
EPID 
measured 
(pixel 
value) 
Predicted 
(pixel 
value) 
dDifference 
(%) 
EPID 
measured 
(pixel 
value) 
Predicted 
(pixel 
value) 
dDifference 
(%) 
10 3 x 3 21.0 21.4 1.5% 6.6E+05 6.7E+05 1.4% 
  5 x 5 22.4 22.8 1.5% 6.9E+05 7.0E+05 1.4% 
  10 x 10 25.3 25.7 1.5% 7.6E+05 7.7E+05 1.6% 
  15 x 15 28.1 28.5 1.5% 8.0E+05 8.2E+05 1.6% 
           
15 3 x 3 16.4 16.5 0.1% 5.2E+05 5.2E+05 0.4% 
  5 x 5 17.7 17.7 0.1% 5.5E+05 5.5E+05 0.4% 
  10 x 10 20.0 20.0 0.1% 6.0E+05 6.0E+05 0.5% 
  15 x 15 22.6 22.7 0.1% 6.5E+05 6.5E+05 0.5% 
           
20 3 x 3 12.9 12.8 -1.3% 4.1E+05 4.1E+05 -0.7% 
  5 x 5 13.8 13.6 -1.3% 4.4E+05 4.3E+05 -0.9% 
  10 x 10 16.1 15.9 -1.3% 4.8E+05 4.8E+05 -1.0% 
  15 x 15 18.5 18.3 -1.3% 5.3E+05 5.2E+05 -0.9% 
           
30 3 x 3 8.2 8.2 -0.2% 2.7E+05 2.7E+05 0.0% 
  5 x 5 8.9 8.8 -0.2% 2.8E+05 2.8E+05 0.0% 
  10 x 10 10.2 10.2 -0.2% 3.2E+05 3.2E+05 0.3% 
  15 x 15 12.6 12.5 -0.2% 3.6E+05 3.6E+05 0.3% 
d Percentage difference was calculated as [(Predicted/EPID measured)-1]*100 
 
Similar to field size 20 x 20 cm2, tests with other field sizes showed very good 
profiles matching between predictions from TPS dose planes and measured with 
EPID. The results show that the proposed model is capable of predicting EPID 
transit dose for field sizes other than the reference, including the very small 3 x 
3 cm2 field. Differences in pixel values in the central region ranged from -1.3% 
to 1.6% for all the phantom thicknesses and field sizes tested. For the same 
phantom thickness, the dose differences were fairly consistent for test fields 
with different sizes.  
 
From these results, it can be summarised that the EPID transit doses can 
generally be predicted to within 2% of direct measurements for open fields of 
various sizes and homogeneous phantoms of various thicknesses. The only 
exception was for the reference beam tested on the smallest phantom with 
thickness 5 cm for the Varian system, where the dose deviation between 
predicted and measured amounted to 3.1%. 
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4.5  Discussion !
In a photon beam produced by a conventional linac, the beam energy spectrum 
varies with off-axis position because of differential beam hardening by the cone-
shaped flattening filter. Since the amount of beam attenuation is dependent on 
the beam energy (Khan, 2010b), the A and B coefficients are expected to vary at 
off-axis positions as well. This effect is obvious in Figure 4-5, where the 
coefficients varied symmetrically away from the central axis. The same trend 
could be observed for both EPID and TPS. Several authors have reported the 
same finding with EPID measurements (Swindell, 1983, Symonds-Tayler et al., 
1997, Kairn et al., 2008, Kavuma et al., 2010) and MC simulation of EPID 
response (Kairn et al., 2008) but no publications could be found for TPS or IC 
measurements. Nevertheless, the relative variation of A and B coefficients at 
off-axis positions highlights the importance of deriving the coefficients for each 
point in the 2D plane. 
 
Although both the EPID and TPS showed the same pattern of relative off-axis 
variations, the absolute values of the A and B coefficients were distinctly 
different (Figure 4-5). This was because the amount of attenuation quantified 
from EPID measured and TPS computed dose planes was different for the same 
reference beam and phantom thickness, as can be seen from Figure 4-4. In this 
study, the A coefficient (analogous to linear attenuation coefficient) was found 
to be higher for the EPID compared to the TPS. This was consistent with the 
observation by Kirkby & Sloboda (2005) where the response to an attenuated 
beam, relative to a non-attenuated beam, was lower (or more attenuation) for 
the EPID compared to IC measurements at the same level. The effect was 
attributed to reduced over-response of the EPID due to removal of low energy 
photons from the attenuated beam. As for the B coefficient, the EPID 
measurements reflected less attenuation than would be expected for a linear 
relationship with increasing attenuator thickness. This less than linear trend for 
EPID measurements also concurred with those reported by other researchers 
(Swindell, 1983, Kairn et al., 2008) and may be an effect of beam hardening 
with increasing attenuator thickness (Kirkby & Sloboda, 2005). However, in 
contrast to the EPID, the TPS graphs indicated more attenuation with increasing 
thickness, compared to a linear relationship. This might be because the TPS M0 
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and M were defined differently in this study, as dose inside the phantom at 1.5 
cm from the beam entrance and exit surface of the attenuator respectively. The 
TPS set-up to compute M0 and M was not designed to satisfy the narrow beam 
geometry for transmission measurements and could have resulted in the 
impression of a beam softening effect. The different deviation from linearity 
was not further investigated as beam spectrum quantification was beyond the 
scope of this study. What was more important for the purpose of this study was 
that both the EPID and TPS transmission data could be fitted very well with a 
quadratic function (Figure 4-4). But recognising the difference, it was imperative 
that the A and B coefficients must be derived separately for EPID and TPS. 
 
By using the respective A and B coefficients, EPL of the attenuator could be 
derived accurately from either EPID measured dose planes or TPS computed dose 
planes (Table 4-2). For both instances, accuracy of the calculated EPLs was 
found to be better than ±0.36 cm. The EPL results from this study compared 
favourably with those reported by previous researchers. Employing the same 
quadratic calibration method for EPID measurements, Kavuma et al. (2010) 
reported that the calculated EPLs deviated by less than ±0.30 cm from the 
expected values, while Kairn et al. (2008) reported that the EPLs calculated 
from EPID measured dose planes and MC simulated EPID dose planes deviated by 
less than ±0.25 cm and ±0.50 cm respectively from the expected values. No 
literature could be found for EPL calculation with TPS computed dose planes 
based on the quadratic calibration method.  
 
In this study, an iterative numerical method was used to calculate all the EPLs, 
where the value from Equation 4-6 served as an initial approximation and the 
calculation repeated itself five times to obtain a converged solution. The choice 
of five iterations was based on the results in Table 4-7. Results from the 
randomly chosen sample showed that convergence could be achieved in five 
iterations for most conditions. Kairn et al. (2008) and Kavuma et al. (2010) also 
reported the same number of iterations for convergence.  
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Table 4-7 Calculated EPL values according to the number of iterations. The 
EPL values were represented by the mean of 12 x 12 pixels in the central region. 
For brevity, results are only presented for a few randomly chosen experimental 
conditions but were representative of all other conditions. In general, 
convergence was observed after five iterations. 
Number 
of 
iteration 
Elekta 
EPL calculated from EPID dose planes (cm) EPL calculated from TPS dose planes (cm) 
Field size: 
3x3cm2; 
Phantom 
thickness: 
10 cm 
Field size: 
5x5cm2; 
Phantom 
thickness: 
15 cm 
Field size: 
15x15cm2; 
Phantom 
thickness: 
30 cm 
Field size: 
20x20cm2; 
Phantom 
thickness: 
35 cm 
Field size: 
3x3cm2; 
Phantom 
thickness: 
10 cm 
Field size: 
5x5cm2; 
Phantom 
thickness: 
15 cm 
Field size: 
15x15cm2; 
Phantom 
thickness: 
30 cm 
Field size: 
20x20cm2; 
Phantom 
thickness: 
35 cm 
1 9.885 14.645 29.851 35.204 9.264 14.651 30.044 34.902 
2 10.119 15.087 29.968 35.204 9.981 15.034 30.042 34.902 
3 10.084 15.021 29.962 35.204 9.803 14.963 30.042 34.902 
4 10.089 15.031 29.963 35.204 9.846 14.974 30.042 34.902 
5 10.088 15.030 29.962 35.204 9.836 14.972 30.042 34.902 
6 10.088 15.030 29.962 35.204 9.838 14.972 30.042 34.902 
7 10.088 15.030 29.962 35.204 9.838 14.972 30.042 34.902 
8 10.088 15.030 29.962 35.204 9.838 14.972 30.042 34.902 
9 10.088 15.030 29.962 35.204 9.838 14.972 30.042 34.902 
10 10.088 15.030 29.962 35.204 9.838 14.972 30.042 34.902 
 
In this EPID dosimetry model, the calculated EPL was used to relate the EPID and 
the TPS (Figure 4-3). Depending on the path chosen by the users, either the in-
phantom exit dose could be reconstructed (Section 4.3.5) or the EPID transit 
dose could be predicted (Section 4.3.6). In either case, a field size correction 
factor, FSF, was required to account for deviation from the reference field size 
that was used to derive the A and B coefficients. Since the EPID and water-based 
TPS were known to respond differently with field size (Greer & Popescu, 2003, 
Van Esch et al., 2004), the FSFs were separately tabulated from dose planes 
measured with the EPID (FSFEPID) and computed with the TPS (FSFTPS) for a range 
of field sizes and phantom thicknesses. Figure 4-10 shows the plot of central axis 
FSFEPID and FSFTPS for the Varian and Elekta system. From the figure, it can be 
noted that the FSF values are dependent on phantom thickness and different 
between EPID and TPS. 
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Figure 4-10 Field size correction factor (FSF) for EPID and TPS. The FSFEPID 
(solid line) and FSFTPS (dashed line) for field size ranging from 3 x 3 cm2 to 20 x 
20 cm2 are shown in the graphs. By definition, FSF values are normalised to the 
reference field size of 20 x 20 cm2. Data plotted represent the central axis 
value. For clarity, only FSF for water-equivalent phantom thickness (PT) 5 cm, 
15 cm and 35 cm were shown in the graphs.  
 
Rather than tabulating the correction factor from a single FSF value taken at the 
central axis, the FSF was tabulated in 2D and the correction was applied based 
on the individual pixel location. The use of 2D FSF correction improved the 
accuracy of off-axis dose reconstruction or prediction considerably, as shown in 
Figure 4-11.  
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Figure 4-11 Field size correction using central axis FSF values versus position 
dependent 2D FSF values. Results on the left column were corrected using 
central axis FSF values while results on the right column were corrected using 2D 
FSF. Doses at off-axis positions were reconstructed/predicted more accurately 
with the 2D FSF correction method. Areas of mismatch (indicated by red arrows) 
seen with doses reconstructed/predicted using central axis FSF value were no 
longer apparent when the 2D FSF method was used. The improvements were 
obvious for both in-phantom exit dose comparisons (top row) as well as EPID 
transit dose comparisons (bottom row). Profiles in this figure were for a 6MV, 
100MU beam with field sizes 3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2 and 15 x 15 cm2, 
tested on 15 cm thick homogeneous water-equivalent phantom for the Elekta 
system. 
 
One of the advantages of the EPID dosimetry model described in this study is its 
simplicity and practicality. Besides field size correction, the model does not 
require any other complex correction, such as those associated with the 
standard flood field correction. As part of the manufacturer’s standard 
procedure, all a-Si EPID panels are corrected with a flood field to eliminate pixel 
sensitivity variations for better imaging quality. However, this standard flood 
field correction removes the characteristic horns of a photon beam from the 
resultant image (“washed-out” effect) and caused dose error up to 8% for fields 
larger than 10 x 10 cm2 (Parent et al., 2007). Different approaches had been 
proposed to overcome the washed-out effect due to standard flood field 
correction. These methods either: (1) create a near uniform beam to be the 
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flood field or (2) restore the lost profile after a standard flood field calibration. 
In the first approach, a near uniform flood field was created by placing an 
appropriate amount of attenuating material in the path of the beam (Greer & 
Popescu, 2003, Siebers et al., 2004) or by systematically irradiating different 
parts of the EPID with multiple small fields, where the beam could be considered 
as flat (Greer, 2005, Parent et al., 2006). As for the second approach, the lost 
profile could be restored based on additional correction derived from IC 
measurement (Renner et al., 2005, Chen et al., 2006), film measurement (Van 
Esch et al., 2004), Monte Carlo simulation (Siebers et al., 2004, Parent et al., 
2007) or TPS generated profiles (Talamonti et al., 2006, Kavuma et al., 2010). 
Although these methods could overcome the washed-out effect of EPID images, 
they were often very cumbersome, with some of the methods requiring a 
dedicated flood field correction procedure that differed from manufacturer’s 
default setting. Deviating from the standard manufacturer’s recommendation is 
often not desirable, and sometimes not possible, in a clinical department.  
 
The washed-out effect due to standard flood field calibration was not an issue in 
this dosimetry model because the (A and B)EPID coefficients were derived from 
EPID dose planes measured with standard flood field calibration and therefore, 
the washed-out effect was inherent in the coefficients. Consequently, for Path 
1, the EPL of the attenuating object could still be calculated correctly from EPID 
dose planes that contained the washed-out effect using the (A and B)EPID 
coefficients.  Once the EPL was correctly calculated, the subsequent in-phantom 
dose prediction would not be a problem because the washed-out effect only 
affects EPID measurements. As for Path 2, the calculation of EPL from TPS 
exported dose planes did not involve any EPID images and is, therefore, 
unaffected by the washed-out effect. Although the subsequent prediction of 
EPID transit dose plane from EPL and (A and B)EPID coefficients would reflect the 
washed-out effect, this was not an issue because the predicted dose plane would 
be directly compared with an EPID measured transit dose plane that had the 
same feature. The ability to use EPID images captured under standard flood field 
calibration in the clinical mode and without additional correction simplifies the 
EPID dosimetry model and makes it practical for other clinical departments to 
adopt the model. 
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In addition, artefacts due to non-uniform backscatter from the metallic 
component of the aS500 support arm were also not an issue in this EPID 
dosimetry model. Several authors had reported that the additional backscatter 
from the support arm could cause the EPID response to increase by 
approximately 4% to 6%, particularly in the in-plane direction (Ko et al., 2004, 
Greer et al., 2009, Berry et al., 2010, Rowshanfarzad et al., 2010). To reduce 
the arm backscatter effect, Ko et al. (2004) suggested that a 0.5 cm lead sheet 
should be placed in between the detector and the support arm. Instead of 
adding a filter to the EPID panel, Greer et al. (2009) incorporated the 
backscatter component in the pixel sensitivity correction matrix by measuring 
the flood field with and without the support arm (by physically detaching the 
EPID from the support structure). Alternatively, Rowshanfarzad et al. (2010) 
derived a backscatter kernel from 1 cm2 pencil beam measured at different 
positions on the EPID panel with and without the support arm. Since the 
backscatter effect is dependent on field size and position, Berry et al. (2010) 
suggested the use of either a series of field size specific 2D correction matrices 
or a generalised correction equation to eliminate the backscatter effect. Again, 
all these methods would add to the complexity of the EPID dosimetry model. 
Furthermore, the methods by Ko et al. (2004), Greer et al. (2009) and 
Rowshanfarzad et al. (2010) involved physical modification of the EPID panel and 
would be impractical in most clinical departments. In this EPID dosimetry model, 
no additional correction was required to account for backscatter from the aS500 
support arm. The correction was not necessary because the use of exit to 
entrance ratio in the dosimetry model would have cancelled off the arm 
backscatter effect, as long as the imager was positioned at the same location for 
the two measurements. As can be seen from the Varian profiles comparisons in 
Figure 4-8 and 4-9, without any additional correction, discrepancies due to the 
arm backscatter effect were not present even for large open fields in the in-line 
direction where the effect was thought to be most prominent. 
 
Besides being simple and practical, this EPID dosimetry model also has the 
advantage of being generic and flexible.  The results presented above for EPID 
and TPS from both Varian and Elekta demonstrate that the model is not 
manufacturer-specific. The proposed model is applicable as long as the 
calibration dose planes were computed and measured for the TPS and EPID of 
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interest. To accommodate the preference of different users, the model also 
offers the flexibility to choose between comparing doses in-phantom or at the 
EPID level. It has been shown that both the comparison of ‘reconstructed versus 
TPS computed in-phantom exit dose’ as well as ‘predicted versus EPID measured 
transit dose’ are feasible and accurate.  
 
However, there are a few weaknesses in the proposed EPID dosimetry model. 
One obvious and general disadvantage that affects all EPID-based dosimetry 
model is related to the relatively small active area, which limits the maximum 
field size that could be analysed. Because a reference field size of 20 x 20 cm2 
was used to derive the A and B coefficients in this study, the quadratic equation 
could only calculate EPL correctly for measurements within this field area. 
Beyond the 20 x 20 cm2 area, the EPL calculation would be inaccurate because 
no proper coefficients were available. The 20 x 20 cm2 field size was selected 
considering that the aS500 EPID has an active area of 30 x 40 cm2 and at 140 cm 
source to detector distance, the maximum field size at 100 cm must be less than 
21 x 28 cm2 to avoid irradiation of EPID electronics. Although the detector 
distance could be reduced to maximise the irradiation field size, the 140 cm 
source to detector distance was chosen to allow for more clearance, since the 
ultimate aim of this study was to extend the application to actual patient 
treatment verification with different gantry angles. As for the iViewGT EPID, 
which has a fixed source to detector distance of 160 cm but a larger active area 
(41 x 41 cm2), the maximum field size that could be used is 25 x 25 cm2. 
However, the same 20 x 20 cm2 reference field size was chosen for both the 
aS500 and iViewGT EPIDs in this study for consistency.  
 
The other disadvantage that was more specific to this study was the use of TPS 
computed dose planes in the calibration process. Although the calibration dose 
planes were simple and could be computed easily with any TPS models, this 
requirement is undesirable because any inaccuracies in the calibration dose 
planes will become an integral part of the EPID dosimetry model. This factor is 
even more critical in the context of this study because the calibration dose 
planes were taken at the entrance and exit level, where inaccuracies in the TPS 
computed doses could be as much as 5% (Tan et al., 2014). Errors in the 
calibration data would propagate to the end results and may mask real 
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inaccuracies in the treatment delivery. For example, as shown in the experiment 
described in Chapter 3, the Eclipse AAA computed dose was 3.8% higher than IC 
measured dose at the exit level of a water-equivalent phantom with thickness 15 
cm, for a 6 MV beam with 20 x 20 cm2 field size. However, this error in the TPS 
algorithm would not be detected in this EPID dosimetry model. The difference 
between reconstructed and TPS computed in-phantom exit dose for the same 
beam and phantom thickness was only 0.4% (Table 4-3). Ideally, the calibration 
data should be as accurate as possible so that real differences between planned 
and delivered dose would be reflected as discrepancies in the EPID dosimetry 
results.   
 
4.6 Conclusions 
 
A novel empirical-based EPID transit dosimetry model that used EPL to relate 
EPID and TPS has been described and proven to be valid. The methods used in 
the dosimetry model were relatively simple and practical without requiring 
modification of the EPID panel or measurements out of clinical mode. The 
described dosimetry model is also generic and has been shown to work with 
linac, EPID and TPS from different manufacturers. In addition, the model is 
flexible and allows users to choose their preferred location for dose 
comparisons, either in-phantom (at 1.5 cm from the exit surface of the 
phantom) or at the EPID level.  
 
In this preliminary study with homogeneous phantoms and open fields, the 
overall discrepancies (taken at the central region) between ‘reconstructed 
versus TPS computed in-phantom exit dose’ and ‘predicted versus EPID measured 
transit dose’ were less than 2%, except for the smallest phantom with thickness 
5 cm where a maximum dose difference of 3.3% was observed. Profiles matching 
across the field were also found to be excellent including the penumbra region.  
 
The issue of reliance on the TPS computed dose planes in the calibration process 
will be discussed and addressed in the next chapter.
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Chapter 5: A dual 2D EPID transit dosimetry model based 
on an empirical quadratic formalism !
5.1 Publication/presentation arising from work in this chapter  
 
• A 2D EPID transit dosimetry model based on an empirical quadratic 
formalism, Tan, Y., Metwaly, M., Glegg, M., Baggarley, S. & Elliott, A., 
2014, Poster presentation, 56th Annual Meeting and Exhibition, American 
Association of Physicists in Medicine (AAPM), Austin, Texas, USA.  
• A dual two dimensional electronic portal imaging device transit 
dosimetry model based on an empirical quadratic formalism, Tan, Y., 
Metwaly, M., Glegg, M., Baggarley, S. & Elliott, A., 2015, British Journal 
of Radiology, 88 (1051), 20140645: 1-15. !
5.2 Introduction !
A novel method was described in Chapter 4 that used the EPL of the attenuator 
to relate the EPID and TPS. Based on this relationship, an empirical 2D EPID 
transit dosimetry model was developed for treatment verification. The 
dosimetry model has the advantage of being simple, practical and generic. 
Another unique advantage of the dosimetry model is the dual nature that can 
either:  
• Reconstruct in-phantom exit dose from EPID measured dose planes. (The 
in-phantom exit dose was defined as dose at 1.5 cm upstream from the 
beam exit surface of a phantom); or  
• Predict EPID transit dose from TPS exported dose planes. 
 
Initial investigation of the dosimetry model using simple square fields of 
different field sizes on homogeneous slab phantoms of various thicknesses 
proved that the model was valid. The overall discrepancies at the central region 
between ‘reconstructed versus TPS computed in-phantom exit dose’ and 
‘predicted versus EPID measured transit dose’ were less than 2%, except for the 
smallest phantom with thickness 5 cm where a maximum difference of 3.3% was 
observed. Comparison of measured and predicted profiles across the field, 
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including the penumbra region, showed excellent agreement for all fields 
investigated.  
 
However, the EPID transit dosimetry model proposed in Chapter 4 required TPS 
calibration dose planes, computed for a reference beam and exported at 1.5 cm 
from the beam entry and exit surface of a water-equivalent phantom, in the 
commissioning process. The accuracy of TPS computed dose at these levels, 
where the amount of build up and backscatter is limited, had been found to vary 
with different TPS algorithms, as detailed in Chapter 3. Comparisons between IC 
measured and TPS computed doses revealed that, while most TPS algorithms 
could accurately compute doses at the entrance level to within 2%, the accuracy 
of TPS computed doses at the exit level were generally poorer with 
discrepancies of up to about 5% (Tan et al., 2014). By using TPS computed 
entrance and exit doses as the calibration dose planes in the commissioning 
process, any inaccuracies from the TPS algorithm would become inherent in the 
EPID dosimetry model. Ideally, the commissioning data for the EPID dosimetry 
model should be as accurate as possible to prevent systematic errors from 
propagating to the end results and affecting the reconstructed/predicted doses.  
 
Therefore, the first objective of this chapter was to replace the TPS calibration 
dose planes, used to derive the quadratic equation coefficients, with calibration 
dose planes measured with IC in water. By using the IC measured calibration 
dose planes rather than TPS computed calibration dose planes, the EPID 
dosimetry model would not be reliant on the TPS computed doses that may 
contain inaccuracy. Also, by using a commissioning method that is independent 
of the TPS, the EPID dosimetry model should be better able to reveal actual 
discrepancies between measured and TPS planned doses. 
 
The second objective of this chapter was to expand the EPID transit dosimetry 
model to allow analysis of modulated fields. The ability of a dosimetry model to 
perform verification of modulated treatment is crucial and more relevant in 
today’s context of radiotherapy practice. This is because modulated treatment 
fields, such as the IMRT, are more complex and place greater demands on the 
treatment planning and delivery systems. As modulated treatments become 
more commonplace, it is imperative that the EPID dosimetry model be capable 
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of verifying modulated fields to reduce the probability of major errors in 
treatment delivery.  
 
The third objective of this chapter was to test the dosimetry model not only on 
homogeneous phantoms but also heterogeneous phantoms. The ability of an EPID 
transit dosimetry model to deal with heterogeneity is another important aspect 
that must be evaluated before the model can be applied for actual patient 
treatment verification, which is the ultimate aim of this research project.  
 
5.3 Materials and methods !
5.3.1 Overview of the EPID transit dosimetry model 
A detailed description of a novel 2D EPID transit dosimetry model was provided 
in Chapter 4. Briefly, the 2D EPID transit dosimetry model was based on a 
quadratic equation (Swindell, 1983) that relates the reduction in intensity, 
represented by the ratio of exit (M) to entrance (M0) dose, to the water-
equivalent thickness or EPL of the attenuator.   !
- ln M i,j
M0 i,j
 = A i,j  × EPL i,j  + B i,j  × EPL2 i,j                                  (5-1) 
(Equation 4-4, Chapter 4) !
where ‘A’ and ‘B’ are the coefficients and (i,j) is the coordinate of pixels in a 2D 
plane. The linear coefficient, A, reflects the linear attenuation coefficients of 
the attenuator while the quadratic coefficient, B, describes the non-linear 
relationship due to spectral variation in a photon beam (Swindell, 1983).  
 
The commissioning of the EPID dosimetry model involved the derivation of the A 
and B coefficients in the quadratic equation from a set of M and M0 calibration 
dose planes measured for homogeneous phantoms with known water-equivalent 
thicknesses under reference conditions. By fitting Equation 5-1, pixel-by-pixel, 
to the set of calibration dose planes measured with phantoms of different 
thicknesses, A and B coefficients can be obtained. With the A and B coefficients, 
the EPL of any attenuator can be calculated from Equation 5-2 (inversion of 
Equation 5-1) if given the amount of reduction in intensity (M/M0). 
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EPL i,j  = 
-A i,j  ± A2 i,j  – 4B i,j  × ln FSF(i,j) × M i,j M0 i,j
2B i,j
                           (5-2) 
(Equation 4-7, Chapter 4) !
where FSF is the field size correction factor, defined as the ratio of dose for the 
reference field size to dose for other field sizes of interest. The FSF was 
tabulated from 2D dose planes measured for a range of field sizes as a function 
of attenuator thicknesses and the correction was applied based on the individual 
pixel location (i,j). 
 
The calculated 2D EPL map, which is a property of the attenuator and 
independent of the measuring system, is then used as a bridge to translate 
between the two different dosimetry systems, EPID and TPS. For the dosimetry 
model to work, two sets of quadratic equations coefficients must be derived 
separately for the EPID and TPS because of the differential response and scatter 
characteristics of the EPID. With two sets of coefficients, the EPL can be 
calculated from either the EPID or TPS dose planes for the treatment field to be 
investigated, giving the model a dual nature. Also, the two sets of coefficients, 
together with the calculated EPL, are required in the dose 
reconstruction/prediction process, as previously illustrated in Figure 4-3 and 
with the updated version shown below in Figure 5-3. 
 
5.3.2 Commissioning process: Calibration dose planes for A and B 
derivation 
In the EPID transit dosimetry model described in Chapter 4, the two sets of 
coefficients, (A and B)EPID and (A and B)TPS, were derived from calibration dose 
planes measured with EPID and computed with TPS respectively. The calibration 
dose planes were measured and computed for the same reference beam (6 MV, 
200 MU and field size 20 x 20 cm2) and the same set of water-equivalent 
homogeneous phantoms of known thicknesses (PT: 0 cm to 35 cm) placed at the 
isocentre. The study was performed in two separate and independent 
institutions equipped with Varian and Elekta linacs and TPSs to demonstrate the 
generic nature of the proposed dosimetry model.  
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The study described in this chapter was only performed in Institution A with 
Varian Clinac 21EX linac and Eclipse TPS (Palo Alto, CA, USA). The same 
reference beam parameters and homogeneous phantom thicknesses were used to 
derive the calibration dose planes in this study. While the EPID measurements of 
calibration dose planes remained largely the same as before, the TPS computed 
calibration dose planes were replaced with IC measurements in water. Methods 
to measure the calibration dose planes are provided in the following sub-
sections, briefly for the EPID measurements and with more detail for the IC 
measurements in water.  
 
5.3.2.1 Measurements of EPID calibration dose planes to derive (A and B)EPID 
The experimental methods to measure EPID calibration dose planes were 
described explicitly in Chapter 4, sub-Section 4.3.3.1. In short, EPID images were 
captured with an aS500 a-Si EPID (Varian, Palo Alto, CA, USA) that had 384 x 512 
pixels using standard manufacturer’s software, IAS3. All images were captured 
using default manufacturer’s settings that automatically perform dark field, 
flood field and defect pixel corrections as part of the standard image processing 
procedure in the clinical mode. The distance from source to EPID was fixed at 
140 cm. The EPID panel was used unmodified, as supplied by the manufacturer, 
for practical implementation. The M0 dose planes were captured without a 
phantom in the beam (0 cm) while M dose planes were captured with water-
equivalent solid phantom (density 1.04 g/cm3, Gammex Inc., Middleton, WI, 
USA) of different thicknesses (5 cm to 35 cm) placed isocentrically (SAD) at 100 
cm. The experimental set-up for the EPID measurements was shown in Figure 4-1 
and is reiterated below in Figure 5-1a for easy reference. Although the EPID 
signal was not absolutely calibrated to dose, the term EPID dose plane was used 
for a more consistent description with the IC and TPS dose planes. 
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Figure 5-1 Set-up for EPID and IC calibration dose planes. (a) Experimental 
set-up for the EPID entrance (M0) and exit (M) calibration dose planes 
measurements. (b) Set-up dimension for the IC entrance (M0) and exit (M) 
calibration dose planes. Additional 1.5 cm build up was required for the IC set-
up dimension to provide adequate electronic equilibrium for the 6 MV beam used 
in this study while an additional 1.5 cm backscatter was chosen for a symmetric 
geometry. The ratio of M to M0, for both EPID and IC set-up, included the same 
set of water-equivalent phantom thicknesses (PT: 0 cm to 35 cm). !
5.3.2.2 Measurements of IC calibration dose planes to derive (A and B)IC 
The first objective of this study was to replace the TPS calibration dose planes, 
described in Chapter 4, sub-Section 4.3.3.2, with dose planes derived from IC 
measurements in water. The IC calibration dose planes were derived to simulate 
the isocentric set-up shown in Figure 5-1b. This set-up was similar to the TPS 
virtual phantom set-up shown in Figure 4-2. As with the TPS calibration dose 
planes, the IC M0 and M were defined as doses at depth 1.5 cm from the beam 
entrance and exit surface in a phantom respectively. The 1.5 cm build up for the 
M0 was necessary to provide reasonable electronic equilibrium conditions for the 
6 MV beam used in this study and the 1.5 cm backscatter was chosen for a 
symmetric geometry. As a result, the vertical dimension of the water phantom 
was effectively (1.5+‘PT’+1.5) cm, where ‘PT’ ranged from 0 cm to 35 cm.  
 
To derive the IC calibration dose planes, cross-line and in-line profiles were 
measured with a CC04 IC (IBA Dosimetry, Schwarzenbruck, Germany) in a 
scanning water tank (IBA Dosimetry, Schwarzenbruck, Germany) at different 
depths from 1.5 cm to 36.5 cm. All measured profiles were normalised to the 
central axis. After that, each of the 1D relative profiles was duplicated to fill a 
2D matrix of 512 x 512 dimension. For each scan depth, there were two matrices 
representing the in-line and cross-line directions. Then, the in-line and cross-line 
matrices for the same scan depth were multiplied to generate a 2D relative dose 
plane. The 2D relative dose plane was cropped to 384 (rows) x 512 (columns) to 
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match the EPID dimension. Finally, all the 2D relative dose planes at different 
depths were converted into 2D absolute dose planes by multiplication with the 
central axis dose calculated from percentage depth dose (PDD).  
 
Since the PDDs, by definition, were measured at a fixed source to surface 
distance (SSD) of 100 cm and with full backscatter, two corrections were 
required to account for: (1) the varying SSD due to the isocentric set-up, and (2) 
the difference in backscatter thickness at the entrance and exit levels. Figure 5-
2 shows the two corrections to translate PDD measurements in a scanning water 
tank with a fixed SSD of 100 cm and with full scatter condition, to the IC 
calibration dose planes with isocentric set-up and with limited backscattering 
material.  
 
!
Figure 5-2 Conversion of dose calculated from PDD to isocentric dose with 
1.5 cm backscatter. Steps to translate dose calculated from PDD, measured in a 
scanning water tank with a fixed SSD of 100 cm and with full scatter condition 
(diagram a), to the dose with isocentric set-up and with 1.5 cm backscatter 
(diagram c). The first corrections, with Mayneord F factor and ratios of TMRs, 
were used to quantify the change in PDD with non-standard SSD. The Mayneord F 
factor and ratios of TMRs account for the inverse square effect and variation in 
phantom scatter respectively. The second correction, BCF, defined as the ratio 
of dose without full backscatter to dose with full backscatter, was used to 
quantify the reduction in backscattered photon due to the different amount of 
underlying material. Corrections 1 and 2 are given in Equations 5-3 and 5-5 
respectively in the text.  
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The first correction was to quantify the change in PDD with SSD due to the 
isocentric set-up required in this study. The PDD, which is the dose at any depth 
relative to the dose at a fixed reference point, decreases with decrease in SSD. 
This is because the reduction in dose between two points due to the inverse 
square law effect is more rapid nearer to the source as opposed to further away 
(Khan, 2010a). The Mayneord F factor (Mayneord & Lamerton, 1941), shown in 
the second term of Equation 5-3, was used to account for this effect. However, 
the Mayneord F factor correction assumes that the field size at the surface, and 
consequently the amount of phantom scatter at depth, remains the same with 
different SSD and only strictly corrects for the inverse square law effect. Since 
the field size stated in this study is defined at 100 cm, the change in phantom 
scatter at depth with different SSD was accounted for using a ratio of TMRs 
(Varian Medical Systems, 2008), shown in the third term of Equation 5-3.   
 
PDD2 = PDD1 × 
SSD2 + dmax
SSD1 + dmax
2
× SSD1 + d
SSD2 + d
2
 × TMR d,fs2
TMR d,fs1
                              (5-3) 
 
where subscript ‘1’ and ‘2’ indicates the fixed SSD and isocentric set-up 
respectively, ‘dmax’ is the depth of maximum dose, ‘d’ is the depth of interest, 
‘fs1’ and ‘fs2’ are the field sizes at depth ‘d’.  
 
Subsequently, the PDD2 is used to calculate the dose at depth ‘d’ with the SSD2 
of the isocentric set-up. The formula for dose calculation is given in Equation 5-
4. 
 
Dosefs
d  = PDD2 × Ddmax × OFfs × 
SSD1 + dmax
SSD2 + dmax
2
                                              (5-4) 
 
where ‘d’ is the depth at which dose is calculated, ‘fs’ is the field size at 
distance 100 cm, ‘Ddmax’ is the dose at depth of maximum for reference field 
size (usually 10 x 10 cm2) and ‘OFfs’ is the field size output factor. The last term 
of Equation 5-4 is to correct for change in Ddmax for different SSD due to the 
inverse square effect. 
 
Up to this point, the dose calculated from scanning water tank measurements 
represents full scatter conditions. A second correction, the backscatter 
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correction factor (BCF), was required to account for the effect of reduced 
backscatter thickness to satisfy the condition of IC M0 and M calibration dose 
planes as shown in Figure 5-1b, where the backscatter thickness for M0 varies 
with different phantom thickness and the backscatter thickness for M was only 
1.5 cm. The BCF, defined as the ratio of dose without full backscatter to dose 
with full backscatter, was measured at the central axis with IC in water-
equivalent solid phantoms. Details of the experimental methods and series of 
BCF values as a function of field size, backscatter thickness and depth for the 6 
MV beam investigated can be found in Chapter 3 and Tan et al. (2014). Since the 
BCF is independent of SSD (Lambert et al., 1983, Tan et al., 2014), the BCF 
value was taken from Table 3-1 of Chapter 3 and incorporated into Equation 5-4 
to yield Equation 5-5. 
 
Dosefs
d  = PDD2 × Ddmax × OFfs × 
SSD1 + dmax
SSD2 + dmax
2
 × BCF!                          (5-5) 
 
Finally, before the IC dose planes were used to derive the (A and B)IC 
coefficients, all the M0 and M dose planes were scaled to the same reference 
level using inverse square distance correction. The isocentre (100 cm from 
source), which is also the mid-plane of the phantom, was chosen as the 
reference level. The inverse square distance scaling was done so that the ratio 
of M and M0 will reflect the reduction of dose due to object attenuation entirely 
without the effect of distance. 
 
The derived (A and B)IC coefficients were then used to replace the (A and B)TPS 
described in Chapter 4. The updated EPID transit dosimetry model is illustrated 
in Figure 5-3 below.  
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Figure 5-3 The role of quadratic equation coefficients (A and B) and EPL in 
relating two different dosimetry systems, EPID and IC (or TPS). The diagram is 
similar to Figure 4-3, except that the (A and B)TPS were replaced by (A and B)IC. 
Equations 5-1 and 5-2 are given in the text. From left to right is the path (Path 
1) to predict in-phantom dose ratio (M/M0)IC from EPID measured dose planes. 
From right to left is the path (Path 2) to predict EPID dose ratio (M/M0)EPID from 
TPS exported dose planes. The predicted dose ratios (M/M0)IC and (M/M0)EPID 
were used to derive in-phantom exit dose and EPID transit dose respectively, as 
described in Sections 5.3.3 and 5.3.4. 
 
5.3.3 Path 1: Reconstruction of in-phantom exit dose 
5.3.3.1 Open field 
Figure 5-3, from left to right, shows the flow to predict the in-phantom exit to 
entrance dose ratio (M/M0)IC from EPID measured dose planes. The process of 
predicting in-phantom exit dose for open fields was basically the same as that 
described in sub-Section 4.3.5. In short, two EPID dose planes, measured with 
(MEPID_tx) and without (M0EPID_tx) the presence of an attenuator for the treatment 
field to be investigated, together with the (A and B)EPID coefficients, were used 
to calculate the attenuator’s EPL according to Equation 5-2. All EPID images 
were smoothed with a moving average filter (Smith, 2003) using a window size of 
eight pixels. Smoothing was applied to the EPID images to reduce random signal 
of low magnitude observed with modulated fields, possibly introduced by MLC 
interleaf leakage that was not accounted for in the Eclipse TPS. The FSFEPID was 
required in Equation 5-2 to correct for treatment fields with field size other than 
the reference 20 x 20 cm2. The FSFEPID is the field size correction factor 
tabulated from EPID measured 2D dose planes for a range of field sizes (5 x 5 
cm2 to 20 x 20 cm2) and attenuator thicknesses (0 cm to 35 cm) and corrected 
based on pixel location. Then, the calculated 2D EPL matrix was used in 
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combination with (A and B)IC coefficients, instead of (A and B)TPS in Chapter 3, to 
calculate the equivalent IC ratio (M/M0)IC using Equation 5-1. Consequently, the 
in-phantom exit dose (MIC pred) can be reconstructed by multiplying this 
equivalent IC ratio with an (reference field size 20 x 20 cm2) IC entrance dose 
plane (M0IC ref) previously derived as part of the commissioning process. An 
inverse square correction was also added to scale dose from the reference level 
(100 cm) to the exit level.  
 
MIC!pred = MM0 IC  × M0IC ref ÷ FSFIC × 100SDD 2                                                (5-6) 
 
where ‘SDD’ is the source to exit distance. ‘FSFIC’ is the field size correction 
factor tabulated from IC derived 2D dose planes for a range of field sizes (5 x 5 
cm2 to 20 x 20 cm2) and attenuator thicknesses (0 cm to 35 cm). 
 
The reconstructed in-phantom exit dose was compared to TPS dose computed 
for the treatment field and exported at the exit level of the phantom, to verify 
the accuracy of treatment delivery.  !
5.3.3.2 Modulated field (wedge and IMRT) 
The effect of beam modulation will not be reflected in the MIC pred from Equation 
5-6. This is because the ratio of MEPID_tx to M0EPID_tx was used to derive the 
equivalent IC ratio and the division of two identical modulated fields with and 
without an object in the beam would have cancelled out the modulation effect. 
Therefore, for verification of modulated treatment fields, an additional 
modulation factor (MF) defined as the ratio of modulated to non-modulated dose 
plane was used (Equation 5-7). The modulated dose plane (M0EPID_tx) was the 
EPID dose plane measured for the treatment field without an object in the 
beam. The non-modulated dose plane (M0EPID_openFSx) was the EPID dose plane, 
also measured without an object in the beam, for a reference open field (100 
MU, 20 x 20 cm2) that was subsequently corrected with FSFEPID based on the field 
size of the treatment field. The effective field size of irregular treatment fields 
was calculated according to the methods described by Monti et al. (1995) with 
the irregular field area for an IMRT delivery defined as the region with dose 
greater than 50% of the maximum dose. Since both the modulated and non-
modulated fields were measured by the EPID without an object in the beam and 
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preferably during the same session, the MF is a relative factor that can be used 
to quantify beam modulation in a field. The MF needs to be derived only once 
for each modulated treatment field. 
 
MFEPID = 
M0EPID_tx
M0EPID_openFSx
                                                                                 (5-7) 
 
Equation 5-6 was modified to include MF, as shown in Equation 5-8, for the 
prediction of in-phantom exit dose for modulated fields. 
 
MIC!pred = MM0 IC  × M0IC!ref ÷ FSFIC × 100SDD 2 × MFEPID                                    (5-8) 
 
In the above description, MF from EPID measurements was used to quantify 
beam modulation for the prediction of TPS in-phantom exit doses. Although the 
MF is a relative factor, the MF from EPID measurements (MFEPID) was found to be 
slightly different from the MF from IC measurements (MFIC). Figure 5-4 shows the 
comparisons of MFEPID and MFIC for enhanced dynamic wedge (EDW) 60 degree 
(EDW60) and 15 degree (EDW15) fields. MapCHECK2 (Sun Nuclear, Melbourne, 
FL, USA) measurements were used to represent the IC dose planes to save 
measurement time. It can be observed from Figure 5-4 that the discrepancies 
between MFEPID and MFIC were more prominent for EDW60 compared to EDW15. 
The difference between MFEPID and MFIC and the effect of different wedge angles 
could be due to variation of EPID response with the changing field size and dose 
rate during delivery. To account for this effect, a generic correction was derived 
to convert MFEPID to MFIC for all wedge angles. This generic correction was 
derived from MFEPID and MFIC measured for the EDW60 field. A graph of MFEPID 
against MFIC for the EDW60 field was plotted and a linear fit was derived (Figure 
5-5). The fitting formula was used to correct the MFEPID to the equivalent of MFIC, 
(MFEPIDIC). Two fitting formulae are shown in Figure 5-5, representing the 
EDW60 fields for field size 10 x 10 cm2 and 20 x 20 cm2. Depending on the field 
size of the test field, the appropriate fitting formula was used for the 
correction. For wedge fields of other angles (θ), a weighting factor (W) was 
calculated and used to determine the fraction of total MF to be corrected 
(Equations 5-9 and 5-10). The weighting calculation was adapted from the 
concept of achieving a desired effective wedge angle by varying the proportion 
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of open field irradiation and nominal wedge field irradiation (Tatcher, 1970, 
Zwicker et al., 1985). 
 
Weighting, W = 
tan θ
tan 60
 ÷ WF
tan θ
tan 60
 ÷ WF  + 1-! tan θ
tan 60
                                                          (5-9) 
 
where ‘WF’ is the conventional wedge factor, defined as the ratio of central axis 
dose measured with wedge 60 degree and open field.  
 
MFcorrected
EPID  = MFEPID→IC × W  + MFEPID × (1-W)                                         (5-10) 
 
where ‘MFEPID’ is the uncorrected MF from EPID measurements as defined in 
Equation 5-7 and the ‘MFEPIDIC’ is the MFEPID corrected to the equivalent of MFIC 
using the fitting formula shown in Figure 5-5. Accordingly, the mathematical 
expression to predict in-phantom exit dose for EDW fields was modified from 
Equation 5-8 to become Equation 5-11. 
 
MIC!pred = MM0 IC  × M0IC!ref ÷ FSFIC × 100SDD 2 × MFcorrectedEPID                              (5-11) 
 
As for IMRT fields, the in-phantom exit dose was also predicted using Equation 5-
11. The MF correction was applied but with the W in Equation 5-10 assumed to 
be one (W = 1).  !
Finally, the reconstructed in-phantom exit dose for wedge and IMRT fields were 
compared to TPS computed exit doses to verify the accuracy of treatment 
delivery.  
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Figure 5-4 Comparisons of MFEPID and MFIC for enhanced dynamic wedge field. 
The comparisons are for EDW15FS20 (wedge angle 15 degree, field size 20 x 20 
cm2) and EDW60FS20 (wedge angle 60 degree, field size 20 x 20 cm2) fields. The 
MFEPID is the modulation factor derived from EPID measurements while the MFIC is 
the modulation factor derived from IC measurements, represented by 
MapCHECK2 measurements. 
 
!
Figure 5-5 Plot of MFEPID versus MFIC for EDW60 field and a linear fit of data. 
Two plots are shown, representing EDW60 field with field size 10 x 10 cm2 and 
20 x 20 cm2. The linear equation was used to convert MF derived from EPID to 
the equivalent of IC (or TPS) and vice versa, MFEPIDIC. 
 
5.3.4 Path 2: Prediction of EPID transit dose 
5.3.4.1 Open field 
Figure 5-3, from right to left, shows the flow to predict EPID transit dose from 
TPS exported dose planes. The treatment plans in this study were computed 
using the Eclipse AAA algorithm from Varian (version 10.0.28, Palo Alto, CA, 
USA) with 0.1 cm grid size. All TPS exported M0 and M dose planes were scaled 
to the same reference level (100 cm) using inverse square distance correction. 
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The entrance (M0TPS_tx) and exit (MTPS_tx) dose planes for the treatment field to 
be verified along with the (A and B)IC coefficients, instead of the (A and B)TPS as 
previously described in Chapter 4, were used to calculate EPL of the attenuator 
from Equation 5-2. The FSFIC was also required in Equation 5-2 to correct for 
treatment fields with field size other than the reference 20 x 20 cm2. The FSFIC 
was the field size correction factor tabulated from IC derived 2D dose planes for 
a range of field sizes (5 x 5 cm2 to 20 x 20 cm2) and attenuator thicknesses (0 cm 
to 35 cm). Subsequently, the methods to predict EPID transit dose from the 
calculated 2D EPL matrix remained the same as described in Chapter 3, sub-
Section 4.3.6. Briefly, the EPL together with (A and B)EPID were used to calculate 
the equivalent EPID ratio (M/M0)EPID using Equation 5-1. As shown in Equation 5-
12 below, which is similar to Equation 4-11, the EPID transit dose (MEPID pred) can 
be predicted by multiplying this equivalent EPID ratio with an EPID dose plane 
captured with 20 x 20 cm2 open field without a phantom in the beam (M0EPID ref).  
 
MEPID!pred = MM0 EPID  × M0EPID ref ÷ FSFEPID                                                 (5-12) 
 
where FSFEPID is the field size correction factor tabulated from EPID dose planes 
measured for a range of field sizes (5 x 5 cm2 to 20 x 20 cm2) and attenuator 
thicknesses (0 cm to 35 cm). 
 
The predicted EPID transit dose was directly compared to the EPID measured 
dose to verify the accuracy of treatment delivery.  
 
5.3.4.2 Modulated field (wedge and IMRT) 
In the prediction of EPID transit dose from TPS dose planes, the MF for beam 
modulation quantification was computed from modulated and non-modulated 
dose planes exported from the TPS at the entrance level:  
 
MFIC = 
M0TPS_tx
M0TPS_openFSx
                                                                                  (5-13) 
 
As described in sub-Section 5.3.3.2, the MF derived from TPS was corrected to 
the equivalent MF of EPID using the same linear equations shown in Figure 5-5. 
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This corrected MF was then incorporated into Equation 5-12 to predict EPID 
transit dose for modulated fields: 
 
MEPID!pred = MM0 EPID  × M0EPID!ref ÷ FSFEPID × MFcorrectedIC                                (5-14) 
 
In this case, the MFcorrected
IC
 is: 
 
MFcorrected
IC  = MFIC→EPID × W  + MFIC × (1-W)                                           (5-15) 
 
where ‘MFIC’ is the uncorrected MF from TPS exported dose planes as defined in 
Equation 5-13 and the ‘MFICEPID’ is the MFIC corrected to the equivalent of MFEPID 
using the fitting formula shown in Figure 5-5. ‘W’ is the weighting calculated 
according to Equation 5-9 for EDW fields with different wedge angles. For the 
prediction of EPID transit dose for IMRT fields, W was taken to be one. 
 
Finally, the predicted EPID transit doses for modulated fields were directly 
compared to the EPID measured dose planes to verify the accuracy of treatment 
delivery.  
 
5.3.5 Phantom measurements 
The accuracy of the model was tested on both homogeneous and heterogeneous 
slab phantoms (Figure 5-6). The homogeneous phantom was a 15 cm thick water-
equivalent solid phantom (density 1.04 g/cm3, Gammex Inc., Middleton, WI, 
USA). The heterogeneous phantom, also with a total physical thickness of 15 cm, 
included an RMI 467 phantom (Gammex Inc., Middleton, WI, USA) placed 
between two slabs of water-equivalent solid phantoms. The RMI phantom had 
cylindrical rods (2.8 cm in diameter and 7 cm in height) with electron densities 
relative to water (ρe) that ranged from 0.001 to 1.69 (air to cortical bone) to 
simulate all possible densities in a human body.  
 
For dose computations with the TPS, the phantoms were CT-scanned (Discovery 
CT590 RT, GE Healthcare, UK) and the CT images were imported into the TPS. 
An additional 1.5 cm of water-equivalent material was added to the top and 
bottom surfaces of both phantoms to provide adequate electronic equilibrium 
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and a symmetric geometry, similar to the condition used in the commissioning 
process.   
 
!
Figure 5-6 Experimental slab phantoms. (a) Homogeneous slab phantom and 
(b) Heterogeneous slab phantom comprised of RMI phantom with rods with 
electron density ranging from 0.001 (air) to 1.69 (cortical bone) placed between 
two slabs of water-equivalent solid phantoms. The cross section of the RMI 
phantom is shown in the inset. For dose computations with the TPS, an 
additional 1.5 cm of water-equivalent material was added to the top and bottom 
surfaces of both phantoms to provide adequate electronic equilibrium and a 
symmetric geometry, similar to the condition used in the commissioning process. 
 
Non-modulated and modulated fields were tested on both phantoms. Non-
modulated fields were open fields 10 x 10 cm2 and 20 x 20 cm2. Modulated fields 
comprised of five enhanced dynamic wedge fields (wedge angle 15, 45 and 60 
degree with field size 10 x 10 cm2; and wedge angle 45 and 60 degree with field 
size 20 x 20 cm2) and seven IMRT fields (three prostate and four head and neck 
fields). The IMRT fields were delivered with 200 MU using the sliding window 
technique with the number of segments in each field ranging from 114 to 178. 
The extent of MLC travel distance for the seven IMRT fields ranged from 10.8 cm 
to 18.5 cm while the Y-jaw opening ranged from 10.5 cm to 18 cm. All beams 
were delivered at a fixed gantry angle of zero degrees and with the phantoms 
positioned at the isocentre. Results were analysed with the Varian Portal 
Dosimetry software (version 10.0, Palo Alto, CA, USA) using 2D global gamma 
analysis in absolute mode. The area of analysis was taken to be 100% of the field 
area for regular fields (open and wedge fields) and defined by the 20% threshold 
for irregular fields (IMRT fields). A dose threshold method was used for irregular 
fields to automatically demarcate the region of interest in a systematic way. 
The 20% value was chosen for IMRT fields to include a larger area of analysis, 
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considering the dose variation in the field and at the same time, to exclude very 
low dose region that may artificially improve the gamma analysis results due to 
global calculation of percentage dose difference.  !
5.3.6 Independent verification with 2D array 
The phantom measurements described in sub-Section 5.3.5 were repeated on 
the same day with a MapCHECK2 device to independently verify results from this 
model. The same homogeneous and heterogeneous phantoms were placed on top 
of the MapCHECK2 device (Figure 5-7). For consistency, MapCHECK2 dose planes 
were interpolated using a bilinear method to match the EPID resolution and 
comparisons between MapCHECK2 measured dose planes and TPS computed dose 
planes were also analysed with the Varian Portal Dosimetry software using 2D 
global gamma analysis in absolute mode. 
 
!
Figure 5-7 Experimental set-up for independent verifications with 2D array 
device.  
 
5.4 Results !
5.4.1 Comparisons of in-phantom exit dose: Reconstructed versus 
TPS 
5.4.1.1 Open field 
Figure 5-8a and 5-8b show comparisons of reconstructed and TPS computed in-
phantom exit dose profiles for a 20 x 20 cm2 open field tested on the 
homogeneous and heterogeneous phantoms respectively. At the central axis, the 
TPS computed exit dose was found to be higher than the reconstructed dose by 
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3.5% for the homogeneous phantom and 1.5% for the heterogeneous phantom. 
Additional central axis measurements with IC placed at the exit level of the two 
phantoms showed the same trend and confirmed that the TPS over-estimated 
the exit doses by 3.8% for the homogeneous phantom and 0.8% for the 
heterogeneous phantom. The same IC verification with a 10 x 10 cm2 open field 
showed a similar finding. From IC measurements at the central axis, the TPS was 
found to over- and under-estimate the exit dose by 2.8% and 0.6% for the 
homogeneous and heterogeneous phantoms respectively. These TPS inaccuracies 
were reflected in the results of this EPID dosimetry model. As can be seen from 
the profiles comparisons in Figure 5-8c and 5-8d for the 10 x 10 cm2 test field, 
the TPS computed exit dose was 2.4% higher and 1.7% lower than the 
reconstructed dose for the homogeneous and heterogeneous phantom 
respectively. The agreement between doses reconstructed from this model and 
doses physically measured by IC in the phantom proved that this EPID dosimetry 
model could accurately reflect the actual discrepancies between delivered and 
TPS planned dose. 
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Figure 5-8 Profiles comparisons between TPS computed and EPID 
reconstructed in-phantom exit dose for open fields. Comparisons between TPS 
computed (red solid line) and reconstructed in-phantom exit dose (blue dashed 
line) are for: (a) 20 x 20 cm2 open field tested on homogeneous phantom, (b) 20 
x 20 cm2 open field tested on heterogeneous phantom, (c) 10 x 10 cm2 open 
field tested on homogeneous phantom and (d) 10 x 10 cm2 open field tested on 
heterogeneous phantom. TPS inaccuracy in computing exit doses was found to 
have contributed to the observed offsets of the profiles. 
 
The profiles in Figure 5-8a were normalised to the central axis and shown in 
Figure 5-9a as relative profiles comparisons between TPS and EPID reconstructed 
exit dose. The TPS computed relative profile was also compared to the IC 
relative profile measured in a scanning water tank at the same depth (Figure 5-
9b). For clearer visualisation of the relative profiles comparisons, a section of 
the graphs was magnified and compared together (TPS computed, IC measured 
and EPID reconstructed) in the inset indicated as Figure 5-9c. Within the field, 
minor discrepancies between TPS and EPID reconstructed relative profiles were 
observed at the penumbra region (indicated by arrows in Figure 5-9c). The same 
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mismatch was also observed between the TPS and IC relative profile, proving 
that the discrepancies were inherent to the TPS and did not arise from the EPID 
dosimetry model.  
 
!
Figure 5-9 Relative profiles comparisons between TPS computed, EPID 
reconstructed and IC measured. (a) TPS computed (solid line) versus EPID 
reconstructed (dashed line) and (b) TPS computed (solid line) versus IC measured 
in a scanning water tank (dashed line). Section of profiles from (a) and (b) were 
magnified and compared together in the inset (c). The good agreement between 
EPID reconstructed and IC measured relative profiles as well as the consistent 
mismatches between these profiles and the TPS computed relative profiles at 
the penumbra region (indicated by arrows) imply that the discrepancies were 
inherent to the TPS and did not arise from the EPID dosimetry model. 
 
The ability of this dosimetry model to reflect actual discrepancies between 
delivered and TPS planned dose, confirmed by on- and off-axis IC measurements 
as described above, is an advantage. However, the common use of gamma 
criteria of 3%/3mm could be a problem because the TPS inaccuracy at the exit 
level could be more than 3% in some cases. Without correcting for the 
inaccuracy of TPS in computing exit doses, the gamma pass rate using 3%/3mm 
criterion was as low as 85.4% (for the 20 x 20 cm2 field tested on homogeneous 
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phantom, with a central axis dose difference of 3.5%). However, when the TPS 
computed exit doses were corrected, the pass rates were above 95.7% for all 
open fields tested on both phantoms. The TPS computed exit dose planes were 
corrected as an overall offset based on IC measurements at the central axis. The 
minor TPS inaccuracy at the penumbra region was not corrected. !
5.4.1.2 Modulated field (wedge and IMRT) 
TPS computed exit doses for modulated fields were also corrected based on IC 
point dose measurements at the central axis. However, instead of performing IC 
measurements for each wedge and IMRT field on the different phantoms, the 
inaccuracies of TPS computed exit doses for these modulated fields were only 
approximated from IC measurements of open fields with the same field size as 
the modulated fields and on the same phantom. For example, the effective field 
size for test field IMRT8 was 10.6 x 10.6 cm2, and from the IC measurement with 
open field 10 x 10 cm2 at the exit level of the homogeneous phantom, it was 
found that the TPS over-estimated the exit dose by 3%. Subsequently, the TPS 
computed exit dose for field IMRT8 on the homogeneous phantom was corrected 
as an overall offset of 3% before comparison was performed with the EPID 
reconstructed dose. Results for gamma comparisons between EPID reconstructed 
and TPS computed exit doses corrected for inaccuracies are given in the column 
‘With Dose Correction’ in Table 5-1. Results for gamma comparisons for the 
same fields but without correcting for TPS inaccuracies are also presented in 
Table 5-1 under the column ‘Without Dose Correction’. MapCHECK2 results are 
included in the table for reference.  
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Table 5-1 Gamma analysis results for comparisons between EPID 
reconstructed and TPS computed in-phantom exit dose with and without 
correcting for TPS exit dose inaccuracy. MapCHECK2 results were included for 
reference. 
 Homogeneous Phantom Heterogeneous Phantom 
 3%/3mm gamma pass rate (%) 3%/3mm gamma pass rate (%) 
 
Without 
Dose 
Correction 
With Dose 
Correction MapCHECK2 
Without 
Dose 
Correction 
With Dose 
Correction MapCHECK2 
EDW15FS10 99.8 99.9 99.9 87.8 95.2 97.5 
EDW45FS10 99.0 99.1 100.0 93.1 96.6 98.1 
EDW60FS10 100.0 99.8 100.0 94.0 96.5 98.1 
EDW45FS20 98.1 98.3 99.9 97.7 96.2 97.6 
EDW60FS20 95.6 98.5 100.0 99.6 99.0 99.1 
Mean Wedge: 98.5 99.1 100.0 94.4 96.7 98.1 
IMRT1 99.5 99.4 98.2 94.7 95.2 95.2 
IMRT2 90.2 96.9 97.9 97.1 97.4 96.8 
IMRT3 81.2 96.2 98.4 95.1 95.1 97.1 
IMRT4 87.9 97.9 99.0 97.0 97.3 95.8 
IMRT5 85.8 97.0 98.6 96.0 95.3 95.3 
IMRT6 91.1 97.7 97.0 95.3 93.5 94.2 
IMRT7 88.8 97.1 97.7 92.8 93.5 90.9 
Mean IMRT: 89.2 97.5 98.1 95.4 95.3 95.0 
Mean Overall: 93.1 98.2 98.9 95.0 95.9 96.3 
 
Comparisons between EPID reconstructed and TPS corrected in-phantom exit 
dose for wedge fields resulted in 3%/3mm gamma agreement that ranged from 
95.2% to 100% with a mean of 99.1% for homogeneous phantom and 96.7% for 
heterogeneous phantom. As for IMRT fields, the gamma pass rates ranged from 
93.5% to 99.4% with a mean of 97.5% for homogeneous phantom and 95.3% for 
heterogeneous phantom. The IMRT fields with pass rates below 95% concur with 
results from MapCHECK2 measurements. The overall mean gamma pass rate (all 
modulated fields on both phantoms) from this model was 97.0%, in good 
agreement with MapCHECK2 measurement results of 97.6%. Figure 5-10 shows 
comparisons of EPID reconstructed and TPS corrected in-phantom exit dose for 
an EDW15FS10 field, an EDW60FS10 field and an IMRT field (IMRT1) tested on the 
heterogeneous phantom. 
 
! 129!
!
Figure 5-10 Examples of results from comparisons between EPID 
reconstructed and TPS corrected in-phantom exit dose. Comparisons between 
EPID reconstructed and TPS corrected in-phantom exit dose for an EDW15FS10 
field (top row), EDW60FS10 field (middle row) and IMRT1 field (bottom row) 
tested on the heterogeneous phantom. From left to right is the reconstructed in-
phantom exit dose plane, 3%/3mm gamma comparison result (red indicating 
areas that failed the gamma criteria) and profiles comparisons between 
reconstructed (dashed line) and TPS computed (solid line) in-phantom exit dose 
across the axis indicated by the arrow. The percentages of points that passed 
the gamma criterion were 95.2%, 96.5% and 95.2% for the EDW15FS10 field (top 
row), EDW60FS10 field (middle row) and IMRT1 field (bottom row) respectively. !
5.4.2 Comparisons of EPID transit dose: Predicted versus measured 
5.4.2.1 Open field 
Comparisons between the EPID measured transit dose and that predicted by this 
model from TPS exported dose planes showed good agreement for open fields. 
The TPS exported exit dose planes were corrected for inaccuracies quantified 
from IC central axis dose measurements before the dose planes were used as 
input for the prediction of EPID transit dose. After correcting for TPS inaccuracy, 
the percentage of points that passed gamma criteria of 3%/3mm was above 
98.9% for all open fields tested on both homogeneous and heterogeneous 
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phantoms. Without correcting for TPS inaccuracy at the exit level, the lowest 
pass rate was 33.6% (for the 20 x 20 cm2 field tested on homogeneous phantom, 
with a central axis dose difference of 4.2%).  !
5.4.2.2 Modulated field (wedge and IMRT) 
Table 5-2 gives the wedge and IMRT gamma comparisons results between the 
EPID measured transit dose planes and that predicted by this model from TPS 
exported dose planes with and without correction for TPS inaccuracy at the exit 
level. After correcting for TPS exit dose inaccuracy based on IC measured dose, 
the predicted EPID transit dose agreed well with EPID measured dose for all 
modulated fields on both phantoms. The gamma pass rate with 3%/3mm 
criterion for wedge fields ranged from 95.8% to 100% with a mean value of 98.6% 
and 98.0% for homogeneous and heterogeneous phantom respectively. For IMRT 
fields, the percentage of points that passed the gamma criteria ranged from 
88.6% to 98.5% with a mean pass rate of 96.2% (homogeneous phantom) and 
94.4% (heterogeneous phantom). The overall mean gamma pass rate from this 
model was 96.5% (MapCHECK2, 97.6%). Figure 5-11 shows comparisons of 
measured and predicted EPID transit dose for an EDW45FS20 field, an 
EDW60FS20 field and an IMRT field (IMRT4) tested on the heterogeneous 
phantom. !
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Table 5-2 Gamma analysis results for comparisons between EPID measured 
transit dose and predicted from TPS dose planes with and without correcting 
for TPS exit dose inaccuracy. MapCHECK2 results are included for reference 
and are identical to those presented in Table 5-1. 
 Homogeneous Phantom Heterogeneous Phantom 
 3%/3mm gamma pass rate (%) 3%/3mm gamma pass rate (%) 
 
Without 
Dose 
Correction 
With Dose 
Correction MapCHECK2 
Without 
Dose 
Correction 
With Dose 
Correction MapCHECK2 
EDW15FS10 99.4 98.6 99.9 93.2 97.5 97.5 
EDW45FS10 97.3 99.1 100.0 92.7 97.4 98.1 
EDW60FS10 95.4 99.4 100.0 98.8 98.8 98.1 
EDW45FS20 85.5 95.8 99.9 98.3 97.0 97.6 
EDW60FS20 78.9 100.0 100.0 99.7 99.1 99.1 
Mean Wedge: 91.3 98.6 100.0 96.5 98.0 98.1 
IMRT1 99.1 97.3 98.2 96.0 96.7 95.2 
IMRT2 89.9 98.0 97.9 98.1 98.5 96.8 
IMRT3 79.0 97.1 98.4 96.3 96.3 97.1 
IMRT4 82.3 97.0 99.0 97.0 97.2 95.8 
IMRT5 81.2 96.5 98.6 94.7 95.3 95.3 
IMRT6 86.4 93.9 97.0 89.2 87.9 94.2 
IMRT7 83.4 93.4 97.7 89.1 88.6 90.9 
Mean IMRT: 85.9 96.2 98.1 94.3 94.4 95.0 
Mean Overall: 88.2 97.2 98.9 95.3 95.9 96.3 !
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Figure 5-11 Examples of results from comparisons between measured and 
predicted EPID transit dose. Comparisons between measured and predicted 
EPID transit dose for an EDW45FS20 field (top row), EDW60FS20 field (middle 
row) and IMRT4 field (bottom row) tested on the heterogeneous phantom. The 
EPID transit dose was predicted after correcting for TPS inaccuracy. From left to 
right is the predicted EPID transit dose plane, 3%/3mm gamma comparison result 
(red indicating areas that failed the gamma criteria) and profiles comparisons 
between measured (solid line) and predicted (dashed line) EPID transit dose 
across the axis indicated by the arrow. The percentages of points that passed 
the gamma criterion were 97.0%, 99.1% and 97.2% for the EDW45FS20 field (top 
row), EDW60FS20 field (middle row) and IMRT4 field (bottom row) respectively. 
 
5.5 Discussion 
 
The first objective of this study was to replace TPS calibration dose planes with 
IC in water calibration dose planes for the commissioning of this EPID dosimetry 
model. Although the methods to derive IC calibration dose planes required more 
effort, this was justified because the TPS computed calibration dose planes 
exported at the entrance and exit level of a phantom could contain 
inaccuracies. Inaccuracies in calibration data could propagate to the end results 
and may mask real discrepancies between planned and delivered dose. For 
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example, the results in Chapter 3 confirmed that the Eclipse AAA failed to 
account properly for the backscatter effect and, as a result, caused a 3.8% over-
estimation of dose at the exit level of a 15 cm thick water-equivalent phantom 
for a 6 MV, 20 x 20 cm2 field. However, this TPS inaccuracy was not reflected in 
the EPID dosimetry result in Chapter 4, where the difference between EPID 
reconstructed and TPS computed in-phantom exit dose for the same beam and 
phantom thickness was only 0.4%. By using IC calibration dose planes in the 
commissioning process, the EPID dosimetry model was able to reveal real 
differences between measured and TPS planned dose. As shown in the results 
section of this chapter, the TPS dose computed at the exit level of the 15 cm 
thick water-equivalent phantom for a 20 x 20 cm2 field was higher than the EPID 
reconstructed dose by 3.5%, in closer agreement with the findings in Chapter 3. 
This result proves that the use of accurate calibration data, independent of the 
TPS, is essential in ensuring that the EPID dosimetry model can reflect actual 
discrepancies between measured and TPS planned doses. 
 
The inaccuracy of exit dose computed by the Eclipse AAA algorithm could be as 
much as 5% at large depth (31.5 cm) and large field size (20 x 20 cm2) (Tan 
2014). In the case where the TPS exit dose error was more than 3%, the use of 
common 3%/3mm gamma criterion to evaluate the agreement of measured and 
planned exit dose planes would result in a disproportionately high rate of failure 
and make it difficult to retrieve meaningful information from the comparison 
results. In this study, additional IC measurements were done at the exit level of 
both phantoms and the inaccuracy of TPS computed exit doses were quantified 
and corrected. The IC measurements were done only for open fields. The TPS 
exit dose inaccuracies for modulated fields were approximated from the open 
fields measurements of the closest setting. To ensure a reasonable 
approximation, the parameters that affect the amount of backscattered photons 
such as beam energy, field size, phantom type and measurement depth were 
chosen from the open field measurements that would represent the conditions 
of the modulated fields. Two sets of comparisons, with and without correcting 
for TPS inaccuracies, were presented in the results section. The purpose of 
presenting the results with TPS dose correction was to evaluate the effect of TPS 
exit dose inaccuracy on the results of this model. It can be observed from Tables 
5-1 and 5-2 that the 3%/3mm gamma comparisons results generally improved 
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after accounting for TPS computed exit dose inaccuracies. However, the 
additional IC measurement at the exit level is not practical for routine clinical 
practice. In the case where IC measurements at the exit level are not possible, a 
higher gamma criterion should be considered. Table 5-3 presents results for 
comparisons of in-phantom exit dose and comparisons of EPID transit dose using 
a 4%/4mm criterion, without any correction to the TPS computed exit dose. The 
criterion was chosen based on previous IC measurements, which showed that the 
inaccuracy of Eclipse AAA computed exit dose for both phantoms were within 
4%. Using this 4%/4mm criterion, all the fields tested on both phantoms had 
more than 90% gamma pass rate. For the in-phantom exit dose comparisons, the 
minimum gamma pass rate was 94.3% with an overall mean of 98.9% for the 
homogeneous phantom and 99.0% for the homogeneous phantom. As for the 
comparisons of EPID transit dose, the minimum gamma pass rate was 91.7% with 
an overall mean of 97.1% and 99.1% for the homogeneous and heterogeneous 
phantom respectively. 
 
Table 5-3 Gamma analysis results, with 4%/4mm criterion, for comparisons of 
in-phantom exit dose and comparisons of EPID transit dose. No correction was 
applied to the TPS computed exit dose. 
 
Comparisons of in-phantom exit dose: 
Reconstructed versus TPS 
Comparisons of EPID transit dose: 
Predicted versus Measured 
 4%/4mm gamma pass rate (%) 4%/4mm gamma pass rate (%) 
 
Homogeneous 
Phantom 
Heterogeneous 
Phantom 
Homogeneous 
Phantom 
Heterogeneous 
Phantom 
Open 10 x 10 cm2 100.0 99.2 99.8 99.7 
Open 20 x 20 cm2 100.0 99.2 97.4 99.7 
Mean Open: 100.0 99.2 98.6 99.7 
EDW15FS10 100.0 97.2 100.0 98.7 
EDW45FS10 100.0 97.8 100.0 98.3 
EDW60FS10 100.0 97.5 100.0 100.0 
EDW45FS20 100.0 99.9 97.1 100.0 
EDW60FS20 99.9 100.0 95.4 100.0 
Mean Wedge: 100.0 98.5 98.5 99.4 
IMRT1 100.0 97.6 100.0 99.6 
IMRT2 98.4 99.5 98.6 99.8 
IMRT3 94.3 99.2 93.7 99.7 
IMRT4 98.7 99.9 96.3 99.9 
IMRT5 96.9 99.4 94.6 99.3 
IMRT6 98.8 99.8 95.1 96.5 
IMRT7 97.4 99.1 91.7 96.5 
Mean IMRT: 97.8 99.2 95.7 98.8 
Mean Overall: 98.9 99.0 97.1 99.1 
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As with any other empirical model, the limited number of measurements that 
can be practically carried out require certain assumptions to be made that may 
affect the accuracy of results. In this model, two assumptions were made in 
using MF, defined as the ratio of modulated to non-modulated dose planes at the 
same level, to quantify beam modulation. First, the MF was assumed to be 
similar for both EPID and IC (or TPS). Second, the MF derived at the entrance 
level was assumed to be representative of the MF at the exit level. 
 
For this first assumption, a minor correction was made, as described in sub-
Section 5.3.3.2, to convert MF derived from EPID to the equivalent of IC and vice 
versa. This correction was derived from EDW60 measurements and used as a 
generic correction for all modulated fields, including IMRT. Without accounting 
for the difference in dose rate between EDW60 and IMRT delivery, the same 
generic MF correction derived from EDW60 measurements was applied to the 
IMRT fields. Figure 5-12 shows the comparisons of MF derived from TPS dose 
planes (MFIC) and EPID dose planes (MFEPID), for IMRT fields. It can be observed 
that the agreement between MF derived from TPS and EPID improved after 
applying the generic correction (MFcorrected
EPID ). The generic MF correction was 
applied according to Equation 5-8 and W in the equation was taken to be one for 
IMRT fields. The MFcorrected
EPID  agreed well with the MFIC despite using a general 
correction derived from EDW60 measurements for IMRT fields. 
 
For the second assumption, the MF at the entrance level was assumed to be the 
same as the MF at the exit level. This assumption is illustrated in Figures 5-13, 
which show comparisons of MF derived from entrance dose planes versus MF 
derived from exit dose planes. The comparisons of MF at the two levels are 
shown for both TPS and EPID dose planes. Within the field of interest, the MFs 
derived at two different levels were reasonably comparable. 
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Figure 5-12 Comparisons of MFs derived from TPS dose planes and EPID dose 
planes and the effect of generic MF correction. MFs derived from TPS dose 
planes, MFIC, are represented by solid line and MFs derived from EPID dose 
planes, MFEPID, are represented by dashed line. Examples are given for field 
IMRT1 (top row) and field IMRT4 (bottom row). Agreement between the two MFs 
improved after applying the generic MF correction (MFcorrected
EPID ), according to 
Equation 5-8 with W taken to be one for IMRT fields.  !
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Figure 5-13 Comparisons of MFs derived from entrance dose planes and exit 
dose planes. Solid lines represent MFs derived from entrance dose planes and 
dashed lines represent MFs derived from exit dose planes. Examples are given 
for field IMRT1 (top row) and field IMRT4 (bottom row). The comparisons were 
performed for both EPID measured dose planes (left column) as well as TPS 
computed dose planes (right column). 
 
5.6 Conclusions !
An empirical 2D EPID transit dosimetry model, commissioned with data 
independent of the TPS, was described and proven to be capable of revealing 
actual discrepancies between measured and planned doses. The dosimetry 
model was tested with open, wedge and IMRT fields on both homogeneous and 
heterogeneous slab phantoms. Results showed that by taking into account the 
TPS exit dose inaccuracies, the 3%/3mm gamma pass rates for open fields were 
above 95.7% for in-phantom exit dose comparisons and above 98.6% for EPID 
transit dose comparisons. As for the modulated fields (wedge and IMRT), the 
overall mean gamma pass rate was 97.0% (range: 93.5% to 99.9%) for in-phantom 
exit dose comparisons and 96.5% (range: 87.9% to 100.0%) for EPID transit dose 
comparisons. The overall results compared favourably with independent 
verification using a commercial 2D array device, with an overall mean of 97.6% 
(range: 90.9% to 100.0%). Without accounting for TPS exit dose inaccuracies and 
with a higher gamma criterion of 4%/4mm, the mean gamma pass rate for all 
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fields tested on both phantoms was 98.9% (range: 94.3% to 100.0%) for in-
phantom exit dose comparisons and 98.1% (range: 91.7% to 100.0%) for EPID 
transit dose comparisons.  
 
The 2D EPID transit dosimetry model developed up to this stage can only be used 
for slab phantoms and with the gantry angle fixed at zero degrees, thus limiting 
its application to pre-treatment verification only. The requirement for the 
incident beam to be perpendicular to a flat surface is to allow the direct export 
of TPS entrance and exit dose planes, at a distance of 1.5 cm from the beam 
entry and exit surface of a phantom. With a non-flat object, the entrance or exit 
doses are no longer located at the same plane and cannot be easily exported 
from the TPS. A solution to this problem will be presented in the next chapter, 
with the aim of extending the current EPID dosimetry model to verification of 
actual patient treatment delivery.  
!!
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Chapter 6: Clinical feasibility of a dual 2D EPID transit 
dosimetry model for actual treatment verification !
6.1 Publication/presentation arising from work in this chapter  
 
• A dual 2D EPID transit dosimetry model for actual treatment 
verification, Tan, Y., Metwaly, M., Glegg, M., Baggarley, S. & Elliott, A., 
2015, Poster presentation, 3rd ESTRO Forum, European Society for 
Radiotherapy and Oncology, Barcelona, Spain.  
 
6.2 Introduction 
 
A dual 2D EPID transit dosimetry model, commissioned with data independent of 
the TPS, was described in Chapter 5 and shown to be effective in reflecting real 
discrepancies between measured and planned doses. In addition to simple non-
modulated square fields, the dosimetry model was also proven to be capable of 
reconstructing and predicting doses for modulated fields such as enhanced 
dynamic wedge (EDW) and IMRT fields. The non-modulated and modulated fields 
were systematically tested on both homogeneous and heterogeneous slab 
phantoms. Using a gamma criterion of 4%/4mm, comparisons of in-phantom dose 
at the exit level (1.5 cm upstream from the beam exit surface of the phantom) 
between TPS computed and reconstructed from EPID measured dose planes 
(Path 1) showed an overall mean gamma pass rates of 98.9% (range: 94.3% to 
100.0%) for the homogeneous slab phantom and 99.0% (range: 97.2% to 100.0%) 
for the heterogeneous slab phantom. As well as in-vivo dose comparison at the 
exit level, the dosimetry model also allowed transit dose comparison at the EPID 
level. The overall mean gamma pass rates for EPID transit dose comparisons 
between measured and predicted from TPS exported dose planes (Path 2) was 
97.1% (range: 91.7% to 100.0%) for the homogeneous slab phantom and 99.1% 
(range: 96.5% to 100.0%) for the heterogeneous slab phantom. Instead of the 
more common 3%/3mm criterion, a higher gamma criterion of 4%/4mm was 
necessary because the TPS computed exit dose was found to contain 
inaccuracies that may exceed 3% for large fields and thick phantoms, as 
confirmed by IC measurements presented in Chapters 3 and 5.  
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The EPID dosimetry model developed in this study is a transit model, where a 
phantom or patient can be present in the beam during the EPID measurement. 
Unlike non-transit models, which require measurements through air and are 
therefore only applicable to pre-treatment verification, the transit model can be 
utilised for both pre-treatment and actual treatment verification. Actual 
treatment verification is especially valuable as a final check to confirm the safe 
delivery of radiotherapy and is highly recommended for routine use in all 
radiotherapy centres (The Royal College of Radiologists et al., 2008). In addition 
to the errors that can be detected by pre-treatment QA, actual treatment 
verification can also detect anatomical changes, obstruction from immobilisation 
devices or table structures, machine performance variation on a particular 
treatment day, set-up error and other types of operator errors (van Elmpt et al., 
2008a). In a study by Ford et al. (2012) that quantified the efficacy of 15 
common QA checks, pre-treatment QA ranked the lowest with an effectiveness 
score of only 1.4% while EPID dosimetry for actual treatment verification ranked 
much higher at fifth place, with an effectiveness score of 33.0%. The author also 
studied the effectiveness of different combinations of QA checks. By combining 
the EPID dosimetry for actual treatment verification with only one other QA 
check (physics chart review), the error detection rate was as high as 80%. In 
addition, Mans et al. (2010b) also found that the EPID dosimetry for actual 
treatment verification was more effective in detecting errors compared to pre-
treatment QA. Nine out of 17 serious errors that were detected by EPID 
dosimetry would have been missed by pre-treatment QA.  
 
Recognising the value of EPID dosimetry for actual treatment verification, the 
ultimate aim of this study was to develop an EPID dosimetry model that could be 
used for this purpose. Although the EPID dosimetry model described in the 
previous chapters is a transit model, all experiments were performed with a 
fixed gantry angle of zero degrees using slab phantoms with a flat surface, 
restricting its application to pre-treatment verification only. The requirement 
for the incident beam to be perpendicular to a flat surface was because the 
entrance (M0) or exit (M) dose points across the field must be located at the 
same plane in the attenuating object to enable direct export from the TPS. 
Since the entrance and exit doses were defined as dose at 1.5 cm from the beam 
entry and exit surface of the object respectively, the M0 or M dose points across 
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the field would not be located at the same plane if the beam were incident on a 
non-flat or irregular surface. 
 
The first objective of this chapter was to develop a method that could extract 
M0 and M dose planes for objects with an irregular surface without relying on the 
direct export of 2D dose planes from the TPS. Since the patient’s surface is 
clearly irregular, the proper extraction of TPS M0 and M dose planes is necessary 
to enable the application of the EPID transit dosimetry model for actual 
treatment verification. The method must also incorporate steps to deal with 
irradiation from different gantry angles, as would be encountered in an actual 
treatment delivery.  
 
In one of the proposed EPID transit dosimetry model pathways, Path 1, the EPID 
measured dose planes were used to reconstruct dose at 1.5 cm upstream from 
the beam exit surface of the phantom, the exit level. The second objective of 
this chapter was to extend the methods in Path 1 to reconstruct in-phantom/in-
vivo dose at other levels besides the exit level. By extending the model to 
reconstruct dose at other levels, users would be able to choose a location that is 
more clinically relevant (such as at the tumour level or critical organ level) for 
the dose verification.  
 
The extended 2D EPID transit dosimetry model was initially evaluated with an 
anthropomorphic phantom using open, 3D conformal, EDW and IMRT fields at 
cardinal and oblique gantry angles. Tests with an anthropomorphic phantom and 
irradiation at variable gantry angles provided a more complete and realistic 
evaluation of the EPID transit dosimetry model before it was used for actual 
patient treatment verification.  
 
Finally, clinical feasibility of the 2D EPID transit dosimetry model for actual 
treatment verification was assessed. Results from a pilot study with patients 
undergoing radiotherapy to the pelvic region are presented. Practical issues 
related to the clinical workflow are discussed also.  
 !
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6.3 Materials and methods !
6.3.1 Extracting TPS M0 and M dose planes 
As described in Chapters 4 and 5, the TPS M0 and M dose planes were required 
for reference comparisons in Path 1 (Comparisons of in-phantom/in-vivo dose: 
EPID reconstructed versus TPS computed) and as input for the prediction of EPID 
transit dose in Path 2 (Comparisons of EPID transit dose: TPS predicted versus 
EPID measured). Since the TPS M0 and M dose planes were defined as dose at 1.5 
cm from the beam entry and exit surface of the attenuating object (either 
phantom or patient), the M0 or M points across the field area would not be 
located in the same plane normal to the beam if the surface were not flat. This 
condition is clearly illustrated in Figure 6-1 for two objects with (a) a flat 
surface and (b) an irregular surface.  
 
!
Figure 6-1 Location of entrance (M0) and exit (M) doses, 1.5 cm from beam 
entry and exit surface of the phantom respectively. For an object with a flat 
surface (a), the M0 or M doses across the field area are located in the same 
plane (indicated by the straight arrows in red) and can be directly exported from 
the TPS as 2D dose planes. However, for an object with an irregular surface (b), 
the M0 or M doses are not located in the same plane across the field area 
(indicated by the curved arrows in red) and cannot be directly exported from 
the TPS as 2D dose planes.     
 
When the M0 or M doses across the field area are not located in the same plane, 
they cannot be directly exported from the TPS as 2D dose planes. As a solution 
to this problem, a Matlab code was written to extract 2D M0 and M dose planes 
from 3D ‘Structure’ and ‘Dose’ DICOM files exported from the TPS. The 
‘Structure’ DICOM file contains information on the location of the external body 
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contour on each slice of the CT scan, which is outlined for all phantoms/patients 
during the planning stage. The ‘Dose’ DICOM file, meanwhile, contains 
information on the 3D dose distribution for a particular treatment field planned 
and computed for the phantom/patient. From these two DICOM files exported 
from the TPS, the 2D M0 and M dose planes were extracted following the steps 
illustrated in Figure 6-2.  
 
!
Figure 6-2 Steps to extract 2D M0 and M dose planes from 3D ‘Structure’ and 
‘Dose’ DICOM files exported from the TPS. The ‘Structure’ DICOM file contains 
information on the location of the body contour on each slice of the CT scan and 
the ‘Dose’ DICOM file contains information on the 3D dose distribution for the 
treatment field calculated for the phantom/patient.  
 
First, the external body contour in the ‘Structure’ DICOM file was used to create 
a binary image. Then, a column-by-column search was done on the binary image 
to locate the edge of the body contour (the surface). The coordinates of the 
entrance and exit points, defined as 1.5 cm from the surface, can then be 
determined from the location of the edge. After that, dose values for these 
coordinates were extracted from the ‘Dose’ DICOM file. These steps were 
repeated for all slices. The dose values for the entrance and exit coordinates 
from each slice were then used to fill a 2D matrix, with each row representing 
one slice, to create the TPS M0 and M dose planes. 
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For treatment fields with gantry angle other than zero degrees, both the 
‘Structure’ and ‘Dose’ DICOM files were rotated around the field isocentre 
before the column search for body edge was performed. The image rotation 
based on field gantry angle was necessary so that the column search would 
correctly identify the coordinates of the entrance and exit points, which were 
dependent on the point of beam entry and exit surface respectively. Figure 6-3 
shows an example of a treatment field with a gantry angle of 90 degrees. 
Without rotating the ‘Structure’ and ‘Dose’ files, the coordinates identified from 
the column search were not in the direction of the beam and, therefore, 
incorrect (Figure 6-3a). By rotating the ‘Structure’ and ‘Dose’ files according to 
the field gantry angle in the anti-clockwise direction, the correct coordinates 
can be identified using the column search technique (Figure 6-3b).  
 
!
Figure 6-3 Example of ‘Structure’ and ‘Dose’ DICOM images for a treatment 
field with a gantry angle of 90 degrees. The dotted line represents the 
entrance coordinates identified using the column search technique. (a) Without 
rotating the DICOM images, the coordinates identified were not in the direction 
of the beam entry surface; (b) After rotating the DICOM images around the beam 
isocentre (Iso) based on the gantry angle, the correct coordinates can be 
identified. 
 
6.3.2 Path 1: Reconstruction of in-phantom/in-vivo dose 
6.3.2.1 Exit level 
The method used to reconstruct in-phantom exit dose from EPID measured dose 
planes was previously described in detail in Chapter 5 (sub-Section 5.3.3). 
Briefly, EPID dose planes measured for the treatment field with (MEPID_tx) and 
without (M0EPID_tx) phantom/patient in the beam and (A and B)EPID were used to 
calculate a 2D EPL map.  Subsequently, the 2D EPL map, in combination with the 
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(A and B)IC, were used to calculate the equivalent dose ratio (M/M0)IC. This 
equivalent dose ratio was used in the final reconstruction of in-phantom/in-vivo 
exit. Finally, the reconstructed exit dose was compared to TPS computed exit 
dose, extracted as described in sub-Section 6.3.1, to verify the accuracy of 
treatment delivery.  
 
6.3.2.2 ‘X’ level 
Besides reconstructing dose at the exit level as summarised above, the EPID 
measured dose planes could also be used to reconstruct in-phantom/in-vivo dose 
at other levels (‘X’), for example at the isocentre plane. For this purpose, a ‘CT 
number’ to ‘EPL relative to water’ (EPLrel) calibration curve must be established. 
A tissue characterisation phantom, RMI 467 phantom (Gammex Inc., Middleton, 
WI, USA), which consisted of multiple cylindrical rods made of materials with 
relative electron densities ranging from 0.001 to 1.69 (air to cortical bone, 
including solid water), was used to establish this curve (Figure 6-4a).  
 
First, the RMI phantom was placed vertically on the CT couch and scanned with a 
CT simulator (Discovery CT590 RT, GE Healthcare, UK) at 120 kVp to get the CT 
number in Hounsfield units (HU) for each rod material in the phantom (Figure 6-
4b). This was the same CT simulator and energy setting used to scan all 
phantoms/patients for the treatment planning process. Then, the CT number 
was correlated to the EPLrel. To get the EPLrel, the same RMI phantom was 
positioned flat on the linac couch and irradiated with the reference beam (6 MV, 
100 MU and field size 20 x 20 cm2). The EPID transit dose plane measured for the 
RMI phantom was used to calculate the 2D EPL map (Figure 6-4c) with the 
quadratic equation (Swindell, 1983). The EPL for each rod material was 
normalised to the EPL for the rod with water density to obtain the EPL relative 
to water (EPLrel).  
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Figure 6-4 Cross-section of RMI 467 phantom, CT axial image and 2D EPL map 
of the phantom. (a) Cross-section of RMI 467 phantom and the arrangement of 
rods representing materials of different densities. Details of the rod materials 
are given in Table 6-1. (b) CT image of the RMI 467 phantom that was used to 
derive the CT number (HU) for rods with different densities. (c) 2D EPL map of 
the same RMI 467 phantom calculated with the quadratic equation using EPID 
dose planes measured for a reference beam (6 MV, 100 MU and field size 20 x 20 
cm2) with and without the RMI phantom in the beam.  
 
Table 6-1 lists the CT number and EPLrel values for various rods in the RMI 
phantom that were made of materials with different densities. A plot of the CT 
number versus EPLrel is shown in Figure 6-5. The plot shows a discontinuity and 
therefore, must be fitted with two linear equations that have different slopes. 
This pattern of plot is characteristic of the relationship between electron 
density relative to water and CT number (HU), with the point of inflection and 
slopes specific to each CT scanner (Constantinou et al., 1992).   
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Table 6-1 List of rod materials and the respective electron density relative to 
water. The CT number (HU) and EPL (cm) for each rod material were obtained 
using methods described in sub-Section 6.3.2.2. The physical length of all rods 
was 7 cm.  
Rod materials 
Physical 
density 
(g/cm3) 
Electron 
density 
relative to 
water 
CT number 
(HU) EPL (cm) 
EPL relative 
to water, 
EPLrel 
Air 0.00 0.00 -900 0.00 0.00 
Lung 300 0.30 0.29 -600 2.00 0.29 
Lung 450 0.41 0.40 -450 3.10 0.46 
Adipose 0.92 0.90 20 6.40 0.94 
Breast 0.98 0.96 50 6.50 0.96 
Solid Water 1.02 0.99 100 6.80 1.00 
Brain 1.05 1.05 130 7.10 1.04 
Liver 1.11 1.07 150 7.30 1.07 
Inner Bone 1.14 1.09 250 7.50 1.10 
B200 Bone 1.16 1.11 260 7.60 1.12 
CB2 30% 1.34 1.28 500 8.50 1.25 
CB2 50% 1.56 1.47 800 9.70 1.43 
Cortical Bone 1.82 1.69 1160 10.90 1.60 !
 
Figure 6-5 CT number to EPL relative to water calibration curve. The CT 
number (HU) to EPL relative to water, EPLrel, calibration curve is plotted for 
materials of different relative electron densities (top row). The vertical line 
marks the point of inflection in the graph (at 150 HU). The data to the left and 
right of that point were separately fitted with a linear equation (bottom row).  
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The two linear equations derived from the CT number to EPLrel calibration curve 
were: 
 
EPLrel = 
 0.0010!HU + 0.91                    HU!≤!150
 0.0005!HU + 0.98                    HU!>!150                                    (6-1) 
 
Using these linear equations, the CT number (HU) for each pixel on the 
phantom’s/patient’s CT simulation images was converted into an EPLrel value. 
Then, EPLrel value for all pixels along a column (j) from the entrance to the level 
of interest, ‘X’, was summed ( EPLrel(i)'X'i=Entrance ). The EPLrel value from entrance 
to the exit level was also summed in the same way ( EPLrel(i)
Exit
i=Entrance ). The 
summation processes were repeated for all CT slices, with the value for each 
slice (z) occupying a row on a 2D matrix. Then, the two 2D matrices were 
divided to become a new parameter, termed as the EPL ratio: 
 
EPL ratio (z,j) = 
EPLrel
'X'
i=Entrance (i)  z,j  
EPLrel
Exit
i=Entrance (i)  z,j
                                                        (6-2) 
 
The effect of beam divergence was neglected in the derivation of EPL ratio. 
Thus, the EPL ratio was regarded as a close approximation. Figure 6-6 illustrates 
the derivation of the 2D EPL ratio from a patient’s CT images. The example 
shown is for a treatment field with gantry at zero degrees. For fields with other 
gantry angles, the patient’s CT images were rotated around the isocentre 
according to the treatment gantry angle and in the anti-clockwise direction 
before the EPLrel values were summed.  
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Figure 6-6 Derivation of 2D EPL ratio from CT simulation images. The 
calibration curve was first used to convert CT number (HU) in the images to 
EPLrel value. Then, the EPLrel value for pixels along each column (j) was summed 
from the entrance to ‘X’ level as well as from the entrance to exit level. The 
dotted contour marked the entrance and exit location, 1.5 cm from the surface. 
The process was repeated for each CT slice (z), resulting in two 2D matrices that 
were subsequently divided to get the EPL ratio.  
 
Since the EPID can only measure radiation after it traverses the full vertical 
length of the phantom/patient, the EPL calculated from EPID measured dose 
planes will always represent the path length from the entrance to the exit level 
of the phantom/patient. The function of the 2D EPL ratio was to scale the full 
EPL so that the EPL now represents the path length from the entrance to ‘X’ 
level, as required in the reconstruction of in-phantom/in-vivo dose at the ‘X’ 
plane. Figure 6-7 shows the pathway to reconstruct in-phantom/in-vivo ‘X’ dose 
from EPID measured dose planes. As can be seen from the figure, the initial 
steps leading to the calculation of EPL from EPID measured M0 and M dose 
planes remained the same as that for exit dose reconstruction (Figure 5-3, Path 
1). After that, the full EPL calculated from EPID measured dose planes was 
multiplied to the EPL ratio. By using this scaled EPL for the subsequent 
calculation of the equivalent in-phantom/in-vivo dose ratio (M/M0)IC, the M now 
would represent the dose at ‘X’ instead of exit dose and the equivalent dose 
ratio can be rewritten as (M‘X’/M0)IC. 
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Figure 6-7 Pathway to predict in-phantom/in-vivo dose ratio (M‘X’/M0)IC from 
EPID measured dose planes. The EPL ratio was used to scale the EPL calculated 
from EPID dose planes, so that the EPL would represents the path length from 
the entrance to ‘X’ level of the phantom/patient. With this scaled EPL, the in-
phantom/in-vivo ‘X’ to entrance dose ratio (M‘X’/M0)IC can be calculated. The 
dose ratio was used in the final reconstruction of dose at ‘X’ for comparison with 
TPS computed dose. The ‘X’ could be any plane inside the phantom/patient as 
chosen by the user. All parameters are in 2D and the (i,j) coordinates have been 
omitted for clearer illustration.  
 
After that, the calculated dose ratio, (M‘X’/M0)IC, was used to reconstruct in-
phantom/in-vivo dose at ‘X’ (MIC pred (‘X’)) according to Equation 6-3. This 
equation was very similar to the equation previously described for exit dose 
reconstruction (Chapter 5, Equation 5-11). But because the dose ratio was 
calculated from the EPL representing the path length from the entrance to ‘X’ 
level, the resultant reconstructed dose is that at the ‘X’ plane.   
 
MIC pred ('X') = 
M'X'
M0 IC
 × M0IC ref ÷ FSFIC × 
100
SDD
2
× MFcorrected
EPID                          (6-3) 
 
where ‘M0IC ref’ is the IC entrance dose plane for a 20 x 20 cm2 reference beam 
that was previously derived as part of the commissioning process, ‘FSFIC’ is the 
field size correction factor tabulated from IC measured 2D dose planes to 
correct for treatment fields with non-reference field size and ‘SDD’ is the 
distance from source to ‘X’ plane. The MFcorrected
EPID  is the modulation factor 
acquired by dividing the EPID dose plane measured for a modulated treatment 
field by EPID dose plane measured for a non-modulated reference field 
corrected for field size. Both the modulated and non-modulated EPID dose 
planes used to derive the MF were measured through air. A general correction, 
described in Chapter 5 (sub-Section 5.3.3.2), was applied to account for 
differences between MF acquired from EPID measured dose planes and IC 
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measured dose planes. For a treatment field without modulation, the MFcorrected
EPID  
was equal to unity. 
 
Finally, the reconstructed in-phantom/in-vivo dose at ‘X’ plane was compared to 
the TPS planned dose to verify the accuracy of treatment delivery.  
 
6.3.3 Path 2: Prediction of EPID transit dose 
A detailed description of the methods to predict EPID transit dose from TPS dose 
planes was provided in Chapter 5 (sub-Section 5.3.4). In short, TPS entrance 
(M0TPS_tx) and exit (MTPS_tx) dose planes, defined as dose at 1.5 cm from the beam 
entry and exit surface of the phantom/patient respectively, were extracted 
from 3D ‘Structure’ and ‘Dose’ DICOM files exported from the TPS according to 
the steps elaborated in sub-Section 6.3.1. Then, the M0TPS_tx and MTPS_tx, together 
with (A and B)IC, were used to calculate the 2D EPL map of the phantom/patient. 
Subsequently, the 2D EPL map and the (A and B)EPID were used to derive the 
equivalent EPID dose ratio (M/M0)EPID. Finally, the (M/M0)EPID was used to predict 
the EPID transit dose for direct comparison with the EPID dose plane captured 
during treatment delivery.  !
6.3.4 Evaluation with anthropomorphic phantom 
The dual 2D EPID transit dosimetry model was first evaluated using an 
anthropomorphic pelvic phantom (The Phantom Laboratory, NY, USA), shown in 
Figure 6-8. The pelvic phantom was scanned with the CT simulator and the 
images were sent to Eclipse TPS (Varian, Palo Alto, CA, USA) for treatment 
planning. Various non-modulated and modulated treatment fields were planned 
for the phantom. The non-modulated treatment field consisted of two simple 
square fields and three 3D conformal fields, while the modulated treatment 
field consisted of three EDW fields and three IMRT prostate fields. The IMRT 
fields were delivered using the sliding window technique, each with 114 
segments. These 11 types of treatment fields were planned for different 
locations on the phantom and with variable gantry and collimator angles, 
resulting in a total of 65 test fields for evaluations. Details of the test fields are 
given in Table 6-2. 
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 Table 6-2 Inform
ation on the test fields used for evaluation w
ith the anthropom
orphic phantom
.  
  
Field nam
e 
Field 
num
ber 
aIsocentre 
G
antry angle (degree) 
Collim
ator 
angle 
(degree) 
Jaw
 positions 
M
LC 
bEquivalent 
square (cm
2) 
M
U
 
X1 (cm
) 
X2 (cm
) 
Y1 (cm
) 
Y2 (cm
) 
Open 
FS10 
1 - 8 
A
 
0, 45, 90, 135, 180, 225, 270, 315 
0 
5.0 
5.0 
5.0 
5.0 
N
one 
10.0
2 
100 
 
9 - 12 
B 
0, 90, 180, 270 
0 
5.0 
5.0 
5.0 
5.0 
N
one 
10.0
2 
100 
 
13 - 17 
C 
0, 45, 135, 180, 225 
0 
5.0 
5.0 
5.0 
5.0 
N
one 
10.0
2 
100 
FS20 
18 - 21 
A
 
0, 90, 180, 270 
0 
10.0 
10.0 
10.0 
10.0 
N
one 
20.0
2 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
3D 
conformal 
Conform
 1 
22 - 23 
A
 
0, 45 
0 
10.0 
5.0 
10.0 
7.5 
Static 
13.4
2 
100 
Conform
 2 
24 - 25 
A
 
0, 135 
0 
5.0 
5.0 
5.0 
5.0 
Static 
7.6
2 
100 
Conform
 3 
26 - 27 
A
 
0, 315 
0 
5.0 
5.0 
5.5 
5.5 
Static 
7.6
2 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wedge  
ED
W
60FS10 
28 - 31 
A
 
0, 90, 180, 270 
90 or 270 
5.0 
5.0 
5.0 
5.0 
N
one 
10.0
2 
100 
 
32 - 35 
B 
0, 90, 180, 270 
90 or 270 
5.0 
5.0 
5.0 
5.0 
N
one 
10.0
2 
100 
ED
W
15FS20 
36 - 37 
A
 
0, 180 
90 or 270 
10.0 
10.0 
10.0 
10.0 
N
one 
20.0
2 
100 
ED
W
60FS20 
38 - 41 
A
 
0, 90, 180, 270 
90 or 270 
10.0 
10.0 
10.0 
10.0 
N
one 
20.0
2 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMRT 
IM
RT 1 
42 - 45 
A
 
0, 135, 180, 315 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.6
2 
200 
 
46 - 49 
B 
0, 135, 180, 315 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.6
2 
200 
IM
RT 2 
50 - 53 
A
 
0, 45, 180, 225 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.3
2 
200 
 
54 - 57 
B 
0, 45, 180, 225 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.3
2 
200 
IM
RT 3 
58 - 61 
A
 
0, 135, 180, 225 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.8
2 
200 
 
62 - 65 
B 
0, 135, 180, 225 
0 
7.5 
7.5 
7.5 
7.5 
D
ynam
ic 
6.8
2 
200 
a Location of field isocentre (lateral, vertical, longitudinal): A = (0 cm
, 0 cm
, 0 cm
), B = (0 cm
, 0 cm
, -7 cm
), C
 = (4 cm
, 0 cm
, 0 cm
). These isocentres are visually indicated in Figure 6-8. 
b The equivalent square field size for an irregularly shaped field w
as calculated using the m
ethod described by M
onti et al. (1995). The field area for 3D
 conform
al fields w
as defined by positions of the M
LC
 
leaves retrieved from
 M
LC
 files exported from
 the TPS. For the IM
RT fields, the field area w
as defined as the region w
ith dose greater than 50%
 of the m
axim
um
 dose, follow
ing the com
m
on definition of 
field size.  
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Figure 6-8 Anthropomorphic pelvic phantom and beam arrangements. (a) 
Anthropomorphic pelvic phantom. (b) Anthropomorphic pelvic phantom 
positioned on the linac couch for EPID measurements. (c) CT images of the 
phantom imported into the TPS for treatment planning. The ‘A’, ‘B’ and ‘C’ 
marked different locations where test fields were centred. !
6.3.5 Actual treatment verification of patients 
After a thorough evaluation with the anthropomorphic phantom, the 2D EPID 
transit dosimetry model was used for actual treatment verification of three 
patients undergoing radiotherapy to the pelvic area. The treatment plans for the 
three patients comprised of 11 3D conformal and EDW fields with irradiation 
from different gantry angles. Details of the treatment fields are given in Table 
6-3. During treatment delivery, the radiation beam after transiting the patient 
!!
154!
was passively captured with the EPID panel. A total of 18 analyses were 
performed with some fields captured on two different treatment days. The 
treatment verification was carried out on random treatment days and might not 
be consecutive. No IMRT fields could be evaluated on patients because the 
department now routinely uses VMAT instead of IMRT for clinical treatment. 
 
Table 6-3 Treatment field information for the three patients included in this 
study.  
   Field name 
Gantry 
angle 
(degree) 
Collimator 
angle 
(degree) 
Wedge 
angle 
(degree) 
Jaw positions 
MLC 
cEquivalent 
square 
field size 
(cm2) 
MU X1 
(cm) 
X2 
(cm) 
Y1 
(cm) 
Y2 
(cm) 
Patient 1 Field 1 0 0 15 7.9 7.3 9.8 7.3 Static 14.92 110 
 Field 2 90 90 60 9.6 7.1 4.0 8.9 Static 13.3
2 112 
 Field 3 270 90 60 9.6 7.1 8.9 4.0 Static 13.3
2 110 
            
Patient 2 Field 4 0 0 None 5.4 6.0 4.3 6.0 Static 9.82 113 
 Field 5 180 0 None 5.9 5.4 4.3 6.0 Static 9.6
2 115 
 Field 6 90 90 30 4.3 6.0 4.0 9.1 Static 10.0
2 105 
 Field 7 270 90 45 4.3 6.0 9.4 4.1 Static 10.1
2 108 
            
Patient 3 Field 8 0 0 None 6.3 7.3 6.1 5.5 Static 11.52 113 
 Field 9 180 0 None 7.4 6.5 6.0 5.5 Static 11.5
2 108 
 Field 10 90 90 10 6.0 5.5 7.4 7.1 Static 11.9
2 96 
  Field 11 270 90 10 6.0 5.5 7.0 7.4 Static 11.82 97 
c The equivalent square field size for an irregularly shaped field was calculated using the method described by Monti et 
al. (1995). Positions of the MLC leaves were determined from MLC files exported from the TPS.  
 
6.3.6 Treatment planning, EPID measurement and evaluation of 
result 
Following the routine clinical practice of the department, all treatment plans 
were computed using the Eclipse AAA algorithm (version 10.0.28) with 0.25 cm 
grid size. Treatments were delivered with a Varian Clinac 21EX linac. The aS500 
EPID panel, attached to the linac, was extended to a vertical distance of 140 cm 
to measure radiation exiting the phantom/patient. No modification was done to 
the EPID panel. The measurements were performed in the integrated mode using 
the manufacturer’s default settings. The EPID signal was not absolutely 
calibrated to dose although the term ‘EPID dose plane’ was used for a more 
consistent description with IC and TPS dose planes. Image processing and dose 
reconstruction/prediction for the 2D EPID transit dosimetry model was 
performed using the MATLAB software (R2011a Student version, The MathWorks, 
Natick, MA). The agreement between two dose planes was evaluated on the 
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Varian Portal Dosimetry platform (version 10.0) using 2D global gamma analysis 
in absolute mode. The gamma criterion was set to 4%/4mm for the phantom 
assessments and 5%/5mm for patient’s actual treatment verifications. A less 
stringent criterion was selected for patient verification in anticipation of day-to-
day variation in positioning and anatomical changes; the 5% criterion was also in 
accordance with ICRU recommendation (ICRU Report No. 24, 1976). For both 
phantom and patient, the area of analysis was taken to be 100% of the field area 
for regular shaped fields. As for irregularly shaped fields, a dose threshold of 
50% and 20% was used for non-modulated and modulated fields respectively. The 
dose threshold method was required for irregularly shaped fields to allow 
automatic demarcation of the region of interest in a systematic way. The 50% 
value for non-modulated fields was used following the common definition of 
field size. Meanwhile, the 20% value for modulated fields was chosen to include 
a larger area, considering the dose modulation in the field and at the same time, 
to exclude very low dose regions that may artificially improve the gamma 
analysis results due to global calculation of dose difference. 
 
6.4 Results !
6.4.1 Anthropomorphic phantom 
A total of 65 fields were evaluated with the anthropomorphic phantom. The 
percentage gamma pass rates with 4%/4mm criterion for all the test fields are 
summarised in the figures below. Figure 6-9 shows the results for comparisons of 
in-phantom dose (Path 1) at the exit level, between reconstructed from EPID 
dose planes versus computed by the TPS. The overall mean gamma pass rate for 
exit dose comparisons was 97.6%, ranging from 90.0% to 100%. When categorised 
into non-modulated (open and 3D conformal fields) and modulated fields (EDW 
and IMRT fields), the mean gamma pass rates were 98.1% (range: 92.9% to 100%) 
and 97.3% (range: 90.0% to 100%) respectively.  
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Figure 6-9 Percentage gamma pass rates for in-phantom dose comparisons at 
the exit level, between EPID reconstructed versus TPS computed. The field 
number corresponds to field listed in Table 6-2. 
 
Besides verifying doses at the exit level, the dose agreements were also 
evaluated at another level, ‘X’, in the phantom. In this study, level ‘X’ was 
chosen to be the isocentre. Figure 6-10 shows the gamma pass rates for 
comparisons between EPID reconstructed and TPS computed in-phantom doses at 
the isocentre level. The overall mean gamma pass rate for the same criterion of 
4%/4mm was marginally higher than comparisons at the exit level, at 98.2% with 
the pass rates ranging from 91.7% to 100%. Between non-modulated and 
modulated fields, the mean gamma pass rates were 98.3% (range: 93.1% to 100%) 
and 98.2% (range: 91.7% to 100%) respectively.  
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Figure 6-10 Percentage gamma pass rates for in-phantom dose comparisons 
at the isocentre level, between EPID reconstructed versus TPS computed. 
The field number corresponds to field listed in Table 6-2. 
 
Alternatively, the TPS computed dose planes could be used to predict EPID 
transit dose for direct comparison with EPID dose plane measured during 
treatment delivery (Path 2). Figure 6-11 shows the gamma results for 
comparisons between predicted and measured EPID transit dose planes. Using a 
gamma criterion of 4%/4mm, the overall mean gamma pass rate was 97.1% with 
a minimum and maximum of 92.9% and 99.8% respectively. For comparisons of 
non-modulated fields, the mean gamma pass rate was 97.3% (range: 93.2% to 
99.8%). As for modulated fields, the mean gamma pass rate was 96.9% (range: 
92.9% to 99.6%).  
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Figure 6-11 Percentage gamma pass rates for EPID transit dose comparisons, 
between predicted from TPS dose planes versus measured. The field number 
corresponds to field listed in Table 6-2. 
 
Examples of comparisons at different levels (comparison in-phantom at the exit 
level, comparison in-phantom at the isocentre level and comparison at the EPID 
level) for various test fields are illustrated in Figure 6-12. From the figure, it can 
be observed that the areas that failed gamma comparisons mostly coincided with 
the location of air cavities, especially in the case of lateral fields (Figure 6-12a 
and 6-12b) where the beam passed through a large amount of air in the phantom 
cavity representative of the transverse colon. In these cases, the TPS computed 
doses were lower than the doses reconstructed from the EPID measured dose 
planes.  
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Figure 6-12 Examples of various dose comparisons performed on the 
anthropomorphic phantom. (a) Comparison of EPID reconstructed and TPS 
computed in-phantom exit dose for a 10 x 10 cm2 field with 90° gantry angle. 
(b) Comparison of EPID reconstructed and TPS computed in-phantom isocentre 
dose for an EDW 60°, field size 10 x 10 cm2 field with 270° gantry angle (c) and 
a 3D conformal field with 315° gantry angle. (d) Comparison of predicted and 
measured EPID transit dose for an IMRT field with 0° gantry angle. Figures from 
left to right are the CT simulation images with the planned fields, 
reconstructed/predicted dose planes, 4%/4mm gamma comparisons results (red 
indicating areas that failed the gamma criteria) and the profiles comparisons 
across the axis indicated by the arrows. The percentages of points that passed 
the specified gamma criterion for the different comparisons were (a) 96.5%, (b) 
97.4%, (c) 99.9% and (d) 98.9%. 
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6.4.2 Actual treatment verification of patients 
Table 6-4 lists the actual treatment verification results for three patients 
treated for cancers in the pelvic area. The percentage gamma pass rates were 
presented for (Path 1) in-vivo dose comparisons as well as (Path 2) EPID transit 
dose comparisons. Similar to the assessment with the anthropomorphic 
phantom, the in-vivo dose comparisons were performed at two levels, the exit 
level and the isocentre level.  Although the dose could be reconstructed and 
compared at any level in-vivo, the isocentre plane was chosen because it 
intersects the target volume for all three patients and therefore, represents the 
most clinically relevant plane to be verified.  
 
Table 6-4 Gamma analysis results, with 5%/5mm criterion, for in-vivo dose 
comparisons (at the exit level and isocentre level) and EPID transit dose 
comparisons. 11 treatment fields (details given in Table 6-3) for three patients 
were verified. The treatment verification process was repeated for two of the 
patients on different treatment days, resulting in a total of 18 analyses.     
 
Treatment 
field 
 
Path 1 
In-vivo dose comparisons: 
Reconstructed versus TPS 
Path 2 
EPID transit dose comparisons: 
Predicted versus Measured 
  5%/5mm gamma pass rate (%) 5%/5mm gamma pass rate (%) 
  Exit level 
Isocentre 
level  
Patient 1 Field 1 Verify 1 98.4 99.6 95.1 
  
dVerify 2 92.4 99.2 90.7 
 Field 2 Verify 1 95.8 96.1 94.6 
  
dVerify 2 97.0 98.2 92.2 
 Field 3 Verify 1 98.0 96.3 95.5 
  
dVerify 2 96.6 98.9 95.4 
      
Patient 2 Field 4 Verify 1 99.5 97.9 98.5 
  
dVerify 2 97.3 96.6 95.9 
 Field 5 Verify 1 94.8 100.0 93.7 
  
dVerify 2 96.9 100.0 93.9 
 Field 6 Verify 1 99.6 99.4 97.5 
  
dVerify 2 97.7 96.1 94.9 
 Field 7 Verify 1 94.3 99.6 94.9 
  
dVerify 2 99.1 99.4 97.7 
      
Patient 3 Field 8 Verify 1 95.8 98.8 96.1 
 Field 9 Verify 1 96.3 99.9 95.8 
 Field 10 Verify 1 98.7 99.8 98.8 
 Field 11 Verify 1 97.3 99.6 99.9 
  Mean 97.0 98.6 95.6 
d Treatment verification was repeated on another treatment day. 
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The 5%/5mm gamma pass rates for in-vivo comparisons between EPID 
reconstructed and TPS computed dose planes at the exit level ranged from 92.4% 
to 99.6% with a mean of 97.0%. Comparisons at the isocentre level resulted in a 
mean pass rate of 98.6%, ranging from 96.1% to 100%. As for the comparisons 
between measured and predicted EPID transit dose, the overall mean gamma 
pass rate was 95.6% with a minimum pass rate of 90.7% and a maximum pass rate 
of 99.9%. The treatment verification was repeated for seven fields (n = 7) from 
two of the patients on different treatment days (Verify 1 and Verify 2). 
Statistical analyses with paired T-test (IBM SPSS Statistics, version 22.0, Armonk, 
NY, USA) showed no statistically significant difference in the mean of gamma 
pass rates between “Verify 1” and “Verify 2” for comparisons at all levels (using 
a significance level of 0.05 and a two-tailed test). The p-values were 0.726, 
0.928 and 0.203 for dose comparisons at the exit level, isocentre level and EPID 
level respectively. However, the statistical analysis may be limited to only 
detecting large differences because of the small sample size. Detailed results of 
the statistical analyses are provided in Appendix C.    
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Figure 6-13 Examples of actual treatment verifications of patients. (a) 
comparison of in-vivo dose at the exit level, (b) comparison of in-vivo dose at 
the isocentre level and (c) comparison of EPID transit dose. Figures from left to 
right are the reconstructed/predicted dose planes, 5%/5mm gamma comparisons 
results (red indicating areas that failed the gamma criteria) and the profiles 
comparisons across the axis indicated by the arrows. The percentages of points 
that passed the specified gamma criterion for the different comparisons were (a) 
92.4%, (b) 96.1% and (c) 99.9%. 
 
6.5 Discussion 
 
The anthropomorphic pelvic phantom has a hollow cavity that mimics the colon 
and rectum structures of the human anatomy. The cavity can be filled with 
water or contrast media but it was left empty for this study. Several test fields 
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were planned in such a way that the beam passed through the whole transverse 
length of the air-filled colon structure, which was approximately 12 cm in 
physical length. An example of such a beam arrangement is shown in Figure 6-
14a. The dose comparison result for this particular test field was previously 
presented in Figure 6-12a and again in Figure 6-14a below for ease of reference. 
From the results, it could be observed that the points that failed gamma 
comparisons were at the area where the air-filled transverse colon was located. 
The profiles comparison revealed that the dose reconstructed from this EPID 
dosimetry model was higher than the TPS computed dose. This over-estimation 
of dose in the presence of air cavity could possibly be a weakness of the EPID 
dosimetry model that uses EPL for heterogeneity correction. It is well known 
that the EPL correction method only accounts for changes in primary beam and 
ignores variations in scatter contribution from materials of different densities 
(Rosenwald et al., 2007). In the case of air cavities, the reduced scatter 
contribution from air relative to water could not be properly accounted for by 
the EPL method, which could explain the over-estimation of dose seen in the 
results. However, this scenario of having the whole colon filled with air is not 
clinically realistic. A much smaller amount of gas would be expected in a real 
patient. Figure 6-14b shows the same lateral beam planned on a different part 
of the pelvic phantom, now passing through the descending colon with a smaller 
cross-section of air cavity (approximately 2.5 cm in diameter). As can be seen in 
the profiles and gamma comparison, the reconstructed dose was still higher than 
the TPS computed dose but the dose discrepancies were less and mostly within 
the 4%/4mm gamma criterion. It would be of future interest to evaluate the 
performance of the EPID dosimetry model with an anthropomorphic chest 
phantom, which has a large volume of low-density lung tissues. Williams et al. 
(1991) suggested the use of modified limit for lung treatments in their 
independent dose verification program. Without accounting for dose 
inhomogeneity, a wide tolerance of 5% to 15% was adopted instead of the 
standard ±2%. Later, in a modified version of the software program, the 
thickness of overlying lung was used as a form of inhomogeneity correction and a 
stricter tolerance was used (the exact tolerance was not stated). In our case, 
the EPL was a form of simple inhomogeneity correction and a stricter tolerance 
should be adequate. The appropriate tolerance could only be determined with 
further experiment with low-density phantoms. Also, the current model could 
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potentially be improved to better account for inhomogeneity correction. A 
better understanding on the weakness of the EPID dosimetry model is crucial to 
ensure appropriate judgement when interpreting gamma comparison results. 
This also implies that careful investigation of gamma results and the 
corresponding CT images is necessary to help ascertain the reason of gamma 
failures.  
 
!
Figure 6-14 In-phantom exit dose comparisons for two identical fields (open 
10 x 10 cm2, gantry 90°) planned and irradiated at different parts of the 
pelvic phantom.  (a) Field passed through the air-filled transverse colon with a 
physical length of approximately 12 cm and (b) Field passed through the air-
filled descending colon with an approximate diameter of 2.5 cm. The columns 
from left to right are the coronal view of the CT plan, field location (yellow box) 
shown on digitally reconstructed radiograph (DRR), 4%/4mm gamma comparisons 
results (red indicating areas that failed the gamma criteria) and the profiles 
comparisons across the axis indicated by the dashed arrows. The percentage 
gamma pass rates were (a) 96.5% and (b) 98.5%. 
 
One of the issues that arise when performing treatment verification from 
different gantry angles is the attenuation by couch structures. The Exact 
treatment couch (Varian, Palo Alto, CA, USA) installed in the linac treatment 
room has a pair of metal sliding support rails below the carbon fibre couch top. 
The beam attenuation by these metal rails is not negligible. Li et al. (2011) 
reported a maximum attenuation of 14.4% when the metal rails at the section of 
the couch near the pelvic region were in the path of a 6 MV 10 x 10 cm2 field. As 
far as patient dose is concerned, the metal rails only affect posterior/posterior 
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oblique fields and the therapists must move the rails to a position out of the 
beam pathway if they were not included in the treatment plan. However, for the 
purpose of EPID dose measurements, where dose is measured after the beam 
transits both the patient and couch, the position of the metal rails affects not 
only the posterior/posterior oblique fields but also the anterior/anterior oblique 
fields. Figure 6-15 shows the effect of rail attenuation if they were accidentally 
left in the beam pathway. The example given is for a 10 x 10 cm2 field irradiated 
from gantry 135° using the anthropomorphic phantom. The 4%/4mm gamma pass 
rate for comparison between EPID reconstructed and TPS computed exit dose 
was only 89.2%, with a distinct rectangular area of gamma failure at the side of 
the field that resembled the metal rail. Comparison of profiles showed that at 
the region of gamma failure, the dose reconstructed from EPID transit dose 
plane was lower than the TPS computed dose by as much as 10%. This was 
consistent with attenuation by the metal rail that was measured by the EPID but 
not accounted for in the treatment planning. If this EPID dosimetry result were 
to appear in the actual treatment verification of patients, it would have 
highlighted to the users that an incident had occurred that might have 
compromised the patient’s treatment. But the same EPID dosimetry results for 
an anterior/anterior oblique field would not have impacted the patient’s 
treatment. Instead, it would mean that the EPID transit dose plane was not 
properly captured and the EPID verification result must be interpreted with 
caution. This issue is not unique to couch structure but also applies to any other 
objects that may be present in the beam pathway, for example certain 
radiopaque parts of patient immobilisation devices. Also, it is important that 
users should always inspect the verification result to look for any suspicious 
pattern of failure. If the affected area is not as large, for example small metal 
joints in an immobilisation device, the gamma pass rate alone may not be 
indicative of a problem and the consistent error may be overlooked. 
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Figure 6-15 Effect of beam attenuation by couch metal rail. The effect of rail 
attenuation (indicated by red arrows) is shown for a 10 x 10 cm2 field irradiated 
from gantry 135° for the anthropomorphic phantom. The metal rail was in the 
beam pathway during the treatment delivery and the reduced transmission was 
measured by the EPID. The in-phantom exit dose reconstructed from the EPID 
measured dose plane (left column) was compared with the TPS computed dose. 
But because the metal rail was not included in the treatment plan, the 
discrepancy in measured and planned dose, of up to approximately 10%, was 
reflected as a region of failure in the 4%/4mm gamma comparisons (centre 
column, red indicating areas that failed the gamma criteria). As a result, the 
gamma pass rate was only 89.2%. Profiles comparison across the axis indicated 
by the dashed arrows is shown in the right column. 
 
Besides detecting unexpected beam obstruction during treatment delivery, the 
EPID dosimetry model could also indicate changes in patient position or 
anatomy. This can be seen in the results for actual treatment verification 
performed on two different treatment days for the same patient. Figure 6-16 
shows an example of how the presence of bowel gas on a certain treatment day 
could be reflected in the EPID treatment verification results.  
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Figure 6-16 Effect of change in patient’s anatomy. The effect of change in 
patient’s anatomy can be seen in the in-vivo exit dose verification results on two 
different treatment days (Patient 2, Field 5). On the first day of treatment 
verification (Verify 1), pockets of high dose region (indicated by solid arrows) 
were visible on the EPID transit dose plane measured during treatment delivery, 
which subsequently led to areas of gamma failures (red indicating areas that 
failed the gamma criterion of 5%/5mm) when the EPID reconstructed dose plane 
was compared to TPS computed dose plane. Profiles comparison across the axis 
indicated by the dashed arrow showed that the EPID reconstructed dose (blue 
dashed line) was higher than the TPS computed dose (red solid line) at the 
region of gamma failure, possibly indicating that the discrepancies were due to 
the presence of bowel gas on treatment day that was not there during CT 
simulation. The areas of high dose were no longer noticeable on the EPID transit 
dose plane measured on another treatment day (Verify 2), leading to better 
agreement with the TPS computed dose. The percentage gamma pass rates for 
the first and second verification were 94.8% and 96.9% respectively.    !
Despite having demonstrated that EPID dosimetry for actual treatment 
verification is useful to detect inconsistency in treatment delivery, the 
additional time and effort required to implement an EPID dosimetry program 
must also be considered for practical reasons. The commissioning process for 
this EPID dosimetry model involved measuring two sets of calibration dose planes 
with the EPID as well as IC in water. The methods to acquire these calibration 
dose planes were explicitly described in Chapter 5 (sub-Section 5.3.2). The 
measurements of EPID calibration dose planes took approximately two hours to 
complete, requiring a total of 32 EPID images measured for water-equivalent 
solid phantom of eight different thicknesses (0 cm to 35 cm, in 5 cm increment) 
and beams with four different field sizes (5 x 5 cm2 to 20 x 20 cm2, in 5 cm 
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increment). These images were inclusive of those needed for tabulation of field 
size correction factors (FSF). Because the EPID response is fairly stable, with less 
than 1% to 2% variation over a year (Van Esch et al., 2004, Winkler & Georg, 
2006), the re-measurements of EPID calibration dose plane will be infrequent. As 
for the IC calibration dose planes, the required PDD and profiles were taken 
from the original linac commissioning measurements performed in a scanning 
water tank. If the PDD and profiles must be measured, the time required is 
estimated to be four hours, including the time taken to set-up the water tank. 
Since measurements in a scanning water tank represent full scatter condition, an 
additional backscatter correction factor (BCF) was used to account for the 
reduced backscatter, especially at the exit level where the thickness of 
underlying material was only 1.5 cm. The measurements of BCF values with IC in 
solid water phantoms, with different backscatter thicknesses and depths (1.5 cm 
to 36.5 cm) as a function of field size (5 x 5 cm2 to 20 x 20 cm2), took 
approximately three hours to complete. However, the BCF values for 6 MV 
beams were found to be very similar for linacs from different manufacturers and 
these values have been published Tan et al. (2014). Moreover, it is very unlikely 
that any of the IC measurements will have to be repeated as long as the linac’s 
dosimetric performance remained the same. Once the EPID dosimetry model had 
been properly commissioned, the subsequent dose reconstruction/prediction 
took less than five minutes to complete for a typical conformal or IMRT field.   
 
The clinical workflows for actual treatment verification with the proposed EPID 
dosimetry model are shown in the figures below. Figure 6-17 illustrates the 
workflow for Path 1, where the EPID measured dose planes were used to 
reconstruct in-vivo dose for comparison with TPS computed dose, to verify the 
accuracy of treatment delivery. First, a plan was scheduled in the Aria oncology 
information system (Varian, Palo Alto, CA, USA) to capture an EPID integrated 
image. On the day of treatment, the patient was set up to the usual treatment 
position. After that, the EPID panel was extended to the calibration position 
(140 cm was used in this study). The EPID detectors then passively capture 
radiation that transits the patient during treatment delivery. Upon completion 
of treatment, the captured EPID transit dose plane (MEPID_tx) was exported from 
the Aria system for the reconstruction of in-vivo dose using an in-house code 
written with the Matlab software. In addition to the EPID transit dose plane 
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measured during treatment delivery, another EPID dose plane measured for the 
same treatment field but without the patient on couch (M0EPID_tx) was required. 
The M0EPID_tx can either be measured once for repeated use in the subsequent 
dose reconstruction or a new dose plane can be captured each time on the day 
of verification. By using the latter, machine output variation for the day was 
taken into account and would not be reflected in the results. Although the 
measurement of M0EPID_tx is relatively easy to perform, it is the intention of 
future study to remove this measurement and minimise the additional workload 
associated with the implementation of EPID transit dosimetry. Finally, the 
reconstructed in-vivo dose was imported into the Varian Portal Dosimetry 
workspace. The TPS computed dose, exported from the TPS and extracted 
according to the steps described in sub-Section 6.3.1, was also imported into the 
Portal Dosimetry workspace as a reference for the gamma analysis.  
 !
!
Figure 6-17 Clinical workflow for actual treatment verification with EPID 
(Path 1). The illustrated workflow is for Path 1 of the dual EPID transit 
dosimetry model, where EPID measured dose planes were used to reconstruct in-
vivo dose for comparison with TPS computed dose.   
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Figure 6-18 illustrates the clinical workflow for Path 2, where the TPS computed 
dose planes were used to predict EPID transit dose for direct comparison with 
the EPID transit dose plane measured on the day of treatment. Prior to the 
treatment day, dose planes for the patient treatment plan were exported from 
the TPS (M0TPS_tx and MTPS_tx) and used to predict the EPID transit dose with an in-
house Matlab code. Then, the predicted EPID transit dose was imported into the 
Varian Portal Dosimetry workspace. In preparation for the treatment 
verification, a plan was scheduled in the Aria system to capture an EPID 
integrated image. On the day of treatment, the EPID panel was extended to the 
calibration position after patient set-up. The EPID transit dose plane measured 
during treatment was saved automatically in the Portal Dosimetry workspace 
and was immediately compared to the predicted EPID transit dose plane. As 
opposed to Path 1, where the EPID dose plane must be exported for post-
processing and causes a delay in the result, this pathway allows the immediate 
analysis of the accuracy of treatment. Furthermore, the prediction of EPID 
transit dose from TPS dose planes is only performed once for each treatment 
field and therefore, requires less time compared to Path 1 where the 
reconstruction of in-vivo dose from EPID transit dose plane, measured during 
treatment, must be performed for each verification session. However, 
evaluation in pixel value at the EPID level may be clinically less meaningful 
compared to in-vivo evaluation. 
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Figure 6-18 Clinical workflow for actual treatment verification with EPID 
(Path 2). The illustrated workflow is for Path 2 of the dual EPID transit 
dosimetry model, where TPS computed dose planes were used to predict EPID 
transit dose for direct comparison with EPID transit dose plane measured during 
treatment.   
 
6.6 Conclusions 
 
The study described in this chapter focuses on the application of a dual 2D EPID 
transit dosimetry model for actual treatment verification. Initial assessment 
with an anthropomorphic pelvic phantom using open, 3D conformal, EDW and 
IMRT fields resulted in a mean 4%/4mm gamma pass rate of 97.6% (range: 90.0% 
to 100%) for comparisons of in-phantom dose at the exit level (Path 1) and 97.1% 
(range: 92.9% to 99.8%) for comparisons of transit dose at the EPID level (Path 
2). The original method in Path 1 was further extended to reconstruct dose at 
other levels besides the exit level. With the extended dose reconstruction, 
verification at the isocentre level resulted in a mean gamma pass rate of 98.2% 
(range: 91.7% to 100%).  
 
Clinical feasibility of the EPID dosimetry model was demonstrated with three 
patients undergoing pelvic radiotherapy. The patients’ treatments consisted of 
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3D conformal and wedge fields. Gamma analyses with a 5%/5mm criterion 
resulted in a mean pass rate of 97.0% (range: 92.4% to 99.6%) and 98.6% (range: 
96.1% to 100%) for in-vivo comparisons at the exit level and isocentre level 
respectively (Path 1). The mean gamma pass rate for EPID transit dose 
comparisons (Path 2) was 95.6% (range: 90.7% to 99.9%). No IMRT fields could be 
evaluated on patients because the department now routinely uses VMAT instead 
of IMRT for clinical treatment. 
 
In conclusion, the dual 2D EPID transit dosimetry model developed in this study 
has been proven to be clinically feasible for actual treatment verification. The 
model is a useful tool that could detect deviation in delivered dose from the 
intended treatment, as shown by the examples given in the discussion section 
for beam obstruction and changes in patient’s anatomy. From a practical 
viewpoint, the EPID transit dosimetry model is suitable for routine clinical 
implementation because the extra workload incurred is minimal once the model 
has been properly commissioned. Therefore, with the implementation of this 
EPID transit dosimetry model, the accuracy of treatment delivered to patient 
could be checked without adding too much burden on the department.
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Chapter 7: Conclusion !
7.1 Summary of thesis 
 
The broad theme of this thesis is improving safety in radiotherapy. Chapter 1 
briefly outlined the risk of radiotherapy and the role of the QA program, 
particularly patient-specific QA, in ensuring safe and accurate delivery of 
treatment to patients. There are many variations to the practice of patient-
specific QA. It can be performed either before treatment (pre-treatment QA) or 
during the actual treatment delivery to the patient (actual treatment 
verification). The role of pre-treatment QA is to test the deliverability of a 
treatment plan, while actual treatment verification confirms that the treatment 
has been accurately delivered to the patient. Ideally, both pre-treatment and 
actual treatment verifications should be performed to check different aspects of 
the radiotherapy process. However, this may not be always possible due to the 
additional cost, manpower and time required to implement these QA 
procedures. Thus, the challenge is to find a cost effective tool and an efficient 
way to carry out these patient-specific QA checks.   
 
Among the different types of radiation measuring devices, EPID is the most 
favourable in terms of cost effectiveness and efficiency. EPID is cost effective 
because it is readily available as an attachment on most linacs and efficient 
because it can be set-up effortlessly using the linac controls. Moreover, the EPID 
produces an immediate high-resolution 2D digital image that does not require 
cumbersome manual processing. But the EPID, which was originally designed for 
imaging purposes, exhibits different scatter and dose response characteristics 
compared to a water-equivalent detector. In Chapter 2, a literature review on 
various methods to overcome the dosimetric challenges of a-Si EPID was 
presented. The literature review included non-transit and transit EPID dosimetry 
models but the focus of this thesis was on the transit model, which could be 
used for both pre-treatment QA as well as actual treatment verification. From 
the literature review, it became apparent that there were few studies on using 
an empirical approach for EPID transit dosimetry, especially for 2D or 3D 
verifications of IMRT or VMAT fields. The transit dosimetry model based on 
empirical methods is advantageous because it involves only general 
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measurements and, thus, is easier to replicate. The limited publications on 
empirical-based 2D EPID transit dosimetry model and the lack of reliable 
commercial software have made it difficult for clinical departments with scarce 
resources to use EPID for the verification of patients’ actual treatment delivery. 
 
The aim of this research was to develop an empirical-based 2D EPID transit 
dosimetry model that was practical, generic and flexible, to facilitate 
implementation in a wide range of radiotherapy centres with very different 
equipment and work practices. In Chapter 4, a novel concept was introduced 
that used the water-equivalent path length or EPL of the phantom/patient to 
relate the non-water equivalent EPID detector and the water-based TPS. The 
EPL was calculated using a quadratic equation (Swindell, 1983) based on the 
amount of beam attenuation, as quantified by the ratio of exit (M) to entrance 
(M0) doses. Coefficients in the quadratic equation were separately derived from 
EPID and TPS entrance and exit calibration dose planes for the same reference 
beam (6 MV, 20 x 20 cm2, 100 MU) and homogeneous water phantom of known 
thicknesses (0 cm to 35 cm). With two sets of coefficients, the EPL could be 
calculated from either EPID or TPS M0 and M dose planes for the treatment field. 
The EPID M0 and M dose planes were measured without and with the 
phantom/patient in the beam respectively, while, the TPS M0 and M dose planes 
were defined as dose at 1.5 cm from the beam entrance and exit surfaces of the 
phantom/patient respectively. The calculated EPL, which is a property of the 
attenuating object and independent of the dosimeter, provided a link to the two 
different dosimetry systems and allowed a two-way relationship for the: (Path 1) 
Reconstruction of in-phantom/in-vivo exit dose from EPID measured dose planes; 
and (Path 2) Prediction of EPID transit dose from TPS computed dose planes. The 
validity of the concept was initially proven with simple square fields of various 
field sizes and homogeneous slab phantoms of different thicknesses. To show 
that the proposed method was generic, the experiment was performed on linacs 
and TPS from different manufacturers: Varian (Clinac/Eclipse AAA) and Elekta 
(Synergy/XiO Superposition).  
 
Because the entrance and exit doses were extensively used in the EPID 
dosimetry model, a study was described earlier on in Chapter 3 to evaluate the 
accuracies of six algorithms from three TPSs (Eclipse, XiO, Monaco) in computing 
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doses at these levels. While the entrance doses computed by all algorithms 
agreed with the measured values to within 2%, discrepancies of up to 5% were 
observed for exit doses computed by the Eclipse PBC and Eclipse AAA algorithms. 
By using TPS computed entrance and exit calibration dose planes to derive the 
quadratic equation coefficients in the commissioning stage, inaccuracies from 
the TPS algorithm would become inherent in the EPID dosimetry model. In 
Chapter 5, the TPS calibration dose planes were replaced with dose planes 
derived from IC measurements in water. Although the methods were more 
cumbersome, they were justified because results from the EPID dosimetry could 
now accurately reflect discrepancies between planned and delivered doses. 
Apart from improvement in the commissioning process, the EPID dosimetry 
model was also extended to include verification of modulated wedge and IMRT 
fields. The updated model was tested with homogeneous and heterogeneous slab 
phantoms on the Varian system (Clinac/Eclipse AAA).  
 
Due to difficulties in directly exporting M0 and M dose planes from the TPS for 
objects with irregular surface, the experiments so far were restricted to slab 
phantoms with irradiation at gantry zero degrees. Instead of relying on the 2D 
export function of the TPS, a method was described in Chapter 6 to extract dose 
planes from 3D ‘structure’ and ‘dose’ DICOM files from the TPS. The extraction 
process also took into account the effect of different gantry angles. This was a 
crucial development that enabled the application of the proposed EPID transit 
dosimetry model for the verification of actual treatment delivery to patients. In 
addition, the original method in Path 1 was extended to reconstruct dose at any 
other planes in-phantom/in-vivo, besides the exit plane. This was achieved by 
quantifying the fractional EPL, from the entrance to the plane of interest, using 
a new parameter, EPL ratio, derived from patients’ CT simulation images and a 
‘CT to relative EPL’ calibration curve. The ability to reconstruct dose at any 
chosen plane allows users to verify dose at a more clinically relevant location, 
such as the isocentre plane that intersects the target volume. Moreover, the 
ability to reconstruct dose at multiple planes in-vivo/in-phantom would make it 
possible for 3D dose reconstruction in the future. The expanded model was 
extensively tested with different fields (open, 3D conformal, wedge and IMRT 
fields at different gantry angles) using an anthropomorphic pelvic phantom. 
Finally, clinical feasibility of the 2D EPID transit dosimetry model was 
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demonstrated for three patients who were undergoing radiotherapy of the pelvic 
region.  
 
7.2 Study limitations 
 
The study conducted in this research has some limitations. First, the EPID panel 
was always positioned at the central position of the beam axis for all the 
experiments. Test fields were created such that the field area was always 
contained within the EPID active area without having to re-position the panel 
away from the beam centre in the lateral or longitudinal directions. Similarly, 
only patients with treatment fields located within the EPID active area, when 
the panel was at the central position, were selected for the pilot study. Since 
the EPID A and B coefficients were derived, pixel-by-pixel, from a set of 
calibration dose planes measured for a reference beam with the EPID fixed at 
the central position, the coefficients for each pixel may no longer be 
appropriate for measurement at other EPID positions. The effect of changes in 
EPID position on the accuracy of the dosimetry model has not yet been studied. 
Besides that, the mid-plane of the phantom/patient always coincided with the 
isocentre of the beam, which was similar to the reference set-up used in the 
commissioning process. Other phantom/patient position that resulted in non-
reference vertical distance (air gap) between the exit surface and the EPID 
detector, and consequently the amount of scattered photons that reaches the 
EPID, was not investigated. Restriction in panel position and phantom/patient 
position limits the type of treatment fields that can be verified with this EPID 
transit dosimetry model at present.  
 
Second, validity of the EPID transit dosimetry model has been proven only for 
the pelvic region, where tissue compositions are relatively homogeneous 
compared to, for example, the chest region. Performance of the EPID dosimetry 
model was not assessed in the presence of large amounts of low-density tissues 
such as lung. Systematic evaluation with a chest phantom is mandatory before 
the EPID transit dosimetry model could be used to verify the accuracy of 
treatment delivered to patients with cancers in the chest region. Evaluation 
with a chest phantom could not be performed in this research because the 
phantom was not available. 
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Lastly, the number of patients included in the clinical feasibility study is very 
small, with only three patients verified. Moreover, all three patients were 
treated with very similar treatment technique, either a three-field or four-field 
box technique. The small number of patients with very similar treatment 
techniques does not adequately represent the diverse treatment types and beam 
configurations encountered in the clinic. Including more patients with different 
treatment techniques and sites may help to reveal problems that are not obvious 
at this point. Also, verification of IMRT fields could only be tested on phantoms 
in this study because the department now routinely uses VMAT rather than IMRT 
for modulated treatment delivery. It would have been more interesting if the 
verification of highly modulated treatment fields could be reported for patient’s 
actual treatment delivery. The current formulation of the EPID transit dosimetry 
model cannot reconstruct/predict VMAT treatment fields.  
 
7.3 Suggestions for future study  
 
VMAT is a treatment technique that continuously delivers radiation while 
rotating the gantry and varying the gantry speed, dose rate and MLC leaves 
positions to achieve highly conformal dose distributions. This complex delivery 
technique is becoming more popular and in some cases, replacing the IMRT 
technique. This trend was reflected in the results of a survey of 65 UK 
radiotherapy centres that showed a considerable increase in VMAT treatment 
from 34% to 74% in the period of 2012 to 2014 (Abolaban et al., 2015). 
Therefore, it would be of great interest to develop the EPID transit dosimetry 
model further for verification of VMAT delivery in the future. In the current 
model, the EPID captures one integrated image for each treatment field that is 
planned and delivered with a fixed gantry angle. For VMAT delivery with 
continuous gantry rotation, capturing one integrated image per treatment field, 
per gantry angle is no longer applicable. Instead, the EPID acquisition must be in 
cine (continuous) mode where a series of images are captured and saved as a 
function of time. The gantry angle for each cine image must be known to enable 
dose reconstruction/prediction with the EPID transit dosimetry model. Different 
methods to retrieve this information have been suggested for the Varian system 
(Woodruff et al., 2013, McCowan et al., 2014) and the Elekta system (Mans et 
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al., 2010a), including the correction strategies required to address the issue of 
time lag that caused inaccurate gantry angle information. In addition, the effect 
of panel sag due to gravitational force at different gantry angles is more 
complex for VMAT verification than for fixed-gantry IMRT verification. Panel sag 
and its effect on each cine image acquired at different gantry angles must be 
investigated (Rowshanfarzad et al., 2012) and corrected (Mans et al., 2010a) to 
ensure that the final cumulated verification is not compromised. Another issue 
that must be considered with VMAT verification is the time required to 
reconstruct/predict the doses. With the angle-resolved acquisition, the dose 
reconstruction/prediction process must be repeated for a large number of 
images before a complete result can be produced. Taking account of these 
problems, it is feasible to extend the current EPID transit dosimetry model for 
VMAT verification; this would require further research on image acquisition 
technique in continuous mode and a faster way to accomplish the dose 
reconstruction/prediction process.   
 
Another interesting aspect for future development is 3D dose reconstruction. In 
the current EPID transit dosimetry model, Path 1 offers 2D in-vivo dose 
reconstruction from EPID measured dose planes. The 2D dose plane can be 
reconstructed in any chosen plane inside the patient that is parallel to the EPID. 
In theory, there is no limit to the number of 2D dose planes that can be 
reconstructed using this technique. So, by reconstructing multiple parallel 2D 
dose planes with acceptably small spacing between them, it would then result in 
a 3D dose reconstruction. From here, the model can be further diversified to 
allow composite treatment verification rather than just a field-by-field 
verification, which is the case for the current model. Composite dose 
verification can possibly be done by assigning a grid system and summing up the 
dose reconstructed for all treatment fields. If information on the target and 
OARs are available, then DVH can also be produced from the reconstructed 3D 
composite dose. The reconstructed DVH for each structure can be compared 
with TPS planned dose and decisions can be made based on the planning 
criteria. This provides an alternative way to evaluate the accuracy of treatment 
that is more clinically relevant than gamma analysis. Also, to produce a more 
accurate reflection of the treated dose, the 3D dose should ideally be 
reconstructed on cone-beam computed tomography (CBCT) images acquired on 
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the treatment day rather than CT simulation images. However, there are still a 
few issues pertaining CBCT, such as HU calibration, HU stability, effect of object 
scatter and image artefacts, which require further research before the images 
can be used for dosimetric purpose. There are several studies that investigated 
the feasibility of using CBCT images for treatment planning and provide useful 
information for future research on 3D dose verification with CBCT. For example, 
the study by Yoo & Yin (2006) and Yang et al. (2007) showed that the HU values 
from Varian KV CBCT were very similar to a conventional CT simulator in the 
absence of motion. The difference in dose computed on the two sets of images 
agreed to within 1%. This result is a promising indication that the Varian KV 
CBCT images may be suitable for 3D dose reconstruction. However, a much 
larger dose difference of approximately 15% was observed between dose 
calculated on the Elekta KV CBCT images versus CT simulation images (Richter et 
al., 2008). The author proposed the use of a site-specific CBCT calibration curve 
to reduce the dose difference to less than 2%. The large variability in 
characteristics between different models of CBCT necessitates a careful 
investigation before the images can be used for 3D dose verification of actual 
treatment delivery. 
 
So far, the verification of actual treatment delivery refers to the checking of 
dose post-treatment (offline verification). This is adequate assuming that the 
error detected after the delivery of a single fraction can be compensated in the 
subsequent fractions. However, to guard against error that is too large to be 
compensated, a more appropriate strategy would be online treatment 
verification. Online verification is the real-time monitoring of dose during 
treatment, where results of comparisons between delivered and expected doses 
are constantly updated while the treatment is ongoing.  With real-time 
verification, the most important factor is processing speed. Therefore, the 
methods in Path 2 of the current model, where EPID transit dose is predicted 
only once beforehand and saved in a database for immediate comparison with 
measured EPID transit dose, is possibly more suitable for further development as 
a real-time verification tool. An international multi-centre research project on 
real-time 2D EPID transit dosimetry (watchDOG), headed by researchers from 
the University of Newcastle, Australia, used a synchronisation method to match, 
and then compare, measured cine EPID images with a reference dataset of 
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predicted cine EPID images. The methods were described by Fuangrod et al. 
(2013) in a feasibility study with dynamic IMRT delivery, which showed that 
synchronisation based on MLC positions could correctly pair the measured and 
predicted cine EPID images in the database and the subsequent comparisons 
could detect a simulated MU dose error of 10% within 10 s and systematic MLC 
leaf positional error of 4 mm within 2.5 s. A brief example on the clinical 
application of this real-time EPID treatment verification was presented for a 
lung stereotactic treatment in a conference abstract, Greer et al. (2015). 
Reports from the watchDOG project could provide invaluable information for the 
future development of our model towards real-time treatment verification.  
 
Another important subject that requires further study is the search for an 
appropriate indicator parameter and action level to define when a treatment 
should be deemed unacceptable. This subject is important for both online and 
offline verification strategies. In an online treatment verification system, the 
feedback mechanism should preferably interrupt the treatment delivery 
automatically when a certain parameter exceeds the specified threshold. Thus, 
a robust parameter and threshold would be crucial to ensure that the monitoring 
system is sensitive enough to catch all true positive events and at the same time 
specific enough to avoid false positive detection that disrupts the treatment 
workflow unnecessarily. As for the offline treatment verification system, 
determining an appropriate parameter and action level are especially important 
if the analysis of results were automated and users were only notified if a 
treatment fraction exceeds the specified threshold. The automation of offline 
analysis and reporting is inevitable for large-scale routine clinical 
implementation of EPID treatment verification to minimise its impact on 
workload. A threshold that is too sensitive and lacks specificity would defeat the 
purpose of reducing workload. On the other hand, all positive events must be 
detected to ensure the reliability of the system. At present, there is no clear 
recommendation on the best parameter and action level to use for EPID 
treatment verification. Studies on this subject are still in the preliminary stage 
with no conclusive results. For example, Rozendaal et al. (2015) suggested a 
method that searched for the presence of hot spots in the in-vivo verification 
result, but retrospective analysis of 1095 cases showed a high rate of false 
positive detections, which hampered its clinical implementation. Alternatively, 
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Fuangrod et al. (2015) proposed the use of statistical process control to derive 
site-specific action level for comparisons between measured and predicted EPID 
transit dose planes. The suggested action level for percentage pass rate with 
4%/4mm criterion (determined from a pool of 10 IMRT patients per site, using 
three standard deviations from mean) was 67% and 50% for prostate and head 
and neck cases respectively. Proposals by different investigators should be 
further studied to determine the best indicator parameter and appropriate 
action level that presents the highest sensitivity and specificity.  
 
One of the important factors to consider for broad-scale implementation of EPID 
transit dosimetry in different departments is the ease of commissioning. The 
commissioning process for the EPID transit dosimetry model proposed in this 
study involves measuring two sets of dose planes, separately with EPID and IC in 
water, to derive the A and B quadratic equation coefficients, field size 
correction factors and backscatter correction factors (for IC in water only). The 
full commissioning process could take up to approximately seven hours to 
complete. Future study could explore the possibility of deriving a generalised set 
of commissioning data for use with different EPIDs and TPSs. The idea is for 
different departments to use a generalised dataset and only perform a limited 
number of measurements to account for variation in EPID sensitivity or to 
confirm the agreement between general and locally measured data. Researchers 
from Università Cattolica del Sacro Cuore, Rome, Italy, had reported an example 
of such approach by deriving generalised correlation functions from 
measurements on three linacs for each manufacturer: Varian (Fidanzio et al., 
2011a), Elekta (Cilla et al., 2011) and Siemens (Fidanzio et al., 2011b). The use 
of generalised correlation functions for their single point EPID transit dosimetry 
model eliminates the need for local IC measurements on every linac and greatly 
simplifies the commissioning process. A more recent report by Tielenburg et al. 
(2015) showed that the generalised approach was also possible for their 2D EPID 
transit dosimetry model, with initial investigation yielding very comparable 
results between doses reconstructed from a generic dataset versus a full 
commissioning dataset. Future study on establishing a generic dataset could 
reduce the amount of time required to commission the EPID transit dosimetry 
model and thus, makes it more attractive for implementation in different 
departments.    
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Future study should also look into the application of the EPID transit model for 
the flattening filter free (FFF) treatment technique, which is becoming more 
common in newer linac models. The FFF beam, produced without the flattening 
filter, can deliver radiation at a very high dose rate (typically up to 2400 
MU/min) and has different beam characteristics compared to the conventional 
flattened-beam. This relatively new technology is most often used for high dose 
stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) 
treatments, mainly because the high dose rate of FFF beam shortens the 
treatment time and as a consequence, leads to improved patient comfort and 
better motion management. Since SBRT and SRS treatments deliver a very high 
dosage over a very limited number of fractions, performing actual treatment 
verification of these treatments in real time, in addition to pre-treatment QA, 
will be most beneficial. A recent report on the new aS1200 EPID (Varian, Palo 
Alto, CA, USA) was encouraging, with no saturation effect observed when tested 
with an FFF beam at the highest dose rate (Nicolini et al., 2015). The response 
of other versions of EPID to an FFF beam must be further investigated so that 
the EPID transit dosimetry model can be used to verify the accuracy of, but not 
limited to, SBRT and SRS treatments with FFF beams. 
 
Finally, future development of the EPID transit dosimetry model must be 
accompanied by research aimed to improve the speed of the verification 
process. The development of VMAT verification, real-time verification and 3D 
dose reconstructions, mentioned in the above paragraphs, can only be 
practically realised if the verification speed is improved. For example, the 
current EPID transit dosimetry model takes about 5 min to reconstruct/predict 
one 2D dose plane for an IMRT field on a personal computer with Intel Core i5, 
2.3 GHz CPU and 8 GB RAM. At this speed, the reconstruction/prediction of a 
single arc VMAT treatment, with 36 cine images saved at every 10° of gantry 
rotation, would take approximately 180 min to complete. The use of a graphic 
processing unit (GPU) to improve computational speed (Zhu et al., 2015) may 
offer a possible solution to this problem and should be further explored.  
 !  
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7.4 Final conclusion  
 
“It is now possible to use EPIDs to measure the dose absorbed by the 
patient (transit dosimetry). This technology is still being developed and is 
not routinely available. … Research into these technologies should be 
encouraged and supported.” (The Royal College of Radiologists et al., 2008) 
 
It is clear that EPID transit dosimetry has many advantages and potentials. In 
this research, a 2D EPID transit dosimetry model based on empirical methods has 
been successfully developed and proven to be valid for application with 
different treatment fields including IMRT. In addition to pre-treatment 
verification with phantoms, the developed model was also shown to be suitable 
for actual treatment verification of patients.  
 
To allow broad-scale implementation, the model used methods that are generic 
and practical, involving only general measurements and does not require 
modification to the EPID panel or measurements under non-clinical settings. The 
model has a unique feature, which allows users to choose either to verify dose 
in-vivo (Path 1) or at the EPID level (Path 2). While verification in-vivo is more 
clinically relevant, verification at the EPID level is more efficient as the 
prediction process is only performed once and therapists can evaluate the 
accuracy of delivery immediately after treatment. The choice of two pathways 
makes it easier for different departments to integrate the EPID transit dosimetry 
program into their existing clinical workflow depending on the local preference 
and clinical needs. Furthermore, the versatility provides greater capacity for 
future development of the current model into a more comprehensive verification 
system for safer radiotherapy.  
 
!!
184!
Appendix A: Beam divergence correction 
 
!
Figure A-1 Accounting for the effect of beam divergence in phantom 
thickness.  
 
Where: 
PT(0,0) = phantom thickness at the central axis,  
PT(i,j) = phantom thickness corrected for beam divergence at point (i,j), 
SDD(0,0) = source to detector (or exit plane) distance at the central axis, 
Θ = angle between the central axis ray and the divergent ray. 
 
From Figure A-1 (left), the angle between the central axis ray and divergent ray 
can be calculated according to Equation A-1: 
 
θ = tan-1
i2+j2
SDD 0,0
                                                                              (A-1) 
 
With the angle Θ known, phantom thickness corrected for beam divergence at 
point (i,j) can be calculated with Equation A-2, as illustrated in Figure A-1 
(right): 
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PT(i,j) = PT 0,0
cos θ
                                                                                  (A-2) 
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Appendix B: Numerical iteration 
 
The quadratic equation is given in Equation B-1: 
 
AT +!BT2!+ ln M
M0
 = 0                                                                                  (B-1) 
 
Where: 
A = coefficient of the linear term,  
B = coefficient of the quadratic term,  
T = thickness of attenuator (or EPL),  
M = exit dose,  
M0 = entrance dose.  
(Note: the Cartesian coordinates (i,j) have been removed for clarity) 
 
Equation B-1 can be re-written according to the steps below to arrive at the 
final Equation B-5, used for the iterative calculation: 
 
AT +!BT2 =!- ln M
M0
                                                                                     (B-2) 
 
AT +!2BT2 =!BT2!- ln M
M0
                                                                              (B-3) 
 
T A + 2BT  = BT2 - ln M
M0
                                                                           (B-4) 
 
T =! BT2!- ln MM0
A +!2BT                                                                                                (B-5) 
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Appendix C: Statistical analysis 
(Software: IBM SPSS Statistics, version 22.0, Armonk, NY, USA) 
 
C.1 Normality tests of differences 
H0: Differences between Verify 1 and Verify 2 are normally distributed 
H1: Differences between Verify 1 and Verify 2 are not normally distributed 
 
a Verify 1 and Verify 2 are verification results (percentage gamma pass rates) for two different 
treatment days. 
 
!
Figure C-1 Histograms and Q-Q plots of differences. !
Interpretation of statistical results: 
The differences between Verify 1 and Verify 2 are normally distributed for all 
comparisons (p-value > 0.05). However, the statistical analyses may be affected 
by the small sample size (n = 7).  
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Path 1 : In-vivo dose 
comparisons at the exit level 
Path 1 : In-vivo dose comparisons 
at the isocentre level 
Path 2 : EPID transit dose 
comparisons 
Plots of Differences (Verify 1 – Verify 2) 
Shapiro-Wilk 
(Difference Verify 1 – Verify 2) 
Test 
statistic 
 
df 
Significance 
(p-value) 
Decision 
(α = 0.05, 2-tailed) 
Pair 1 
Path 1: In-vivo dose 
comparisons at the exit 
level 
0.974 7 0.926 p-value > 0.05 Accept H0 
Pair 2 
Path 1: In-vivo dose 
comparisons at the 
isocentre level 
0.949 7 0.718 p-value > 0.05 Accept H0 
Pair 3 Path 2: EPID transit dose comparisons 0.932 7 0.570 
p-value > 
0.05 Accept H0 
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C.2 
Paired t-test 
Justification for using paired t-test: 
1. 
The variables are continuous (from
 0 to 100). 
2. 
The independent variable consists of tw
o related groups, w
ith the sam
e subjects present in both groups. 
3. 
There is no obvious outlier in the differences betw
een the tw
o related groups. 
4. 
D
ifferences betw
een the tw
o related groups are approxim
ately norm
ally distributed. #
#
H
0 : There is no difference in the m
ean gam
m
a pass rates for verification perform
ed on tw
o different days, “Verify 1” versus “Verify 2” 
H
1 : There is a difference in the m
ean gam
m
a pass rates for verification perform
ed on tw
o different days, “Verify 1” versus “Verify 2” 
 
Paired T-test 
(D
ifference Verify 1 – Verify 2) 
M
ean 
difference 
Standard 
deviation 
95%
 C
onfidence Interval 
of the difference 
Test 
statistics 
df 
Significance  
(p-value) 
D
ecision  
(α = 0.05, 2-tailed) 
Low
er 
U
pper 
Pair 1 
Path 1: In-vivo dose com
parisons 
at the exit level  
0.4857 
3.5035 
-2.7545 
3.7259 
0.367 
6 
0.726 
p-value > 
0.05 
Accept H
0  
Pair 2 
Path 1: In-vivo dose com
parisons 
at the isocentre level  
0.0714 
1.9964 
-1.7750 
1.9178 
0.095 
6 
0.928 
p-value > 
0.05 
Accept H
0  
Pair 3 
Path 2: EPID
 transit dose 
com
parisons  
1.3000 
2.4049 
-0.9241 
3.5241 
1.430 
6 
0.203 
p-value > 
0.05 
Accept H
0  
 Interpretation of statistical results: 
The verification results for tw
o treatm
ent days are not significantly different for all com
parisons (p-value > 0.05). H
ow
ever, the 
statistical analyses m
ay be lim
ited to only detecting large differences because of the sm
all sam
ple size (n = 7). 
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